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BET proteins function as epigenetic readers, and BET inhibition has been shown to 
have activity against many different cancers. BET inhibitors have been fast-tracked 
into first clinical trials, however the effects of these inhibitors are still poorly 
understood. A more detailed understanding about the physiological effects of BET 
inhibition is important and may lead to improved clinical applications as well as 
allowing safer use of BET inhibitor drugs.  
In this thesis we have been able to identify that BET inhibition unexpectedly leads to 
an increase in RNA synthesis that is associated with conflicts between transcription 
and replication, leading to replication fork slowing, a sign of replication stress. We 
have identified BRD4 as the main target of BET inhibition in this process which is 
needed for normal fork progression. Interestingly, our data suggest that increased 
RNA synthesis requires free P-TEFb to be released from its inhibitor complex 
HEXIM1 to allow increased RNA polymerase II phosphorylation. HEXIM1 is required 
for BET inhibitor-induced replication-transcription conflicts.  
We have shown that BET inhibitor-induced fork slowing does not activate the 
canonical ATR-Chk1 replication stress response pathway. However, it activates the 
homologous recombination factor RAD51, which is recruited into nuclear foci in 
response to BET inhibitor treatment. RAD51 depletion followed by BET inhibition 
prevents replication fork slowing but activates the replication stress response. 
HEXIM1 depletion has the same effect, preventing fork slowing and activating the 
replication stress response. These data suggest that i) replication fork slowing is 





depends on HEXIM1, which is upstream of transcription-replication conflicts, and 
RAD51, which acts downstream of transcription-replication conflicts.  
Our data shed light on the initial stress response during the first 8 hours of BET 
inhibition. They implicate HEXIM1 and RAD51, which both play potential roles in BET 
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1.1: Transcription and its regulation by HEXIM1  
 
1.1.1: Transcription overview 
 
Transcription is an important biological process in which a DNA template 
information can be read and lead to synthesis of various RNA species. In eukaryotic 
cells there are three different RNA polymerases (RNA Pols) that carry out RNA 
synthesis in the cell: RNA Pol I, RNA Pol II and RNA Pol III.  
RNA Pol I and III transcribe the majority of non-protein coding RNA such as transfer 
RNA’s (tRNAs), ribosomal RNA’s (rRNAs) and U6 small nuclear RNA’s (snRNAs) 
which accounts for the vast majority of RNA in the cell. In particular RNA Pol I 
transcribes ribosomal RNA while RNA Pol III transcribes tRNAs and snRNAs (Paule 
and White 2000). RNA Pol II is involved in transcribing messenger RNA (mRNAs) 
from thousands of genes that help encode for protein synthesis. The process of 
transcription can be further divided into three crucial steps: initiation, elongation and 
termination. The mechanism and structure of RNA Pol II has been widely studied 







1.1.2: Transcription initiation    
                                                                                                                                                                                                                                                        
RNA Pol II transcription is a highly regulated and controlled process and requires 
many factors to allow for transitions between the three stages. Eukaryotic RNA Pol 
II consists of a 12 subunit complex (RPB1-12), and have a catalytic core consisting 
of 10 subunits (Armache, Kettenberger et al. 2003). RNA Pol II has a mass over 
500kDa (Fu, Gnatt et al. 1999, Liu, Bushnell et al. 2013). The RNA Pol II represents 
a claw shape over a central cleft for DNA. There are two channels for incoming 
nucleotide triphosphates (NTPs) and the newly ongoing synthesised RNA molecule 
(Bernecky, Herzog et al. 2016).  
The initiation step of RNA Pol II is a highly regulated process. Firstly, the DNA is 
highly organised and compacted into chromatin. Transcription start sites (TSS) in 
highly compacted chromatin are inactive (Chiang 2006). However decomposition 
and opening of chromatin from external signals or Transcription factor (TF) 
recruitment allows TSS to recruit RNA Pol II and allow for transcription (Chiang 
2006). 
To help recruit the RNA Pol II to the gene start site there is a promoter region just 
before the transcription start site. A promoter can be defined as a sequence of DNA 
that is required for proper initiation of an RNA polymerase (Krishnamurthy and 
Hampsey 2009). The positioning of the promoter is key to allow proper initiation and 
transcription of the downstream gene. Most promoters are approximately no more 
than a 100 base pairs (Bp) from the TSS (Krishnamurthy and Hampsey 2009). An 





Kadonaga 2003). A promoter may have promoter elements to help recruit specific 
transcriptional machinery to the TSS, for example the TATA box has an Initiator 
(Inr) and a downstream promoter element (DPE) (Smale and Kadonaga 2003). 
Although most promoters contain some of these elements it is not essential for the 
promoter to function.  
For initiation to take place it requires the formation of the preinitiation complex (PIC) 
which requires the general transcription factors (GTFs). The GTFs are TFIIB, TFIID, 
TFIIE, TFIIF and TFIIH (Matsui, Segall et al. 1980, Buratowski, Hahn et al. 1989, 
Chiang 2006). Without the GTFs RNA Pol II is unable to recognize the promoter 
(Chiang 2006). Another component of the PIC is the large mediator complex. In the 
case of TATA box promoter, the TATA binding subunit of TFIID can recognize and 
bind to the TATA sequence (Nikolov, Hu et al. 1992, Krishnamurthy and Hampsey 
2009, Louder, He et al. 2016). If there is another promoter, binding can happen with 
another subunit of TFIID which can recognize the promoter sequence. TFIIB 
recognizes the TATA-binding protein (TBP) and DNA complex and binds to DNA to 
form a TFIIB-TFIID-DNA complex (Nikolov, Hu et al. 1992, Krishnamurthy and 
Hampsey 2009). This complex can help recruit the RNA Pol II which is helped by 
TFIIF. Finally TFIIE binds to complete the PIC (Krishnamurthy and Hampsey 2009) 
(Figure 1.1). The mediator complex helps RNA Pol II interact with regulatory signals 
coming from proteins bound to enhancers (Davis, Takagi et al. 2002, Lewis and 








Figure 1.1: Diagram showing how RNA Pol II is recruited to the TSS via GTF’s, 
promoter sequences (TATA Box) and enhancers.  
 
1.1.3: Transcription elongation 
 
To allow a transition of RNA Pol II into the elongation phase requires C-terminal 
domain (CTD) phosphorylation and elongation factors (Heidemann, Hintermair et al. 
2013). RNA Pol II elongation requires regulation throughout the process. Regulation 
of transcription often happens when RNA Pol II is paused roughly around 30-100 
nucleotides (Nt’s) downstream of TSS in a process known as promoter-proximal 
pausing of RNA Pol II (Adelman and Lis 2012). This process happens in the initial 
stages of transcription elongation. This step is the rate limiting step in transcription 
which helps regulate the process and act to ensure correct modifications to RNA 
Pol II and 5’ capping has occurred before elongation occurs. Proximal pausing of 
RNA Pol II occurs after initiation of transcription has occurred and requires 





















transcription factors negative elongation factor (NELF) and DRB-sensitivity inducing 
factor (DSIF) to induce pausing and stabilize RNA Pol II that is paused downstream 
of the TSS (Wada, Takagi et al. 1998, Yamaguchi, Takagi et al. 1999, Jonkers and 
Lis 2015). RNA Pol II pausing is an extremely dynamic mechanism which leads to 
continuous turnover of RNA Pol II causing premature terminations rather than stable 
persistent paused RNA Pol II (Krebs, Imanci et al. 2017). To allow for RNA Pol II to 
continue for productive elongation further signals are required.  
A key factor in allowing release of paused RNA Pol II is the positive elongation 
factor b (P-TEFb) complex which includes the cyclin-dependent 9 kinase (CDK9). 
Research has shown how important the CDK9 activity is in allowing transition into 
productive elongation. A study showed that if P-TEFb is inhibited in the cell it affects 
95% of genes actively transcribed indicating the importance of the transition 
between initiation and elongation as a key regulatory step in transcription (Jonkers, 
Kwak et al. 2014). P-TEFb is recruited to the RNA Pol II via its interactions with 
transcriptional co-factors. A large number of co-factors have been shown to interact 
with P-TEFb including BRD4 (Peterlin and Price 2006, Adelman and Lis 2012). 
Once recruited, P-TEFb can lead to phosphorylation of the CTD at Serine 2 (Ser2) 
and NELF and DSIF (Marshall and Price 1992, Wada, Takagi et al. 1998, 
Yamaguchi, Takagi et al. 1999, Yamada, Yamaguchi et al. 2006). P-TEFb can form 
activating complexes with BRD4 or the super elongation complex (SEC) (Smith, Lin 
et al. 2011, Itzen, Greifenberg et al. 2014). P-TEFb has an inhibitory complex 
HEXIM1-7SK which can help regulate RNA Pol II transcription as well (Quaresma, 





allow productive elongation to occur (Peterlin and Price 2006, Jonkers and Lis 
2015) (Figure 1.2). 
 
Figure 1.2: Diagram illustrating key events that lead to escape from RNA Pol II 
proximal pausing.  
 
Transcription elongation can occur through diffusion of RNA Pol II through different 
conformational states rather than being driven by an ATP dependent process 
(Herbert, Greenleaf et al. 2008). The first state which occurs when a new nucleotide 
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the active site is empty after the RNA Pol II has moved one nucleotide along the 
DNA allowing for another nucleotide to be incorporated (Bar-Nahum, Epshtein et al. 
2005, Herbert, Greenleaf et al. 2008, Liu, Bushnell et al. 2013). The last state is 
when the polymerase moves backwards (backtrack) moving the newly incorporated 
nucleotide back out of the active site (Herbert, Greenleaf et al. 2008). For RNA Pol 
II to move forward and be stable in each state requires the binding and hydrolysis of 
the correct nucleotide which is to be incorporated into the growing chain (Bar-
Nahum, Epshtein et al. 2005, Herbert, Greenleaf et al. 2008, Liu, Bushnell et al. 
2013).  
It is crucial to ensure that the correct nucleotides are incorporated into the growing 
RNA chain. Backtracking can help allow regulation of correct nucleotides (Selth, 
Sigurdsson et al. 2010). Studies have shown that when an incorrect nucleotide is 
incorporated then it can lead to slowing down of the incorporation of the next 
nucleotide, increasing its ability to be cleaved by RNA Pol II which has 
endonuclease activity to allow for removal of incorrect nucleotides (Sydow, 
Brueckner et al. 2009, Selth, Sigurdsson et al. 2010). This mechanism is aided and 
stimulated by elongation factor TFIIS which increases the removal of incorrect 
nucleotides (Selth, Sigurdsson et al. 2010). 
Another mechanism to insure RNA Pol II fidelity is the trigger loop structure in RNA 
Pol II of the Rpb1 subunit (Kaplan, Larsson et al. 2008). The trigger loop resides 
below the active site. It functions by forming a plethora of different interactions with 
the new incoming nucleotide (Wang, Bushnell et al. 2006). These interactions serve 
to ensure that the incoming nucleotide correctly orientates with the trigger loop 





phosphodiester bond between the incoming nucleotide and the growing RNA chain. 
If a nucleotide is disorientated with the trigger loop it causes slowing down of the 
formation of phosphodiester bond allowing RNA Pol II to cleave or backtrack to 
ensure its removal (Wang, Bushnell et al. 2006, Kaplan, Larsson et al. 2008). 
Recent studies in yeast have shown that the Rpb9 subunit can also affect RNA Pol 
II fidelity (Nesser, Peterson et al. 2006). Further research highlighted that Rpb9 may 
act to slow closure of the trigger loop on the incoming nucleotide (Walmacq, Kireeva 
et al. 2009). 
Transcription elongation does not happen uniformly but varies in elongation rate 
(Selth, Sigurdsson et al. 2010, Adelman and Lis 2012, Jonkers, Kwak et al. 
2014). This may be due to a number of factors including elongating through 
chromatin or DNA sequences that are hard to transcribe and perform barriers to 
elongation such as G-quadruplexes or R-loops (Jonkers and Lis 2015). Factors 
such as histone chaperones or chromatin re-modellers can help loosen DNA to 
help facilitate transcription (Chiang 2006, Jonkers and Lis 2015). Modifications to 
histones can also signal for changes to chromatin structure (Jonkers and Lis 
2015). Overall elongation is subject to significant pausing while transcribing with 
average elongation rates usually are around 20-30 nucleotides/second, however 
there have been rates of 70 nucleotides/second measured when elongation is not 







1.1.4: Transcription termination 
 
Although many details of transcription have been widely studied, transcription 
termination is just only now being defined. Although the complicated mechanism of 
termination is clearer now it is still poorly understood. Firstly the process of 
transcription termination can occur at any point within the gene (Proudfoot 2016). 
The process of termination of RNA Pol II also linked with mRNA processing which 
occurs co-transcriptionally (Proudfoot 2016). Genes are regions of genome that 
make up one transcription unit from the promoter to the terminator region of the 
gene (Proudfoot 2016). When the RNA Pol II transcribes over the terminator the 
rate of RNA Pol II movement slows down. The terminator is a sequence of DNA that 
provides signals in the new RNA transcript (poly-A) that trigger processes such as 
the releases of mRNA and RNA Pol II (Porrua and Libri 2015, Proudfoot 2016). This 
is due to the recognition of the poly-A signal appearing in the transcript which is 
recognised by 3’end cleavage and polyadenylation complex (CPA) (Takagaki, 
Ryner et al. 1989, McCracken, Fong et al. 1997, Proudfoot 2004). When the mRNA 
transcript is formed, R-loops are more readily formed due to the terminator 
sequence transcribed which is more likely to form R-loops. The transcript will then 
invade the antisense DNA strand which has been transcribed to further slowdown 
RNA Pol II (Skourti-Stathaki, Kamieniarz-Gdula et al. 2014). CPA can lead to 
cleavage of the mRNA at the poly-A signal releasing the mRNA from the RNA Pol II 
(Xiang, Tong et al. 2014, Proudfoot 2016). RNA Pol II will still transcribe despite the 
release of the mRNA and requires further action to dissociate. At the same time 





RNA transcript one nucleotide at a time (Proudfoot 2004, Porrua and Libri 2015). 
When the Xrn2 reaches the RNA Pol II it causes conformational changes to the 
RNA Pol II and its active site leading to RNA Pol II being released from the DNA 
(West, Gromak et al. 2004, Porrua and Libri 2015, Proudfoot 2016).  
Termination is important for gene regulation, firstly genes can generate a multitude 
of different mRNAs varying in length caused by alternative poly-A sites which lead 
to termination at various points (Tian and Manley 2013). This produces mRNAs with 
different 3’UTR sequences which can encode for various functions (Tian and 
Manley 2013, Proudfoot 2016). Termination can also serve to rid the cell of 
transcription errors, as mis-synthesised RNA can cause early termination before the 
gene end and allows for degradation of the RNA (Proudfoot 2016). Aberrant 
termination can lead to prolonged transcription through the downstream gene 
leading to downregulation of gene expression of this gene (Shearwin, Callen et al. 
2005). Once mRNA is transcribed it can be processed, spliced and is ready for 
exportation. 





































1.1.5: RNA Pol II CTD code 
 
RNA Pol II subunit Rpb1 contains CTD which contains multiple heptad repeats 
consisting of Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 which is repeated 26 times in 
yeast and 52 times in vertebrates (Corden 1990). The CTD is heavily modified, 
mostly via phosphorylation, at each position which gives rise to different patterns 
during the transcription processes and helps regulate and modulate this process 
(Phatnani and Greenleaf 2006, Hsin and Manley 2012). This modification of the 
CTD can lead to recruitment of various transcription factors associated with 
initiation, elongation and termination allowing for regulation of these processes and 
for transition between the stages.  
A general model of transcription highlights that at the beginning of transcription as 
one of the first events of initiation serine 5 (Ser5) is phosphorylated by Cyclin 
dependent kinase 7 (CDK7) kinase of the initiation factor TFIIH (Guidi, Bjornsdottir 
et al. 2004, Phatnani and Greenleaf 2006, Harlen and Churchman 2017). During 
elongation Ser2 is increasingly modified by phosphorylation via the P-TEFb’s CDK9 
kinase, as Ser5 is gradually removed by phosphatases (Peterlin and Price 2006, 
Phatnani and Greenleaf 2006, Harlen and Churchman 2017). These 
phosphorylation’s can broadly act as markers for different stages of transcription 
with Ser2 for elongation/termination and Ser5 through initiation.  
The CTD via modification can serve to recruit histone modifiers and chromatin re-
modellers to the RNA Pol II to help regulate transcription processes through 





regulatory roles in pre-mRNA processing roles such as capping, splicing, and 3’ end 
processing (Proudfoot, Furger et al. 2002, Hsin and Manley 2012). Phosphorylation 
at Ser5 can lead to 5’ capping enzymes being brought to the RNA Pol II and within 
vicinity of the mRNA ongoing transcript being produced (Burley and Sonenberg 
2011). Research has recently shown Ser5 having a role causing chromatin 
remodelling and histone modification (Krogan, Keogh et al. 2003, Ng, Robert et al. 
2003). Studies have shown that serine 7 (Ser7) is normally phosphorylated during 
transcription initiation as well. Ser7 is phosphorylated by CDK7 too, meaning both 
are phosphorylated by the same kinase during transcription initiation (Glover-Cutter, 
Larochelle et al. 2009). Studies in yeast cells indicate that Ser7 remains 
phosphorylated throughout elongation before being removed at termination 
(Hajheidari, Koncz et al. 2013). Ser7 acts to recruit RPAP2 and integrator complex 
to snRNA which is important in 3’ processing of the mRNA, which can only happen 
once Ser5 is dephosphorylated (Egloff, Zaborowska et al. 2012).  
Ser5 phosphorylation is removed by RPA2 and Ssu72 phosphatase in aid with PIN1 
(Egloff and Murphy 2008, Krishnamurthy, Ghazy et al. 2009). Ssu72 is also involved 
in removing Ser7 phosphorylation as well (Zhang, Mosley et al. 2012). Removal of 
Ser5 is crucial to allow pre-mRNA processing mechanisms to function.  
As mentioned earlier Ser2 phosphorylation is key in allowing processive elongation 
to occur after proximal pausing. This occurs via the activity of P-TEFb CDK9 kinase. 
The phosphorylation of Ser2 lasts through termination and functions by recruiting 
both elongation and termination transcription factors to the RNA Pol II (Meinhart and 
Cramer 2004, Yoh, Cho et al. 2007, Lunde, Reichow et al. 2010). Ser2 





where the splice sites are and allows for spliceosome assembly (Hsin and Manley 
2012). It also serves a function is 3’ end processing by recruiting Pcf11 (Meinhart 
and Cramer 2004). Ser2 phosphorylation is removed by phosphatase Fcp1. Thr4 is 
phosphorylated by CDK9 kinase during transcription elongation as well (Cho, Kobor 
et al. 2001, Ghosh, Shuman et al. 2008).  
During transcription termination the CTD has some key roles. A protein dimer of 
p54/PS4 can bind to a phosphorylated Ser2 on the CTD. This dimer can facilitate 
termination by recruiting Xrn2 nuclease (Kaneko, Rozenblatt-Rosen et al. 2007, 
Hsin and Manley 2012). When p54 was depleted there were termination defects 
seen in HeLa cells (Kaneko, Rozenblatt-Rosen et al. 2007).  
 
1.1.6: RNA polymerase I and III 
 
As mentioned earlier there are three different RNA polymerases that transcribe 
RNA molecules. The previous chapter has been focusing on the role of RNA Pol II. 
There are some key differences between the three RNA Pol’s in how they transcribe 
DNA.  
Firstly, both RNA Pol I and RNA Pol III lack the heptad repeat on CTD  which as 
described above is crucial for RNA Pol II function and regulation (Hsin and Manley 
2012). RNA Pol I has the same mechanisms of transcription initiation, elongation 
and termination as RNA Pol II but has different transcription factors to allow 
transcription. The PIC of RNA Pol I requires specific transcription factors. SL1 acts 
to recognize specific RNA Pol I promoters, and UBF and RRN3 mediate promoter 





Friedrich, Panov et al. 2005, Lin, Comai et al. 2006, Goodfellow and Zomerdijk 
2012). Proximal pausing is relieved by phosphorylation of RRN3 allowing its release 
from RNA Pol I (Hirschler-Laszkiewicz, Cavanaugh et al. 2003, Bierhoff, Dundr et 
al. 2008). Both UBF and SL1 help mediate elongation with combination with other 
RNA Pol I specific elongation factors (Stefanovsky, Langlois et al. 2006, Denissov, 
Lessard et al. 2011). Termination employs a similar method to RNA Pol II but uses 
endonuclease RNT1 to cleave nascent pre-RNA followed by Xrn2 exonuclease to 
release RNA Pol I (Goodfellow and Zomerdijk 2012). 
Less is known about the RNA Pol III mechanism. Again initiation requires three 
transcription factors: TFIIIA, TFIIIB and TFIIIC (Acker, Conesa et al. 2013). TFIIIB is 
composed of Brf1, Bdp1 and TBP. TFIIIC is a large complex that functions to 
recognize the promoter (Sentenac and Riva 2013, Turowski and Tollervey 2016). 
TFIIIC can lead to the recruitment of TFIIIB which can lead to RNA Pol III 
recruitment to DNA (Deprez, Arrebola et al. 1999). Events following initiation are 
less clear. Both elongation and termination occur in similar mechanisms to RNA Pol 
II, while having specific RNA Pol III transcription factors to allow for these processes 
to occur (Turowski and Tollervey 2016).  
 
1.1.7: Role of 7SK-snRP and HEXIM1 
 
As mentioned previously, P-TEFb has a vital role in regulating RNA Pol II 
transcription and allowing its release from a paused state. It is therefore crucial that 
the P-TEFb is tightly regulated. This actually requires the work of RNA Pol III, which 





able to bind to P-TEFb and inactivate its kinase ability (Nguyen, Kiss et al. 2001). 
More recent research has actually shown that 7SK functions as a scaffold for other 
proteins. This scaffold forms a base for which a complex known as the 7SK-snRNP 
can be formed which enables inhibition of P-TEFb and enhances 7SK stability 
(Quaresma, Bugai et al. 2016). The 7SK-snRNP comprises of four proteins: 7SK, 
LARP7, MePCE as well as the P-TEFb inhibitor HEXIM1 (Yik, Chen et al. 2003, 
Jeronimo, Forget et al. 2007, He, Jahchan et al. 2008). The majority of P-TEFb is 
found sequestered in this complex and can only be activated by disruption of the 
complex and release of free P-TEFb (Yik, Chen et al. 2003) (Figure 1.4).  
 
 
Figure 1.4: Diagram illustrating the formation of the 7SK-snRNP complex to 
sequester P-TEFb. 
 
To form the 7SK-snRNP complex, firstly 7SK is folded and forms a structure that 
consists of four stem loops (SL1-4) (Quaresma, Bugai et al. 2016, Brogie and Price 



















of SL1 and the 7SK 3’terminal U-rich region (Chambers, Kurilla et al. 1983, Muniz, 
Egloff et al. 2013). This helps prevent 7SK degradation and caps the 5’end of the 
7SK which triggers LA being replaced by LARP7 which associated with both the U-
rich region and SL4 providing 7SK stability (Chen, Xue et al. 2009). HEXIM1 
contains an N-terminal regulatory domain, an arginine rich binding motif (ARM), an 
acidic and a coil-coil region which mediates HEXIM1 dimerization (Zhou and Yik 
2006). The last part involves HEXIM1 binding to the 7SK SL1 via its ARMS which 
acts as a 7SK binding domain (Michels, Fraldi et al. 2004). This allows the dimeric 
coil-coil region of HEXIM1 to bind to P-TEFb which has been phosphorylated at 
Threonine (Thr) 186 by CDK7 to complete the 7SK-snRNP complex (Blazek, 
Barboric et al. 2005). This phosphorylation on P-TEFb has been shown to be crucial 
for the 7SK-P-TEFb interaction. This is the crucial step, and HEXIM1 is suggested 
to inhibit P-TEFb by stopping ATP association with the CDK9 kinase (Li, Price et al. 
2005). The acidic domain interacts with the dimerised basic region in the ARM to 
prevent early binding of P-TEFb to HEXIM1 without interaction with the 7SK (Zhou 
and Yik 2006). When P-TEFb is released, the 7SK-snRNP still remains stable and 
can rebind free P-TEFb (Bartholomeeusen, Xiang et al. 2012, Quaresma, Bugai et 
al. 2016) . 
7SK-snRNP complexes have been shown to be anchored to chromatin near 
promoters and enhancers by chromatin adaptor factors (Flynn, Do et al. 2016, 
Quaresma, Bugai et al. 2016). This allows the inactive pool of P-TEFb to be in close 
proximity to RNA Pol II allowing activation of P-TEFb and release of RNA Pol II from 





P-TEFb is released from 7SK via a series of post-translational modifications and 
proteolysis. Firstly, HEXIM1 is phosphorylated along a number of residues just 
before its coil-coil domain which hinders its ability to bind to P-TEFb (Contreras, 
Barboric et al. 2007). P-TEFb phosphorylation at Thr 186 is dephosphorylated (Cho, 
Schroeder et al. 2009). These changes allow P-TEFb to be released. While this 
process is reversible as 7SK core remains intact, there are a few changes that 
cause P-TEFb activation to be irreversible by destabilizing the 7SK core as shown 
in a recent study in megakaryopoiesis (Elagib, Rubinstein et al. 2013). This involves 
the MePCE proteolysis and demethylation of 7SK. In addition LARP7 was also 
downregulated, possibly by proteolytic pathways and transcriptional and 
posttranscriptional repression, which lead to 7SK core being completely destabilized 
(Elagib, Rubinstein et al. 2013). The post translational modifications (PTMs) 
involved are normally a result of a cell signalling cascade. For example, 
hexamethylene bis-acetamide (HMBA) treatment lead to phosphorylation of 
HEXIM1 via the PI3K/AKT pathway which lead to P-TEFb activation (Contreras, 
Barboric et al. 2007). HIV 1-Tat virus can cause global release of P-TEFb or can 
prevent its sequestration to allow for continued viral transcription (Matija Peterlin, 
Yik et al. 2007). Various transcription factors can allow for P-TEFb release from 
7SK-snRNP to allow for transcription elongation. These include BRD4, SRSF2 and 






1.2: BET proteins and their role in transcription 
 
1.2.1: BET proteins overview 
 
BET proteins are at the cutting edge of new experimental targets for cancer 
treatment. Pre-clinical data as well as latest research show that targeting BET 
proteins can potentially be used and developed as an effective anticancer 
therapeutic in the future. They have been seen to play a role in the maintenance of 
DNA replication as well (Da Costa, Agathanggelou et al. 2013). A more detailed 
understanding of these proteins and their function is a necessity to further 
understand and develop future clinical applications.  
There are approximately 61 bromodomains discovered in humans coming from over 
46 human proteins (Filippakopoulos and Knapp 2012). Human bromodomain 
proteins are further sub-classified; one particular subfamily of bromodomains is 
known as the BET family (Figure 1.5). The BET subfamily of bromodomain proteins 







Figure 1.5: Phylogenetic tree depicting bromodomains based on structure. 
Retrieved from (Philpott, Rogers et al. 2014). 
 
 
1.2.2: BET protein architecture 
 
Each BET protein has a conserved architecture, consisting of two N-terminal 
tandem bromodomains and contain an extra terminal (ET) domain which is involved 





also contain other motifs such as A, B or the serine-glutamine-aspartate rich region 
(SEED motif). BRD4 and BRDT also contain a C-terminal motif (Filippakopoulos, 




Figure 1.6: BET family protein domain organisation comprising of two tandem 
bromodomains, extra-terminal domain, a SEED motif and A and B motifs. BRD4 
long isoform and BRDT also comprise of a C-terminal Motif (CTM).  
 
The conserved bromodomains consists of a highly conserved motif of 110 amino 
acids, and all have the same conserved fold forming a left-handed bundle of four 
alpha-helices: αz, αa, αb, αc. These alpha helices are linked together by highly 
variable loop regions called ZA and BC loops (Dhalluin, Carlson et al. 1999, Zeng 
and Zhou 2002) (Figure 1.7).  
 






Figure 1.7: Diagram of the structure of BET-family bromodomains, illustrating a left 
handed bundle of four α-helices and two loop regions ZA and BC. Retrieved from 
(Nakamura, Umehara et al. 2007). 
 
In between the two tandem bromodomains in BET proteins is a conserved 12 
amino acid stretch (KGVKRKADTTTP). This stretch of amino acids serves to 
localise BET proteins to the nucleus. A study using HEK293T cells showed that 
deletion of this region led to mis-localisation of BET proteins (Fukazawa and 
Masumi 2012). A study resolved the extra-terminal domain structure, showing that 








1.2.3: BET protein interactions 
 
Chromatin may be modified in numerous ways; one modification of chromatin is the 
N-terminal acetylation of ɛ-lysine residues on histone tails. This modification is 
commonly associated with increased transcriptional activation and with open 
chromatin structure (Marushige 1976).  
The diverse loop regions of the BET protein contain some conserved residues 
including a PxY motif at the C-terminal of the ZA loop region. A tyrosine residue is 
situated in the αB loop allowing a salt bridge to form to another residue on the αB 
loop which allows for fold stabilisation (Fujisawa and Filippakopoulos 2017). 
High resolution crystal structures have shown that binding of BET protein 
bromodomains to acetylated lysine’s on histones requires the conserved 
asparagine residue at the beginning of the BC loop (Owen, Ornaghi et al. 2000). 
By acetylating the lysine side chains, the lysine charge is neutralized. A stable 
hydrogen bond between the acetylated lysine and asparagine can promote the 
interaction (Filippakopoulos, Qi et al. 2010). A small hydrophobic binding pocket 
to allow binding of the acetylated lysine side chain is formed though the four α-
helices (Dhalluin, Carlson et al. 1999, Fujisawa and Filippakopoulos 2017). 
Once the conserved asparagine has initiated binding for the acetylated lysine’s, 
the peptide backbone of the acetylated lysine forms interactions with the charged 
surface around the acetylated lysine binding pocket of BET proteins (Fujisawa 





Not only can the bromodomains interact with acetylated lysine’s on histones, but 
they can also interact with a large number of other acetylated proteins such as 
transcription factors GATA1 and TWIST (Gamsjaeger, Webb et al. 2011, Shi, 
Wang et al. 2014). 
BET proteins can form interactions with a myriad of diverse proteins via their ET 
domains. The ET domains consists of approximately 80 amino acids. The ET 
domain can regulate different BET protein functions by recruiting specific effector 
proteins such as NSD3. (Rahman, Sowa et al. 2011).  
 
1.2.4: BET proteins role in transcription 
 
BET proteins have been shown to play a multitude of roles in transcription. BET 
proteins have the ability to act as a scaffold to help recruit and build larger protein 
complexes including transcription factors via their ET domain (Rahman, Sowa et 
al. 2011). Binding of BET protein complexes to acetylated histone tails can help to 
increase transcription activation by increasing the effective concentration of 
transcription activators around the promoter region. 
The BET protein BRD2 is a known Serine/Threonine kinase and its activity is 
upregulated with cellular proliferation (Denis and Green 1996). BRD2 functions as 
an important protein in cell-cycle progression. Research using 3T3 fibroblast 
showed that BRD2 promotes the activity of transcription factor E2F (Denis, Vaziri et 
al. 2000). E2F functions as a cell cycle transcription factor, which leads to the 





through the G1/S transition (Lee, Chang et al. 2002). BRD2 has also been shown to 
recruit TBP to the E2F-1 protein complex at promoters (Peng, Dong et al. 2007). In 
addition to E2F proteins, BRD2 can recruit histone deacetylases (HDACs) and 
histone acetyltransferases (HATs) which are involved in chromatin remodelling to 
regulate transcription (Houzelstein, Bullock et al. 2002). Genome wide associated 
studies (GWAS studies) showed that BRD2 regulates the expression of 1450 
different proteins in the cell. It was also shown in HeLa cells that BRD2 could 
promote alternative splicing of genes while not changing the ability of RNA Pol 2 
processivity around the alternative spliced elements in the gene (Hnilicová, Hozeifi 
et al. 2013). Other findings have shown that insufficient amounts of BRD2 protein in 
mice can lead to reduced number of neuronal cells hence BRD2 plays an important 
role in neuronal development as well (Shang, Wang et al. 2009, Tsume, Kimura-
Yoshida et al. 2012).  
Recent studies using an in vitro transcription assay in HeLa cells have shown that 
both BRD2 and BRD3 contain nucleosome chaperone activity, which can help 
RNAPII to elongate along the DNA and produce transcripts through regions that 
have heavily hyperacetylated nucleosomes (LeRoy, Rickards et al. 2008). A similar 
study using transcription assays confirmed that BRD4 also plays a similar role in 
helping the elongation of RNA Pol II through hyperacetylated nucleosomes (Kanno, 
Kanno et al. 2014).   
BRD3 plays another role in transcription regulation in cells. BRD3 has been 
shown to directly interact with transcription factor GATA1 via GATA1’s acetylated 
lysine residues (Gamsjaeger, Webb et al. 2011, Lamonica, Deng et al. 2011). 





(Katsumura, DeVilbiss et al. 2013). Erythropoiesis is the process which leads to 
the formation of red blood cells (Hattangadi, Wong et al. 2011). By disrupting 
BRD3’s ability to bind to chromatin, transcriptional repression of GATA1 mediated 
transcription can occur. ChIP-sequencing data showed that all four BET proteins 
occupy GATA-1 bound loci, however the amount of BRD3 increase at these loci 
following GATA1 activation is the most significant (Stonestrom, Hsu et al. 2015). 
Interestingly, BRD3 depletion in G1E-ER cells showed very little marked effect on 
erythroid transcription after GATA1 activation. BRD2 and BRD4 depletion lead to a 
more marked effect leading to less erythroid gene activation and lower levels of 
GATA1 transcript levels (Stonestrom, Hsu et al. 2015). However, when BRD3 is 
depleted in cells already depleted of BRD2 the effect on erythroid gene activation is 
greatly exacerbated (Stonestrom, Hsu et al. 2015). This points to maybe a 
synergistic effect of these proteins suggesting that BET protein functions may 
overlap with each other. 
In addition to the roles shown above BRD2 is thought to promote transcription 
activation of HOXA11 and D11 shown in HEK293 cells (LeRoy, Rickards et al. 
2008). BRD2 can also interact with LANA of KSHV which leads to episomal 
replication and persistence of viral genomes (Platt, Simpson et al. 1999, Viejo-
Borbolla, Ottinger et al. 2005). BRD3 can promote the transcriptional activation of 
HOXB3-B6, C8-C10 and A3,A5-7 as shown in HEK293 cells (LeRoy, Rickards et al. 
2008). 
BET proteins BRD4 and BRDT are key regulators of transcriptional elongation in the 
cell. These proteins can actively recruit positive transcription elongation factor P-





2005). P-TEFb is activated once free of its inhibitory complex HEXIM1 and can act 
as a protein kinase (Schroder, Cho et al. 2012). To allow for recruitment of P-TEFb, 
BRD4 interacts with JMJD6 protein via its JmjC domain. This causes demethylation 
of 7SK and H4K3me2, allowing release of P-TEFb from HEXIM1 (Liu, Ma et al. 
2013). P-TEFb is recruited by BRD4 to chromatin where it can freely phosphorylate 
RNA Pol II on its CTD predominately at serine 2 (Itzen, Greifenberg et al. 2014). 
This phosphorylation allows RNAPII, which is paused at the transcription start site, 
to be activated and allow normal transcription elongation to occur (Phatnani and 
Greenleaf 2006) (Figure 1.8). Research has shown that BRD4 occupation can be 
widespread throughout the genome allowing it to stimulate transcription of both 


























Figure 1.8: Diagram illustrating the role of BRD4 in recruiting higher order 
complexes such as P-TEFb to the RNAPII leading to increased transcription 
downstream. 
 
BRD4 can also play a role in transcription regulation via the ET domain interactions. 
These interactions lead to changes of chromatin environments around BET protein-
targeted genes. This was shown when NSD3 interacts with BRD4 via its ET 
domain. NSD3 can change and regulate levels of histone H3 K36 methylation which 
is a modification leading to more active transcription (Rahman, Sowa et al. 2011). 
BRD4 can also lead to transcriptional activation of Nanog which helps maintain 
pluripotency of embryonic stem cells (Liu, Stein et al. 2014). BRD4 can stimulate 
transcriptional activation of HOXB2- B8, A4, and C5 in HEK293 cells nucleosomes 






















































controls episomal maintenance and DNA replication of the human papillomavirus 
(HPV) genome (Schweiger, You et al. 2006).  
BRD4 also has several other functions that it can perform in the cell. BRD4 plays an 
important role in the cell cycle and loss of BRD4 can lead to aberrant mitosis 
leading to genome instability. BRD4 associates with late mitotic/early G1 genes 
during mitosis acting as a transcriptional bookmark, which lead to quick activation of 
these genes after mitosis in the daughter cells (Dey, Nishiyama et al. 2009). 
However, BRD4’s predicted role as a mitotic bookmark has been recently 
challenged by work done in the Blobel lab, who have observed that loss of BRD4 
from the chromatin did not impair post-mitotic activation of transcription. They 
suggest that BRD4 is not functioning as a mitotic bookmark, but that BRD4 is 
probably a mitotic passenger gene. Additionally, their work suggests that BRD4’s 
binding may be associated with restoring lineage-specific transcription patterns post 
mitosis (Behera, Stonestrom et al. 2019). BRD4 plays a role in cell differentiation 
and development. BRD4 is not a general transcription factor but actually regulates 
genes that either control cell differentiation or are involved in cell cycle (Whyte, 
Orlando et al. 2013). BRD4 is important in maintaining ESC identity and 
maintenance of other cellular differentiation programs such as B/T cells 
differentiation in the lymph node (Bolden, Tasdemir et al. 2014, Di Micco, 
Fontanals-Cirera et al. 2014). 
The protein BRDT is expressed only in the testis (Jones, Numata et al. 1997, 
Shang, Salazar et al. 2004). BRDT is essential for the process of 
spermatogenesis (Shang, Nickerson et al. 2007). BRDT is expressed firstly at 





meiotic stage of spermatogenesis (Gaucher, Boussouar et al. 2012). Studies 
using transcriptome analysed have shown that BRDT regulates over 3000 genes 
(Gaucher, Boussouar et al. 2012). One such gene is Cyclin A1, which is vital to 
allow spermatocytes to enter the first meiotic division (Liu, Matzuk et al. 1998). 
BRDT regulates expression involved in allowing meiotic progression through the 
process of spermatogenesis. BRDT can also modulate chromatin remodelling 
during spermatogenesis (Berkovits and Wolgemuth 2011). 
BRDT can interact and recruit P-TEFb complex to chromatin to help it function to 
regulate transcription during spermatogenesis and suggested that BRDT is a 
testis tissue specific paralogue of BRD4 (Gaucher, Boussouar et al. 2012). BRDT 
can interact with Smarce1 which is a member of the SWI/SNF family. Smarce1 is 
part of the multimeric chromatin remodelling complexes which act to regulate 
transcriptional activation during spermatogenesis (Dhar, Thota et al. 2012).  
 
1.2.5: BET proteins role in DNA replication and DNA damage response 
 
Recent research into the role of BET proteins have indicated a role for these 
proteins in the biological processes of DNA replication and the DNA damage 
response, both of these processes will be described in more depth later in the 
introduction. 
Research done by the Stankovic group showed that inhibiting BET proteins using 
BET inhibitor JQ1 in acute lymphoblastic leukaemia (ALL) cell line Nalm 6 could 





(Da Costa, Agathanggelou et al. 2013). This suggested BET proteins may play a 
role in replication. Further studies have highlighted that BET proteins BRD2 and 
BRD4 bind to TICRR/TRESLIN protein. This protein is needed for DNA replication 
initiation and loss of this interaction with BET proteins causes abnormal S-phase 
progression (Sansam, Pietrzak et al. 2018). In addition, loss of this interaction lead 
to slower euchromatin replication in U20S cells. The findings in this paper suggest 
that BET proteins are directly involved in regulating DNA replication via the 
interaction of BET-TICRR by being able to recruit replication factors to chromatin. 
DNA replication initiation is regulated by BET proteins. BET protein BRD4 also 
interact with replication protein RFC, which is part of the DNA replication machinery 
and is essential for DNA replication and cell cycle progression. Deletion of this 
interaction lead to dysregulation of cell cycle progression into S-phase indicating the 
importance of this interaction on cell cycle regulation (Maruyama, Farina et al. 
2002). BRD4 has also be known to interact with and regulate cell division cycle 6 
(CDC6), a replication pre-factor ((a replication factor required for formation of the 
pre-replicative complex (pre-RC) at a replication origin)) which functions in DNA 
replication checkpoint signalling. Loss of this interaction led to erroneous replication 
re-initiation (Zhang, Dulak et al. 2018). These results suggest that BET proteins play 
a role in DNA replication from regulating its timing to regulating DNA replication 
initiation and progression.  
Research done by Floyd et al. pointed to a role of BET protein BRD4 in the DNA 
damage response. They observed that BRD4 depletion led to no visible increase in 
replication stress damage marker γH2AX. They also observed that BRD4 loss 





damage signalling and survival in response to irradiation (Floyd, Pacold et al. 2013). 
This suggested a role of BRD4 in modulating DNA damage signalling in response to 
damage that induces double strand breaks (DSB’s). More recent studies have also 
shown that inhibiting BET proteins or BRD4 depletion led to no changes in amount 
of DNA damage signalling seen even in the presence of replication stress (Zhang, 
Dulak et al. 2018). However, notably factors involved in HR such as Radiation 
sensitivity gene 51 (RAD51) were downregulated in response to BET inhibitor 
treatment (Yang, Zhang et al. 2017, Pawar, Gollavilli et al. 2018). Cells that had 
acquired resistance to BET inhibition showed increase DNA damage and repressed 
expression of DNA damage repair and signalling factors (Pawar, Gollavilli et al. 
2018). Taken together this suggests that BET proteins have important roles in DNA 
damage signalling in response to specific DNA damage and play a role in regulating 






1.3: BET inhibitors to target BET protein roles in cancer 
 
 
1.3.1: Role of BET proteins in cancer 
 
BET proteins function as transcription regulators and epigenetic readers that allow 
the regulation of a myriad of different transcriptional programs including 
spermatogenesis and erythropoiesis. As key transcriptional regulators, any 
dysfunction can potentially lead to disease and cancer formation.  
Recent research suggests that BET family bromodomains are potential targets for 
the use in cancer therapy. Research has shown that BET family proteins are 
involved in oncogenic functions, such as affecting cell proliferation and viability, of 
many different cancers ranging from haematological malignancies to solid tumours 
which will be described in more detail later in this chapter.  
MYC is a useful example to illustrate how BET family bromodomains can be 
involved in cancer pathology. C-MYC oncoprotein is a crucial regulatory factor of 
cell proliferation. C-MYC oncoprotein pathogenesis in human cancers works by 
causing a coordinated upregulation of transcriptional programmes which help 
promote cell division and cell survival (Dang 2009). C-MYC oncoprotein is involved 
in the pathogenesis of the majority of human cancers, including many cancers 
where BET family proteins play a role (Mertz, Conery et al. 2011). The transcription 
of the MYC gene will usually be accompanied with increases in histone lysine 
acetylation on the chromatin (Frank, Parisi et al. 2003). This increase of histone 





to that area of chromatin (LeRoy, Rickards et al. 2008). BET proteins can recognise 
histone acetylation and bind to the transcriptional start sites of the MYC gene 
(Figure 1.9). BRD4 is bound to the transcriptional start sites when the cell is 
undergoing the M/G1 transition marking them for transcriptional memory, which 
helps allow BRD4 to influence the initiation of transcription for these genes when 
the cell exits mitosis (Dey, Nishiyama et al. 2009). BRD4 promotes increases in 
transcription by regulating transcription elongation. It will serve this by allowing 
recruitment of P-TEFb (Jang, Mochizuki et al. 2005, Yang, Yik et al. 2005). The 
recruitment of P- TEFb to BRD4 on the chromosome during mitosis will lead to the 
increased transcriptional activation of the MYC gene, which will lead to an increase 
in the expression of growth promoting and cell survival MYC dependent target 












Figure 1.9: The role of BET proteins on MYC driven cancers. BRD4 transcription 



















































Another example is the role BRD2 plays in induced lung adenocarcinoma. BRD2 
can form a complex with RUNX3 transcription factor dependent on K-RAS 
oncogene. This led to increased expression of p21 a cell cycle inhibitor allowing 
cells to freely proliferate (Lee, Lee et al. 2013). 
Another cancer where BET proteins play a role is the Nut midline carcinoma, which 
is an aggressive human squamous carcinoma (French, Miyoshi et al. 2001). BRD4 
has been identified in this carcinoma which consists of a t (15; 19) chromosomal 
translocation, and this translocation has both the tandem bromodomains of BRD4 
and the NUT protein fused together and expressed forming the NUT midline 
carcinoma (NMC) protein (French, Miyoshi et al. 2003). Research undertaken has 
shown that BRD4-NUT oncoprotein mediates characteristics such as proliferation 
advantage for this malignancy (French, Ramirez et al. 2008). It has been shown that 
this fusion acts upstream of the MYC promoter allowing constant MYC 
overexpression (Grayson, Walsh et al. 2014). Conversely, using RNA silencing of 
the BRD4-NUT oncoprotein arrests proliferation (Filippakopoulos, Qi et al. 2010). 
With this information we can see that there is a wide-ranging therapeutic use for a 
molecule that can act as a specific inhibitor of human bromodomain proteins.  
 
1.3.2: BET inhibitor JQ1 
 
As BET proteins are implicated in diseases such as cancer, it opened a potentially 
new therapeutic way to treat cancer by targeting BET proteins with small-molecule 





possible due to the hydrophobic nature of the binding pocket in bromodomains 
which potentially allowed for the development of small-molecule compounds.  
Recently in 2010, there was the discovery of two small-molecules that could inhibit 
BET bromodomains, one of which was JQ1 and the other being I-BET 
(Filippakopoulos, Qi et al. 2010, Nicodeme, Jeffrey et al. 2010). JQ1 is a cell-
permeable small molecule that binds competitively to bromodomains. JQ1 is a novel 
thieno-triazolo-1, 4-diazepine. JQ1 contains a t-butyl ester functional group at C6. 
JQ1 has a stereo centre at C6 and hence consists of two stereoisomers: (+)-JQ1 
and (-) - JQ1 (Filippakopoulos, Qi et al. 2010). 
 
‘ 
Figure 1.10: Chemical structure of small molecule inhibitor (+)-JQ1. 
 
JQ1 was known as an inhibitor of bromodomains; how selective it was for inhibiting 





screening all human bromodomains was done by sub-cloning all human 
bromodomains into bacterial expression vectors, which yielded soluble protein to 
screen all bromodomain subfamilies. A differential scanning fluorimeter screen 
(thermal shift assay) highlighted the selectivity of JQ1 for BET family bromodomains 
exclusively, indicating that JQ1 is a highly specific inhibitor of BET family 
bromodomains (Filippakopoulos, Qi et al. 2010). It also further highlighted that (+)-
JQ1 was a highly selective ligand for BET proteins while (-)-JQ1 showed no 
discernible interaction with BET protein indicating (+)-JQ1 is an active ligand 
against BET proteins. Further research using a luminescence proximity 
homogenous assay (alpha-screen) that was adapted to BET bromodomains, 
showed that JQ1 was competitively binding with acetylated lysine’s that were found 
on histone tails (Filippakopoulos, Qi et al. 2010). 
This was further evidenced using co-crystal structures of JQ1 bound to BRD4. Here 
(+)- JQ1 was bound to the bromodomain of BET proteins that would normally be 
interacting and binding with acetylated histones, hence competitively inhibiting 
binding of BET proteins to chromatin (Filippakopoulos, Qi et al. 2010). The crystal 
structure also showed JQ1 has shape complementarity with the acetylated lysine 
binding site. JQ1 when bound to BRD4 will occupy the whole binding pocket, and its 
bound state is usually being stabilised by hydrophobic interactions with BET 
residues from the ZA and BC loop regions as well as a hydrogen bond with the 
conserved asparagine (Filippakopoulos, Qi et al. 2010). BRD2 was later shown to 
bind JQ1 in the same way as BRD4 (Filippakopoulos, Qi et al. 2010). Therefore, 








1.3.3: JQ1 and cancer treatment 
 
JQ1 has potential as a cancer therapeutic and this has been followed up with 
various studies carried out in mouse models. When JQ1 was first reported, it was 
shown that its treatment in midline carcinoma cell lines can cause the release of 
BRD4-NUT from chromatin leading to terminal squamous cell differentiation and 
apoptosis (Figure 1.11). The report also showed that JQ1 treatment helped 
decrease tumour size and extend the survival in mice models of NMC. This was the 
first test that showed JQ1 as a potential cancer therapeutic (Filippakopoulos, Qi et 
al. 2010). 
 
           
 
Figure 1.11: JQ1’s mechanism in inhibiting proliferation of tumour cells. Here 
acetylated lysine’s can be bound by epigenetic readers in BRD4 hence increasing 
the oncogenic activity of the BRD4-NUT oncoprotein. Once JQ1 bound to BRD4 
inhibits the binding to acetylated lysine’s and hence inhibit proliferation of these 







































Studies from several laboratories, including at Birmingham, have identified 
therapeutic effects for BET inhibitors in mouse models of haematological 
malignancies, such as acute myeloid leukaemia, multiple myeloma, Burkitt’s 
lymphoma and B-cell lymphoma (Delmore, Issa et al. 2011, Mertz, Conery et al. 
2011, Ott, Kopp et al. 2012, Da Costa, Agathanggelou et al. 2013). MYC 
oncoprotein regulates the transcription and cell cycle in all the above mentioned 
malignancies (Dang 2009). As of yet, current cancer treatments i.e. cytotoxic 
treatments, are often non-specific and can have side effects. A new way was 
hypothesised to target C-MYC transcriptional function, by potentially disrupting the 
chromatin-dependent signal transduction. BET proteins are required for the cancer-
promoting transcriptional activities of oncogenes such as MYC, as discussed 
earlier. Studies have shown that MYC transcription can be regulated by 
bromodomains. Recent research was undertaken using JQ1, to understand the role 
of BET proteins in MYC-dependent transcription and to find out the potential of BET 
proteins having a role as cancer promoters. Multiple myeloma (MM) cell lines were 
used as a model system, which is an incurable hematologic malignancy and 
features dysregulation of MYC (Shou, Martelli et al. 2000, Wu and Chiang 2007). 
MYC rearrangement or translocation is one of the most common events in MM and 
more than 60% of patient MM cells have MYC pathway activation, which presents 
MYC dysregulation as a commonly observed molecular feature present in MM 
(Chng, Huang et al. 2011). Results for this experiment showed that BET inhibition 
by JQ1 can hinder BRD4 binding to the MYC gene enhancers and hence leading to 
the inhibition of MYC transcription. With the downregulation of MYC transcription 





2011). Reports have stated that the inhibition of the MYC transcription may 
represent a major mechanism of the cellular killing caused by BET inhibition in 
tumour cells (Delmore, Issa et al. 2011). JQ1 leads to the suppression of C-MYC 
driven malignancies such as testis- midline carcinoma, acute myeloid leukaemia 
(AML) and multiple myeloma, by displacement of BET family proteins from the MYC 
promoter/enhancer (Dawson, Prinjha et al. 2011, Delmore, Issa et al. 2011, Cheng, 
Gong et al. 2013, Da Costa, Agathanggelou et al. 2013) (Figure 1.12). In summary, 
JQ1 produces a powerful antiproliferative effect showcased by cell cycle arrest and 














Figure 1.12: Diagram illustrating how JQ1 dirsupts BRD4 from binding to the 

















































JQ1 could also play a role as a therapeutic in solid tumours as well. Non-small cell 
lung cancer are sensitive to JQ1 as are some neuroblastomas that 
contain NMYC amplifications (Lockwood, Zejnullahu et al. 2012, Puissant, Frumm 
et al. 2013). Other solid tumours that have shown sensitivity to JQ1 are 
glioblastoma, medulloblastoma, hepatocellular carcinoma, colon cancer, pancreatic 
cancer, prostate cancer, and breast cancer (Cheng, Gong et al. 2013, Asangani, 
Dommeti et al. 2014, Bandopadhayay, Bergthold et al. 2014, Kumar, Raza et al. 
2015, Sengupta, Biarnes et al. 2015, Zhang, Tong et al. 2015, Li, Guo et al. 2016, 
Shu, Lin et al. 2016). Here, we can understand the role of JQ1 could have against a 
widespread set of malignancies. 
Downregulation of MYC is not the only effect of BET inhibition. Other mechanisms 
are also affected such as in ALL where there is reduction in interleukin 7 receptor 
gene and in large B cell lymphoma where there is reduction in other transcription 
proteins such as E2F1, POU2AF1, BCL6, IRF8, and PAX5 (Ott, Kopp et al. 2012, 
Chapuy, McKeown et al. 2013). BET inhibitor transcriptional effects are normally 
very specific to each cell type. When leukaemia cells are treated with JQ1 there is a 
significant reduction in MYC transcript levels, which is not the same as when JQ1 is 









1.3.4: I-BET151 and Cancer 
 
Another BET inhibitor used is I-BET151 (GSK1210151A) which was first reported in 
2011 (Dawson, Prinjha et al. 2011). I-BET151 has shown to be effective in mixed-
lineage leukaemia (MLL) where treatment led to apoptosis and cell cycle arrest in 
MLL cell lines. Inhibition of BET proteins in particular BRD3 and BRD4 by I-BET151 
caused decreased amounts in the BCL-2 (regulates apoptosis), MYC, and Cyclin 
dependent kinase 6 (CDK6) (regulates cell cycle progression) genes causing cell 
death (Dawson, Prinjha et al. 2011). It works similarly to JQ1 by competitively 
inhibiting binding of BET proteins to acetylated histones and has been shown to 
have potent anti-myeloma activity through repression of MYC (Chaidos, Caputo et 
al. 2014). I-BET151 has also shown to have activity against myeloproliferative 
neoplasms, glioblastoma, nucleophosmin 1 (NPM1)-mutated acute myeloid 
leukaemia seen in both cell lines and murine models (Dawson, Prinjha et al. 2011, 








Figure 1.13: I-BET151 chemical structure. 
 
1.3.5: Current status of BET inhibitors as therapeutics 
 
The table below shows the current pre-clinical studies of BET inhibitors in cancer. 
Thirteen BET inhibitors have since been taken into early-phase clinical studies to be 




















BAY1238097  Undisclosed Solid tumours and 
lymphoma 
I (terminated) 
BI 894999  
 






Undisclosed Solid tumours  I/II 














BRD2/3/4/T AML/MDS I 
































OTX015/MK-8628 BRD2/3/4 AML, DLBCL, solid 
tumours 
I 






 AML, MDS, Solid 
tumours 
I 
ZEN003694  BRD2/3/4 Metastatic CRPC I 
 
Table 1.1: Table depicting BET inhibitors that are in pre-clinical trials, their targets 
and which tumours they are looking to target. Adapted from (Doroshow, Eder et al. 
2017). 
 
These phase1 trials for BET inhibitors have shown mixed results so far. CPI-0610 
was trialled in hematologic malignancies in patients with refractory/respiratory 
lymphoma, where out of 44 patients there were 2 complete responses, 1 partial 
response and 5 with responses not qualifying as a partial response (Abramson, 
Blum et al. 2015). MK-8628/OTX015 inhibitor was used in hematologic 
malignancies. 33 patients were treated for lymphoma and 12 for myeloma. 3 
patients with diffuse large B-cell lymphoma showed a partial response while no 
effect was seen with those with myeloma (Amorim, Stathis et al. 2016). Patients 
presented with diarrhoea and fatigue at the dose limiting toxicity for this drug, in 
addition to which nausea and skin changes were also seen (Amorim, Stathis et al. 
2016). Clinical trials have also investigated the effect in solid tumours. OTX015 was 
tested in 47 patients with either NMC,  castrate-resistant prostate cancer (CRPC) or  
non-small cell lung cancer (NSCLC) (Massard, Soria et al. 2016). Four partial 
responses (PR’s) were observed with 3 being in NMC. Side-effects included 





testing BAY1238097 in patients with solid tumors was halted due to side-effects 
such as vomiting, migraines and lower back pain when the dose was below 
therapeutic levels (Postel-Vinay, Herbschleb et al. 2016). These are just a couple 
examples of the results seen, and a fully detailed list of all the BET inhibitors and 
responses in clinical trials can be found in (Doroshow, Eder et al. 2017). 
Overall these preliminary results have been mixed and the anti-cancer response 
effects have been short-lived so far. However, more pre-clinical data has shown that 
BET inhibitors may be more therapeutic when used in combination therapy 
(Doroshow, Eder et al. 2017). For example, JQ1 was shown to reduce tumor 
volumes and weights when combined with trametanib in ovarian cancer cell lines, 
while JQ1 treatment alone led to only cell cycle arrest (Jing, Zhang et al. 2016). 
Other potential combinations are with immune checkpoint inhibitors. JQ1 treatment 
combined with a PD1 (immune checkpoint regulator) inhibitor led to decreased 
tumor volume and size in a KRAS-mutant NSCLC xenograft (Adeegbe, Liu et al. 
2017). Combination with epigenetic therapies has been shown to have significant 
effects in pre-clinical studies, including synergistic effects with HDAC inhibitors 
(Borbely, Haldosen et al. 2015, Heinemann, Cullinane et al. 2015, Shahbazi, Liu et 
al. 2016). Combination treatments may be the future for BET inhibitors as 
therapeutic tools.  
Nevertheless, a major concern for the continuation of BET inhibitors as therapy 
drugs are their toxicity profile, which can cause patients with unwanted side-effects. 
Despite moving BET inhibitors forward in clinical trials, there are concerns regarding 






Most BET inhibitors as of yet are not selective for a specific BET protein and as 
mentioned before BET proteins regulate numerous transcription pathways. BET 
protein have crucial roles in numerous processes including insulin production, 
cytokine gene regulation and T cell differentiation (Wang, Liu et al. 2009, Belkina, 
Nikolajczyk et al. 2013). There is also research indicating that BET inhibitors can 
lead to the re-activation of HIV in human cells (Banerjee, Archin et al. 2012). BET 
inhibitors also work as transcriptional repressors and activators to a host of different 
genes. There could be serious safety issues if BET inhibitors currently in clinical 
trials were to be used as therapeutics. How BET inhibitors work in transcriptional 
regulation of different pathways affecting metabolism, differentiation and secretory 
pathways is still barley understood. These are reasons as to why BET inhibitors 
should be studied more intensely with regard to their biological roles and functions 
before using them as a cancer therapy tool. This is further backed with the results 









1.4: DNA replication and replication stress 
 
1.4.1: Overview of DNA replication 
 
DNA replication is the biological process in which two identical copies of DNA are 
produced from one DNA molecule. Allowing the genome to be faithfully replicated is 
vital for allowing successful transmission of genetic information and preserving 
genome stability. In order for this to be accomplished, it necessitates the navigation 
of different endogenous and exogenous sources of DNA modifications, which can 
lead to replication stress locally or globally (Branzei and Foiani 2010). The process 
of DNA synthesis mostly occurs in the S-phase stage of the cell cycle (Leman and 
Noguchi 2013). Replication occurs in three distinct stages: initiation, elongation and 
termination all of which need to be tightly regulated. In this section I will describe the 
process of replication and what happens when it encounters blocks on the DNA. 
 
1.4.2: Initiation of DNA replication   
 
DNA replication in eukaryotes starts from multiple points on the DNA termed 
replication origins, which when fired lead to the formation of bi-directional replication 
forks leading to new double strand DNA synthesis (Fu, Yardimci et al. 2011, 
Fragkos, Ganier et al. 2015). DNA replication in eukaryotic cells needs to start from 





et al. 2010). Before replication can be initiated each origin is required to be licensed 
before it is fired.  
Origin licencing requires the Origin recognition complex (ORC) being recruited to a 
potential origin on the DNA (Bell and Stillman 1992). How ORC is recruited to the 
origin still remains unknown, however evidence suggests that more chromatin 
compaction and epigenetic marks play a role (MacAlpine and Almouzni 2013). 
CDC6 bound with an ATP will associate with ORC (Wang, Feng et al. 1999). 
Chromatin licensing and DNA replication factor 1 (CDT1) is also recruited to the 
ORC followed by the minichromosome maintenance complex (MCM) which is a 
hexamer. MCM 2-7 is loaded as a double hexamer onto the DNA. The MCM 
consists of six subunits (MCM 2-7). ORC, CD6 and MCM2-7 are AAA+ ATPase’s 
(Evrin, Clarke et al. 2009, Remus, Beuron et al. 2009). This forms the pre-RC. 
Licencing starts in G1 phase when the pre-replicative complex is assembled at each 
origin. Origin firing needs the pre-RC to be activated which can only occur in S 
phase (Pacek and Walter 2004, Sun, Fernandez-Cid et al. 2014).  
Origin firing involves the formation of the pre-initiation complex (pre-IC) and the 
activation of the MCM helicase complex. The pre-IC is formed via the activities of 
CDKs and DBF4 dependent kinases (DDKs), which are activated at the G1-S phase 
transition. DDKs phosphorylate MCM 2-7, which leads to the recruitment of 
Treslin/TICCR and CDC45. CDKs phosphorylate Treslin/TICRR which leads to the 
recruitment of TOBP1 and GINS allowing for the formation of the CMG helicase 
(Sheu and Stillman 2006, Francis, Randell et al. 2009, Boos, Sanchez-Pulido et al. 
2011, Heller, Kang et al. 2011, Kumagai, Shevchenko et al. 2011, Boos, Yekezare 





et al. 2016). The MCM2-7 double hexamer splits into two different hexamers 
allowing for bi-directional replication forks to be established. Activated helicases can 
recruit RFC, proliferating cell nuclear antigen (PCNA) and replication protein A 
(RPA) and other DNA polymerases such as DNA polymerase α to convert the pre-
IC into a replication fork (Gambus, Jones et al. 2006, Moyer, Lewis et al. 2006). The 
replication fork (replisome) consists of a CMG complex (CDC45, MCM helicases 
and GINS complex) with PCNA, DNA Ligase1 and FEN1 and the DNA polymerases 
δ and ε (Gambus, Jones et al. 2006, Moyer, Lewis et al. 2006). Only about a third of 
origins are activated in a replication unit. This means that the initiation of these 
origins must be tightly controlled, and they are inhibited by ATM and Rad4 related 
(ATR) and Ataxia telangiectasia mutated (ATM kinases) which activate checkpoint 1 
kinase (CHK1) or checkpoint 2 kinase (CHK2) (Fragkos, Ganier et al. 2015). 
After firing; replication needs to replicate DNA faithfully at a fast rate bi-directionally. 
During replication not every origin is activated initially, but additional origins can be 
fired later on, if needed to help complete replication if previously established 
replication forks have stalled (Branzei and Foiani 2010, Fragkos, Ganier et al. 
2015). Thus, replication origins are not all activated at the same time and are 
controlled in a specific manner which is normally regulated by chromatin structure, 
transcriptional programmes and rate-limiting replication factors (Fragkos, Ganier et 






Figure 1.14: Diagram illustrating the steps and mechanism of replication initiation 
as detailed in the chapter above. Adapted from (Fragkos, Ganier et al. 2015). 
 
 



















+ CDC45, MCM10, 










1.4.3: Replication progression 
 
A replication fork is formed to allow the process of replication elongation. In a 
replication fork structure double stranded DNA is unwound by an activated CMG 
helicase which hydrolyses ATP to unwind dsDNA. This leaves two strands of single 
stranded DNA (ssDNA) which allows access to unpaired DNA nucleotides 
(Gambus, Jones et al. 2006, Moyer, Lewis et al. 2006, Sengupta, van Deursen et al. 
2013). CMG is a 3′-5′ helicase and translocates on the leading strand (Moyer, Lewis 
et al. 2006). Thus, nucleotides can be read, allowing for complementary base 
pairing of free nucleotides to form two identical double-stranded DNA molecules.  
The formation of complementary base pairing to allow the formation of the daughter 
DNA molecule, are catalysed by DNA polymerases. There are three different 
replicative DNA polymerases involved in replication elongation: α, δ, and ε, all of 
which are members of the B family of DNA polymerases (Leman and Noguchi 2013, 
Burgers and Kunkel 2017). DNA polymerases can move along ssDNA and elongate 
the new DNA strand being formed by reading the template (original) strand. They 
catalyse the incorporation of new bases which can either be adenine, guanine, 
thymidine or cytosine hence extending the 3’ end of the newly synthesised DNA 
(Leman and Noguchi 2013). They also require the replication clamp PCNA loaded 
onto the DNA by clamp loader RFC to allow DNA polymerases to elongate further 
without falling off (Mailand, Gibbs-Seymour et al. 2013). 
Free deoxyribonucleotides used for DNA synthesis need to contain three phosphate 





et al. 2002). DNA polymerases catalyse the reaction of these nucleotides with the 
free 3'-hydroxyl group on the previous nucleotide that has be incorporated. This 
reaction leads to two phosphates being released (pyrophosphate) which provides 
the energy for the polymerization reaction allowing the remaining 5' monophosphate 
to covalently bond to the 3' oxygen forming a phosphodiester bond (Alberts, 
Johnson et al. 2002, Leman and Noguchi 2013). Some DNA polymerases also have 
the ability to proofread to ensure the right nucleotide is being incorporating into the 
DNA (Alberts, Johnson et al. 2002). 
There are two strands of DNA that are replicated at the same time after being 
unwound. These are known as the leading and lagging strands (Figure 1.15). 
Both strands require Pol α–RNA primase complex to allow for DNA synthesis to 
occur (Leman and Noguchi 2013). To allow DNA synthesis an RNA primer needs to 
be laid down first (Leman and Noguchi 2013, Burgers and Kunkel 2017). Pol α has 
two activities, one being RNA primase activity and the other being DNA polymerase 
activity. Primase normally elongates for approximately 10 nucleotides long before 
Pol α can synthesise further (Bullock, Seo et al. 1991, Nethanel, Zlotkin et al. 1992). 
This leads to it leaving a RNA-DNA primer in a 5’-3’ direction allowing other more 
processive polymerases to continue DNA synthesis after (Pellegrini and Costa 
2016). Pol α has high error rate as it lacks exonuclease activity and has low 










Figure 1.15: The replication fork consisting of both the leading and laggings strands 
being synthesised. 
 
The leading strand elongates DNA using the CMG helicase and Pol ε (Pursell, Isoz 
et al. 2007, Muramatsu, Hirai et al. 2010, Sengupta, van Deursen et al. 2013). Pol ε 
(epsilon) synthesizes DNA continuously in the same direction that the DNA is being 
unwound in. CMG is a 3′-5′ helicase so the DNA is being unwound in this direction 
(Moyer, Lewis et al. 2006). All polymerases including Pol ε synthesise DNA from 5’-
3’ direction (Leman and Noguchi 2013). This means that DNA synthesis can occur 
in a continuous fashion on the leading strand. Pol ε has both DNA polymerization 











Osterman et al. 2013). Pol ε contains a small cleft in the catalytic domain allowing 
Pol ε to encircle newly formed double stranded DNA (dsDNA), which is likely why 
Pol ε has high processivity and hence can replicate continuously on the leading 
strand (McCulloch and Kunkel 2008). The 3′-exonuclease activity of Pol ε allows it 
to check the newly synthesised DNA and correct any replication errors that may 
have occurred (Pursell, Isoz et al. 2007, Burgers and Kunkel 2017). 
The other stand is known as the lagging strand. On the lagging strand, Pol α DNA 
synthesis can only synthesise DNA for approximately 20–30 NT’s (Bullock, Seo et 
al. 1991, Nethanel, Zlotkin et al. 1992). After the primer is laid down, DNA synthesis 
can continue further with DNA Pol δ. The lagging strand cannot be synthesised 
continuously as it is being unwound due to it having opposite directionality to the 
DNA helicase. When DNA synthesis occurs of the lagging strand, it consist of small 
stretches of discontinuous DNA replication known as Okazaki fragments which are 
approximately 100 to 200 bases long (Ogawa and Okazaki 1980). As DNA 
synthesis occurs in stretches and not continuously like on the leading strand, it 
causes a much longer stretch of ssDNA. To protect the ssDNA from forming 
secondary structures or activating any other responses due to exposed ssDNA, the 
ssDNA is coated by single-stranded binding proteins. These proteins help to 
stabilize ssDNA stretches and help prevent secondary structure formation. This 
ssDNA binding protein is known as RPA which is a heterotrimeric complex (Wold 







Figure 1.16: The replisome with Pol ẟ and Pol ε leading DNA synthesis with the 
CMG helicase complex unwinding DNA. Adapted from (Leman and Noguchi 2013). 
 
As each Okazaki fragment is synthesised it will run into the previous Okazaki 
fragment synthesised. When this occurs DNA pol δ can displace the RNA primer. A 
small segment (usually not more than 1 nucleotide) of DNA upstream of the RNA 
primer is also displaced leaving a flap like structure (Bae, Bae et al. 2001, Leman 
and Noguchi 2013, Burgers and Kunkel 2017). This flap acts as a substrate for 
FEN1 endonuclease which can cleave the flap one nucleotide at a time 
(Balakrishnan and Bambara 2013, Stodola and Burgers 2016). Sometimes due to 
loss of regulation of either DNA Pol ẟ or FEN1 long flaps can be produced. These 
flaps are too long for FEN1 to cleave so DNA replication helicase/nuclease 2 
(DNA2), a nuclease/helicase, can act to cleave this flap using its 5’-3’ endonuclease 





The cleavage of the flap results in a small nick in DNA which can be ligated by the 
enzyme DNA ligase1 (Bambara 1993) (Leman and Noguchi 2013). DNA ligase I 
can bind to the clamp loader PCNA that helps the stabilization of DNA ligase onto 
DNA substrate (Vijayakumar, Chapados et al. 2007). Due to the discontinuous 
nature of DNA replication synthesis on the lagging strand, it is often less efficient 
and requires more time than leading-strand synthesis. Hence, there are 
mechanisms in place that help coordinate both leading and lagging strand 
synthesis. Research done in T4 bacteriophages showed that the lagging strand 
needed to be looped back through the replisome as shown in Figure 1.16 in a 
model termed ‘The trombone model’ (Alberts, Barry et al. 1983). This was further 
shown in E.coli systems as well (O'Donnell 1987). How coordination between the 
two strands occur in eukaryotic systems is less well understood, however a study in 
yeast showed that Ctf4 protein is able to bind and interact with both DNA pol α and 
ε and linking these two machineries together suggesting a potential role in 
coordination between these two (Simon, Zhou et al. 2014). 
 
1.4.4: Replication termination 
 
The final step of DNA replication is replication termination. Previous steps of 
replication; initiation and elongation, have been extensively researched and studied 





There are approximately about as many replication termination events occurring as 
there are replication initiation events during a normal S phase of mammalian cells 
(McGuffee, Smith et al. 2013, Dewar and Walter 2017). 
There are no defined termination sites for replication. Most termination events will 
occur wherever two replication forks will converge into each other. As initiation 
events at origins are changing due to which origins are activated, this causes 
termination sites to change as well depending on where origins are being activated 
(McGuffee, Smith et al. 2013, Petryk, Kahli et al. 2016). The lack of defined 
termination sites is adapted to the ever-changing activation of origin firing that exists 
in cells.  
When replication is almost complete two replication forks will approach each other 
which promotes formation of supercoils in the regions of DNA yet to be replicated 
(Dewar and Walter 2017). During this step topological stress formed previously can 
be relieved by topoisomerase 1 and topoisomerase 2 enzymes (Keszthelyi, Minchell 
et al. 2016, Dewar and Walter 2017). However as forks converge closer, it is harder 
for these enzymes to act so forks are rotated to form catenanes (Keszthelyi, 
Minchell et al. 2016).  
When replication forks converge, the meeting of two different CMG’s does not lead 
to any detectable replication stress. This is because the two converging CMGs can 
bypass each other as they both are bound to leading strands (Fu, Yardimci et al. 





Once the CMG helicases have bypassed each other, they continue to synthesise 
downstream to at least a few bases away (Dewar, Budzowska et al. 2015). How the 
last Okazaki fragment is matured and synthesised is still unclear.  
The replisome machinery (CMG) is stably bound to the DNA throughout DNA 
synthesis. A key step to allow replication termination is to be able to disassemble 
this machinery once DNA synthesis is complete. During replication termination, it 
can be covalently modified by undergoing polyubiquitylation on its MCM7 subunit 
(Maric, Maculins et al. 2014, Priego Moreno, Bailey et al. 2014). These polyubiquitin 
chains can be made either by SCFDIA2 (Skp, Cullin, F-box-containing complex 
associated with DIA2) or CRL2LRR1 (Cullin RING ligase 2 associated with LRR1) 
(Maric, Maculins et al. 2014, Dewar, Low et al. 2017, Sonneville, Moreno et al. 
2017). After the MCM7 has been poly-ubiquitylated it is recognized by 
p97/VCP/Cdc48 protein complex that can lead to CMG being removed from 
chromatin (Maric, Maculins et al. 2014, Priego Moreno, Bailey et al. 2014).  
The catenanes are removed by topoisomerase type 2 which resolves the two 







Figure 1.17: Model of the mechanism of replication termination in eukaryotic cells. 






1.4.5: Replication stress 
 
Replication stress is defined as the slowing or stalling of replication fork 
progression, leading to incomplete DNA synthesis, and can be induced by a variety 
of different hindrances (Zeman and Cimprich 2014). Replication stress frequently 
involves the increased formation of single stranded DNA due to slowing or stalling 
of the DNA polymerase. Replication stress causes genome instability and 
decreases cell survival (Ciccia and Elledge 2010). 
 
1.4.6: Sources of replication stress 
 
 
Figure 1.18: Diagram illustrating the various sources that can lead to replication 
stress in the cell. Retrieved from (Zeman and Cimprich 2014). 
 
Replication stress occurs through blockages and obstacles formed either 
endogenously or exogenously to the replication fork that slow its progression 





blockages and obstacles, which will in turn lead to increased amounts of replication 
stress. These sources usually provide barriers that prevent the DNA polymerases 
from synthesising the DNA at its normal rate. Replication stress usually leads to the 
formation of physical structures, namely the formation of large stretches of ssDNA 
which are coated by RPA (Pacek and Walter 2004). ssDNA is formed when the 
replicative polymerase is stalled by a blockage to replication, but the helicase 
continues to unwind. This uncoupling leads to formation of large stretches of ssDNA 
(Pacek and Walter 2004). There are however some blockages that can lead to 
impediment of both helicases and replicative polymerases such as interstrand cross 
links (ICL’s) or DNA-protein complexes (Lambert and Carr 2013). 
Nicks and gaps in the DNA as well as ssDNA can act as sources of replication 
stress. In a lot of recombination and repair pathways, nicks and gaps in the DNA act 
as intermediates in the process, and if the replisome comes into contact with these 
nicks/gaps in the DNA this can lead to the conversion into double stranded breaks 
(Zeman and Cimprich 2014). 
Unrepaired DNA damage lesions act as physical block to replication fork 
progression which can lead to replication stress (Zeman and Cimprich 2014). There 
are a lot of endogenous and exogenous causes of DNA damage which lead to the 
formation of lesions on the DNA.  
Exogenous damages include exposure to toxic agents such as Ultra-violet (UV) or 
organic compounds found in tobacco smoke (benzo-a-pyrene) or cooked foods that 
can react with DNA to form bulky lesions. UV causes the formation of bulky adducts 





photoproducts (6-4 PPs) (Chatterjee and Walker 2017). These bulky lesions cause 
blockages to the DNA polymerase but are bypassed by the helicase leading to 
replication stress (Yajima, Lee et al. 2009). Other DNA lesions such as ICL’s and 
DNA- protein cross-links can form potent blockages to both the helicase and DNA 
polymerase (Lambert and Carr 2013). Endogenous damages that can lead to the 
formation of single stranded breaks (SSB’s) include oxidative base damages or the 
misincorporation of bases by DNA polymerases all of which can cause a barrier that 
impedes DNA polymerases from normal replication (Ciccia and Elledge 2010). 
These are usually dealt with by a host of different DNA repair mechanisms but any 
fault or errors in the DNA repair pathway can lead to increased replication stress.  
Nucleotide depletion is another mechanism of replication stress. These depletions 
can either be caused through endogenous or exogenous sources. Increased firing 
of origins can lead to nucleotide depletion for example in the case of oncogene 
activation due to deregulation of normal replication firing (Sørensen and Syljuåsen 
2012). HU a genotoxic compound can cause nucleotide depletion exogenously 
(Koç, Wheeler et al. 2004) 
Incorrect ribonucleotide incorporation has been shown to be another source of 
replication stress. Replicative polymerases have high processivity and fidelity when 
carrying out base pairing, however incorporate ribonucleotides instead of 
deoxyribonucleotides at a high frequency. This is due to ribonucleotides, being 
many folds more abundant in the cell than deoxyribonucleotides, anywhere from 36 
to 190 fold higher in S. cerevisiae depending on which base (Dalgaard 2012). 





DNA it can lead to replication fork progression to slow and lead to genome 
instability (McEllin, Camacho et al. 2010).  
Overexpression of oncogenes can be a major driving force leading to replication 
stress (Bartkova, Rezaei et al. 2006). Oncogenes such as cyclin E and MYC have 
been shown to cause replication stress when overexpressed (Jones, Mortusewicz 
et al. 2013, Srinivasan, Dominguez-Sola et al. 2013). Cyclin E overexpression for 
example is associated with impaired replication fork progression and DNA damage. 
Cyclin E-induced replication slowing, and DNA damage has been shown to be due 
to the consequence of excessive origin firing as well as due to interference between 
replication and transcription. An increase in origin firing and replication-transcription 
conflicts are both sources for increased replication stress (Jones, Mortusewicz et al. 
2013). 
There are a lot of DNA sequences that can be challenging for the progression of 
replication, examples include secondary DNA structures or trinucleotide repeats. 
These secondary DNA structures such as hairpins basically block fork progression. 
These sequences not only provide obstacle for replication but also promotes 
replication slippage (McMurray 2010, Kim and Mirkin 2013). The replication stress 
response is crucial for stabilising these sequences. G-quadruplexes, which 
commonly occur in regions of DNA that are rich in guanine and cytosine (GC), are 
also secondary structures that act as a block to replication and slow replication 
speeds and lead to increased DSB’s (Bochman, Paeschke et al. 2012). Stabilising 
these structures chemically slows replication fork speeds and increases amounts of 





There are certain regions in a genome that are hard for polymerases to replicate; 
these are known as fragile sites. These sites can be divided into two classes, 
common fragile site (CFS) or early replicating fragile sites (ERFS) (Barlow, Faryabi 
et al. 2013). Fragile sites are prone to replication stress and increased double 
strand breaks (Mazouzi, Velimezi et al. 2014). It has been suggested that these 
fragile sites may lead to increase stress and DSB formation as there are no 
replication origins in these regions, making it harder to rescue stalled forks 
(Debatisse, Le Tallec et al. 2012). Recent research has linked these fragile sites 
with transcription. These sites overlapped with extremely long genes which means 
that transcription will take a long time to fully transcribe one of these genes. A study 
done in CSF’s showed that transcription was happening at the same time as 
replication, indicating that the increased breakages may be due to increased 
transcription-replication interference (Helmrich, Ballarino et al. 2011). Additional 
research showed that these CSF’s were enriched for long genes and indicates that 
the reason for increased fragility is linked to transcription (Le Tallec, Millot et al. 
2013). Similar findings were found with ERFS sites where these sites overlap with 
transcribed genes that are highly expressed again linking the fragility of these sites 
with transcription (Barlow, Faryabi et al. 2013). I will describe transcription-









1.4.7: Transcription-replication conflicts. 
 
A major cause of replication stress in cells is the conflicts that occur between the 
two processes of replication and transcription (Bermejo, Lai et al. 2012). Cells have 
tried to develop a variety of mechanisms to reduce and prevent these collisions 
including co-orientating these processes or genome organization (Merrikh, Machon 
et al. 2011, García-Muse and Aguilera 2016). Replication fork collisions with 
transcription will occur because both processes act on DNA, and as transcription is 
needed for cell survival and viability while replication is required for cell proliferation 
(Helmrich, Ballarino et al. 2013). The interference between both mechanisms is 
particularly common in eukaryotic cells as eukaryotic cells fire multiple origins 
(Bermejo, Lai et al. 2012). DNA replication only requires a single replisome on the 
DNA to be replicated, however when transcribing a gene multiple RNA Pol are 
present to ensure a gene is fully transcribed. Hence when a replisome encounters 
the first RNA Pol it can’t replicate further as there are multiple RNA Pol’s present 
behind the first RNA Pol hence replication is impeded (Azvolinsky, Giresi et al. 
2009, Merrikh, Machon et al. 2011). 
Conflicts between transcription and replication can occur in two orientations (figure 
1.19) (García-Muse and Aguilera 2016). A head-on orientation conflict means the 
replisome and RNA Pol are moving in opposite directions occurs on the lagging 
strand, hence both the replisome and the RNA Pol ll clash against each other on the 
DNA, which will lead to fork stalling and replication stress (Prado and Aguilera 2005, 
Poveda, Le Clech et al. 2010). This will also lead to the dissociation of the 





collapsed fork (Prado and Aguilera 2005, Poveda, Le Clech et al. 2010). Further 
studies have shown that transcription can enhance recombination in a process 
called transcription associated recombination (TAR). Increased TAR requires both 
increased amounts of transcription and the cell being in S-phase (Gottipati, Cassel 
et al. 2008). As I will describe later in this chapter, recombination is an important 
factor in dealing with stressed forks and DSB’s, indicating that head-on collisions 










Figure 1.19: Diagram illustrating how transcription-replication can occur in cells. 
These collisions can either happen in two orientations: head on and co-directional. 
 
The other orientation these conflicts can occur is co-directional orientation occurring 
on the leading strand. Both the RNA Pol and replisome occur in the same direction 
and if the replisome moves faster than RNA Pol it can cause conflicts with the RNA 
Replisome 


















Pol (Mirkin and Mirkin 2007, Soultanas 2011). These conflicts can be resolved by 
the removal of the RNA Pol from the DNA. Co-directional conflicts can also lead to 
fork stalling and induce DNA breaks (Merrikh, Machon et al. 2011). Research has 
shown that conflicts in the head-on orientation can have a much more dramatic 
effect on replication and genome stability (Prado and Aguilera 2005, Srivatsan, 
Tehranchi et al. 2010).  
There is also evidence that when these two processes come together this leads to 
replication stress in an indirect mechanism before the replication and transcription 
machineries even meet. This may include R-loop formation, DNA secondary 
structures such as G quadraplexes and or topological stress from supercoiling 
(Huertas and Aguilera 2003, Tuduri, Crabbe et al. 2009, Aguilera and Garcia-Muse 
2012, Alzu, Bermejo et al. 2012, García-Muse and Aguilera 2016). 
When replication and transcription converge in a head-on orientation it can lead to 
the formation of torsional stress via supercoiling (García-Muse and Aguilera 2016). 
Research has shown that enzymes such as helicases and topoisomerases relieve 
stress and prevents these collisions (Bermejo, Doksani et al. 2007, Tuduri, Crabbe 
et al. 2009, Alzu, Bermejo et al. 2012). This shows that the torsional stress 











RNA: DNA hybrids form naturally during transcription and replication. These formed 
hybrids are usually short, however longer forms can be generated. These longer 
forms are generated when the nascent RNA can be hybridised with the template 
DNA during transcription leaving a displaced ssDNA (Huertas and Aguilera 2003). 
These forms are known as R-loops and form when the nascent RNA exits the RNA 
Pol (Huertas and Aguilera 2003). There are different situations where-in R-loop 
formation can be favoured such as DNA supercoiling, high G content or whether 
there are nicks in the DNA (Huertas and Aguilera 2003). 
R-loops have been shown to have a number of roles in cells including: regulating 
gene expression, DNA replication and DNA repair (Costantino and Koshland 2015, 
Sollier and Cimprich 2015). R-loops have been linked to causing DNA damage 
(Bermejo, Capra et al. 2011, Aguilera and Garcia-Muse 2012, Sollier, Stork et al. 
2014). An experiment overexpressing RNaseH1, which helps resolve R-loops, in 
cells with high levels of R-loops showed a decrease in DSB marker γH2AX 
(Chernikova, Razorenova et al. 2012). This implies R-loops as a source of DNA 
damage in the cell. Further studies have strengthened the link between R-loops and 
DNA damage, including genome wide screens that show DNA damage being 
supressed in a ribonuclease H (RNase H) dependent manner (Paulsen, Soni et al. 





Studies have indicated that R-loop formation can hamper on-going replication fork 
progression and induce DNA breakage (Aguilera and Garcia-Muse 2012, Sollier, 
Stork et al. 2014). As mentioned earlier, research has shown that the fragility of 
CFSs and ERFs can be due to the increased number of collision between 
replication and transcription (Helmrich, Ballarino et al. 2011, Barlow, Faryabi et al. 
2013). Indeed studies have shown that inhibiting replication in either yeast or 
human cells can prevent the DSB DNA damage caused by R-loop formation 
(Wellinger, Prado et al. 2006, Tuduri, Crabbe et al. 2009, Gan, Guan et al. 2011). 
This indicates that the interference between replication and R-loops is leading to R-
loop associated DNA damage.  
Overall, R-loops are an emerging source of induced DNA damage and genomic 
instability in the cell. Research has shown that R-loops are directly involved in 
transcription-replication interference and cause fork stalling and could be a major 
source of DNA breaks in the cell. 
As transcription replication conflicts and R-loops can provide a major problem for 
the cell, pathways have evolved to try and prevent these collisions and to resolve R-
loops. These factors include RNA Pol backtracking using GreA and GreB to help 
allow reactivation of transcription (Pomerantz and O'Donnell 2010, Tehranchi, 
Blankschien et al. 2010, Dutta, Shatalin et al. 2011). Replication fork barrier which 
prevents collisions in budding yeast which requires RFP protein FOB1 (Torres, 
Bessler et al. 2004, Merrikh, Brewer et al. 2015). FACT which remodels chromatin 
to allow both processes to occur without collisions (Abe, Sugimura et al. 2011, 





There are many different ways in which cells have now adapted to try and prevent 
excessive R-loop formation. As mentioned earlier R-loops can be resolved by 
RNase H enzymes of which there are two types 1 and 2 (Wahba, Amon et al. 2011). 
These enzymes act by degrading the RNA in the RNA: DNA hybrids. Helicases are 
also known to help prevent R-loop formation. Some examples of helicases that can 
prevent R-loops are the DHX9 RNA helicase and the SETX RNA-DNA helicase. 
The SETX helicase has functions that remove R-loops and resolving transcription-
replication conflicts (Skourti-Stathaki, Proudfoot et al. 2011). DHX9 helicase 
preferably unwinds R-loops and G-quadraplexes and is involved in resolving 
transcription-replication conflicts (Chakraborty and Grosse 2011). The presence of 
RECQL5 helicases which recent studies show that can help prevent excessive R-
loop formation (Li, Xu et al. 2011, Li, Pokharel et al. 2015). Topoisomerase 
enzymes help supress excessive R-loop formation by relieving torsional stress 
behind the RNA Pol (Tuduri, Crabbé et al. 2009, Yang, McBride et al. 2014). 
 
1.4.9: Increased transcription causing replication stress 
 
Replication-transcription interference has now been identified as a main source of 
replication blockages to ongoing replication (Kotsantis, Silva et al. 2016, Stork, 
Bocek et al. 2016, Gorthi, Romero et al. 2018, Lavado, Park et al. 2018, Nojima, 
Tellier et al. 2018). Recently, there have been a growing number of studies 
illustrating that an increase in transcription activity from steady state levels can 





In a recent project in our lab, increasing levels of oncogenic HRAS was shown to 
lead to increased RNA synthesis in the cell (Kotsantis, Silva et al. 2016). Further 
experiments using DNA fibre analysis illustrated that ongoing DNA replication was 
being stalled and slowed down at the same time. By inhibiting transcription in 
conjunction with HRAS induction it was shown that this replication stress phenotype 
could be rescued towards control levels (Kotsantis, Silva et al. 2016).  
Overexpression of transcription factor TBP further illustrated that increased RNA 
synthesis in a cell could directly lead to increased replication stress. Further work 
done in this project also illustrated the importance of increased R-loop formation. 
Cells overexpressing HRAS were shown to lead to increased R-loop formation. 
Using DNA fibre analysis, they showed a rescue of normal fork speeds in cells with 
overexpressed HRAS which were treated with RNase H1 to suppress R-loops. This 
showed that increased R-loop formation in cells can lead to increased replication 
stress (Kotsantis, Silva et al. 2016).  
More studies have highlighted similar findings. A recent study showed that loss of 
SPT6 could lead to increased transcription and R-loop formation. This led to 
increased replication stress and DNA damage in the cell (Nojima, Tellier et al. 
2018). The hormone estrogen (E2) induces increased transcription and R-loops in 
cells leading to replication stress, which can be alleviated by RNase H1 (Stork, 
Bocek et al. 2016). A recent study saw that activation of transcription co-activators 
YAP/TAZ, regulated by the Hippo pathway, leads to increased transcription in the 
cell. This increased transcription led to increased replication stress, DNA damage 
and apoptosis (Lavado, Park et al. 2018). This increased transcription in cells has 





protein caused increased transcription levels and R-loops in the cells, leading to 
increased replication stress and impaired homologous recombination (HR) (Gorthi, 
Romero et al. 2018).  
These findings illustrate the importance of increased transcription in the cell in terms 
of replication stress. These studies show evidence that when increased 
transcription is induced in cells that it can directly lead to replication stress. 
Alleviating this increase in transcription can restore normal replication progression 
and loss of replication stress.  
 
1.4.10: Replication stress and genomic Instability 
 
Genomic instability is one of the hallmarks of most cancer cells. Cancer is a broad 
term to describe a range of conditions that have abnormal cell growth and 
proliferation or an inability to regulate these processes. Cells have a myriad of 
signalling pathways to control cell division and growth which when dysregulated can 
give rise to uncontrollable cell growth and lead to tumour formation, For the onset of 
tumorigenesis to happen there must be a cascade of numerous events for the onset 
to begin. One major event that often occurs is genomic instability.  
Genomic stability is described as either the loss or gain of genetic material either 
through mutations or chromosomal rearrangements including translocations, 
deletions and inversions (Hanahan and Weinberg 2000, Hoeijmakers 2001). 
Genomic instability can arise most commonly from faulty DNA repair or DNA 





mutation in genes encoding for DNA repair or mutations in genes controlling cell 
division or tumour suppressor genes. Defects in processes such as the DDR, cell 
cycle checkpoints or cellular senescence/cell death pathways can help result in 
accumulation or transmission of DNA damage leading to genome instability and 
onset of tumorigenesis.  
Replication stress can lead to breakage, chromosomal rearrangement or mis-
segregation of chromosomes (Hills and Diffley 2014). Increased DNA damage will 
lead to increased replication stress which can be defined as a source of genomic 
instability and is often seen in cancerous cells (Gaillard, Garcia-Muse et al. 2015). 
There are numerous pathways that can deal with replication stress to try and protect 
genome stability by protecting stressed replication forks and allowing faithful 
replication. Further repair mechanisms help cells deal with consequences of 
replication stress such as DSB’s to prevent increased genomic instability. Overall 
increased replication stress leads to persistent stalling and either ssDNA gaps or 
breakage which can in turn generate genomic instability in the cell (Hills and Diffley 






1.5: Cell response to replication stress  
 
1.5.1: DNA damage overview 
 
To allow DNA to be replicated each cell cycle faithfully, the cell has a series of DNA 
replication stress and DNA damage response pathways to help facilitate cell cycle 
arrest and DNA repair and ensure DNA replication restart.  
To allow for these pathways to be activated, signalling is required which in the case 
of the DNA damage response involves phosphorylation by specific kinases. The 
three kinases that control the signalling pathway are DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs), ATR and ATM (Ciccia and Elledge 2010). These 
three kinase respond to specific types of damages, in the case of ATM and DNA-PK 
this is mainly DSBs and in the case of ATR it is persistent ssDNA (although there is 
crosstalk between the three kinases), and set in motion the response to deal with 
the damage by phosphorylating a myriad of different downstream proteins (Ciccia 
and Elledge 2010, Blackford and Jackson 2017).  
 
1.5.2: Replication stress response overview 
 
If replication stress is persistent it can cause fork collapse and formation of DSBs, 
or under-replicated DNA can lead to the development of DNA damage, mutations 
and disease. Ultimately replication stress can lead to cell death via collapsed forks 





catastrophe. Understanding how BET inhibition can lead to tumour cell death and 
senescence would be crucial for eventual future clinical applications. 
 
1.5.3: Replication stress response 
 
Replication fork stalling has the potential to lead to the generation and persistence 
of ssDNA at the replication fork (Cimprich and Cortez 2008). This ssDNA occurs as 
the replicative helicase (MCM helicase) still continues to unwind DNA, while the 
replicative polymerase has stalled (Pacek and Walter 2004). The continuing 
presence of ssDNA leads to it being bound by RPA which acts as a signal for the 
activation of the replication response pathway (Byun, Pacek et al. 2005). The 
presence of RPA-bound ssDNA will signal to recruit and activate a number of 
replication stress response proteins, including the protein kinase ATR. The ATR 
kinase is a serine/threonine kinase and a member of the PI3K like protein kinase 
family. ATR will bind to the RPA coated ssDNA via its partner protein ATR 
interacting protein (ATRIP) (Zou and Elledge 2003). ATR-ATRIP recruitment does 
not lead to full activation of ATR. In addition, the RPA-coated ssDNA allows the 
binding of the RAD17-RFC2-5 clamp loader. The RAD17-RFC2-5 clamp loader can 
then load PCNA-related, RAD9-HUS1-RAD1 (9-1-1) heterotrimer leading to the 
activation of TOPBP1 which can stimulate ATR kinase activity leading to optimal 
activation of ATR (Cimprich and Cortez 2008). 
ATR is crucial for the survival of proliferating cells and in allowing cells to deal with 





pathway is not present, there is an increase of genome instability during S phase of 
cell cycle indicating the importance of the ATR pathway in keeping the genome 
stable during DNA replication (Flynn and Zou 2011). ATR activation leads to 
phosphorylation of factors that can help stabilise forks that have encountered 
stress, factors that help fork repair, fork recovery and forks restart to counter 
replication stress. One such factor is histone H2AX, which is phosphorylated by 
ATR to form γH2AX. Activation of ATR substrates allow the cell to complete DNA 
replication faithfully and promotes cell survival (Buisson, Boisvert et al. 2015). A 
major kinase activated by ATR is CHK1 via Claspin phosphorylation (Cortez, 
Guntuku et al. 2001). CHK1 is phosphorylated specifically on its serine residues 317 
and 345 by the ATR kinase (Liu, Guntuku et al. 2000). Further factors that increase 
CHK1 activation have been discovered such as DONSON, Timeless, TIPIN and 
RAD17 (Bao, Tibbetts et al. 2001, Unsal-Kacmaz, Chastain et al. 2007, Reynolds, 
Bicknell et al. 2017). CHK1 leads to fork stabilisation and inhibits cell cycle 
progression by activating cell cycle checkpoints which allows time for the replication 
stress to be dealt with before going through another cell cycle (Gonzalez Besteiro 
and Gottifredi 2015). CHK1 also inhibits firing of new origins to prevent additional 
replication forks from encountering blocks and give the cell more time to repair the 
damage (Yekezare, Gómez-González et al. 2013). ATR pathways can lead to fork 
stabilisation and if the replication stress source can be eradicated then replication 







   
 
 
Figure 1.20: Diagram illustrating the process of the replication stress response in 














Replisome encounters obstacle. Can lead to 





There are many mechanisms that may lead to the restart of replication which 
include: firing of dormant origins, repriming at the replication fork, reversing the 
stalled fork which will be discussed later, or activation of DNA damage tolerance 
pathways which help bypass lesions (Elvers, Johansson et al. 2011, McIntosh and 
Blow 2012, Mailand, Gibbs-Seymour et al. 2013). If the replication stress response 
does not stabilise the replication fork and the replication stress is persistent, the fork 
is susceptible to collapse which can lead to the formation of a DSB at the fork 
(Sirbu, Couch et al. 2011). The mechanism that leads to the formation of DSB is still 
under investigation. There is mounting evidence that persistent stalled forks can be 
subject to recombination pathways which can form structures that are vulnerable to 
endonucleoytic attack by endonucleases such as Mus81 (Hanada, Budzowska et al. 
2007, Petermann, Orta et al. 2010, Schlacher, Christ et al. 2011). I will discuss this 
in much more detail later in this chapter. In addition, persistent ssDNA or stalled 
forks can also be subject to endonucleolytic attack or even subject to passive 
breakage leading to break formation (Lopes, Cotta-Ramusino et al. 2001, Sogo, 
Lopes et al. 2002, Lopes, Foiani et al. 2006).  
 
1.5.4: Double strand break repair overview 
 
DSBs are toxic lesions for cells, which have evolved a variety of different repair 
mechanisms to deal with their formation. There are four major mechanisms to allow 
for DSB repair: Non-homologous end joining (NHEJ), HR, alternative-NHEJ (alt-





recognised and sensed by different proteins depending on context. This can lead to 
a signalling pathway that requires recruitment of a myriad of different signalling and 
effector proteins. This initial sensor can set up a pathway to help trigger DSB repair 
in the cell. DSB repair also requires a host of different PTMs to the chromatin and 
repair proteins around the lesion to facilitate fast and accurate repair (Bekker-
Jensen, Lukas et al. 2006, Bekker-Jensen and Mailand 2010, Ciccia and Elledge 
2010). 
 
1.5.5: Non-homologous end joining 
 
NHEJ is a DSB repair pathway that can occur throughout the cell cycle. NHEJ 
allows a rapid but more error-prone repair of DSBs involving re-ligation of the 
broken ends of the DNA. Here DSB are sensed by KU70/80 which bind to DSB 
ends (Walker, Corpina et al. 2001, Mahaney, Meek et al. 2009). KU70/80 can 
recruit and activate DNA-PKcs, forming DNA-PK which initiates NHEJ. DNA PK 
stabilizes DSB ends by preventing DNA end resection (Mahaney, Meek et al. 2009). 
DNA-PK can then auto-phosphorylate on its ABCDE cluster, allowing dissociation 
from DSB ends. This allows ARTEMIS, an end processing enzyme, to access DSB 
ends (Meek, Dang et al. 2008). XLF and XRCC4/DNA Ligase 4 is recruited by DNA-
PK and functions to re-ligate the broken ends (Koch, Agyei et al. 2004, Mahaney, 








1.5.6: Homologous recombination 
 
Homologous recombination is a DSB repair mechanism that occurs during the S/G2 
phases of the cell cycle and uses identical sister chromatids as a template for repair 
(Rothkamm, Kruger et al. 2003). Unlike NHEJ, HR is an error-free type of repair 
(You, Chahwan et al. 2005). The MRE11-NBS1-RAD50 (MRN) complex can be 
recruited to DSBs that are required to be repaired by HR and set of a signal 
cascade to allow for HR-mediated repair (Williams, Williams et al. 2007). MRN is 
composed of three components RAD50, MRE11 and NBS1, all of which have 
different roles in HR repair. MRE11 is crucial to enable the first steps of DNA 
resection, which is a crucial process for HR repair, and contains both exonuclease 
and endonuclease activity to help it carry out this function (Williams, Williams et al. 
2007). RAD50 functions both to interact with MRE11 via its ATPase domains and to 
bind to DSB ends (Williams, Williams et al. 2007). NBS1 interacts and binds to ATM 
through its C-terminal end, allowing for MRN to be able to recruit ATM to the DSB 
(de Jager, van Noort et al. 2001, Paull and Lee 2005, Jazayeri, Falck et al. 2006). 
ATM recruitment is critical to help regulate the process of DNA end resection and 
functions to recruit Ct-BP interacting protein (CtIP), which is a nuclease, to the DSB 
(Sartori, Lukas et al. 2007, You, Shi et al. 2009). CtIP interacts with both MRN and 
also with Breast cancer type 1 susceptibility protein (BRCA1), allowing for the 
formation of the BRCA1-C complex (Sy, Huen et al. 2009). The BRCA1-C complex 
functions to regulate the initial stages of resection at the DSB. Before this initial 





as P53 Binding protein 1 (53BP1) which helps promote NHEJ by stopping resection 
of DSB ends (Bunting, Callen et al. 2010). Studies have shown that the removal of 
53BP1 to allow for DSB end resection can be mediated by the BRCA1-C complex 
(Bunting, Callen et al. 2010, Densham, Garvin et al. 2016). Another complex that is 
vital in the resection process is the BRCA1-BARD1 E3 ligase enzymatic activity 
(Densham, Garvin et al. 2016). The BRACA1-BARD1 complex help promotes 
extended resection by helping reposition 53BP1 by SMCARCAD1 chromatin 
remodelling (Densham, Garvin et al. 2016). After the initial DNA resection has been 
completed, extensive resection at the DSB needs to occur. This extended resection 
of the DSB can be mediated by Exonuclease 1 (EXO1), DNA2 and Bloom 
syndrome RecQ like helicase (BLM). Their activation is mediated via ATM 
phosphorylation which also allows for their recruitment to the DSB and therefore 
facilitates for extended resection to take place (Cejka, Cannavo et al. 2010). 
Resection of the DSB leads to the formation of a 3’ssDNA overhang. Exposed 
ssDNA after resection is recognized and bound by RPA. RPA can thereby act to 
protect and stabilize the exposed ssDNA (Wold 1997). RAD51 homolog 1 (RAD51) 
can then replace the RPA bound to ssDNA (West 2003). Breast cancer type 2 
susceptibility protein (BRCA2) is important for HR to take place. BRACA2 can 
recruit and interact with RAD51 and helps facilitate with the loading RAD51 to 
ssDNA (Davies and Pellegrini 2007, Esashi, Galkin et al. 2007). The requirement of 
phosphorylation of RAD51 by CHK1 allows for increased regulation of RAD51 
recruitment to the DSB. Further regulation of RAD51 can also occur by 
phosphorylation by both DSS1 and RAD52 (Sugiyama and Kowalczykowski 2002, 





RAD51 molecules allows for strand invasion into the homologous sequences of the 
template sister chromatid, causing D-loop formation (West 2003, San Filippo, Sung 
et al. 2008). The invading strand can be extended at the 3’ end by DNA 
polymerases until the DNA missing at the break is newly synthesised. The newly 
synthesised DNA can then be reannealed to the processed other end of the break 
(West 2003). This process can be performed by synthesis-dependent strand 
annealing (SDSA) or by second-end capture. Holiday Junctions (HJ) are formed 
after strand invasion and D-loop formation, as well as after second-end capture 
(West 2003, San Filippo, Sung et al. 2008). BLM helicase and Topo IIIα are able to 
dissolve the HJ structure avoiding the need for endonuclease cleavage (Wu and 
Hickson 2002). HJ can also be resolved by the action of endonucleases such as 
MUS81/MMS4, GEN1 or SLX1/SLX4 which by cleaving DNA can either lead to 
genetic information being crossed over between the two sister chromatids, or to the 



















1.5.7: HR at replication forks 
 
Recently, HR and its factors have been shown to play roles at replication fork 
processes such as replication stress in addition to DSB repair. HR has been shown 
to be activated in response to replication stress inducing compounds such as HU or 
thymidine. Here HR proteins such as RAD51 or BRCA2 can be recruited to stalled 
forks (Petermann, Orta et al. 2010, Kolinjivadi, Sannino et al. 2017). When these 
factors bind they can induce recombination and HR at these forks leading to 
prevention of fork collapse and potentially fork restart (Arnaudeau, Lundin et al. 
2001, Lundin, Schultz et al. 2003, Carr and Lambert 2013, Willis, Chandramouly et 
al. 2014). 
Stalled forks can be restarted either in the presence or absence of DSB formation. 
When the replication fork encounters stress through a blockage a one-ended DSB 
can be formed through specific fork cleavage. One-ended DSB can only be repaired 
through an HR-mediated fork restart mechanism called break-induced replication 
(BIR) (Hanada, Budzowska et al. 2007, Pepe and West 2014). RAD51 is crucial in 
this process as it is loaded onto a resected ssDNA end at the one-ended DSB and 
can stimulate strand invasion and homology searching (Chung, Zhu et al. 2010). 
This leads to D-loop formation, as seen in HR before, which allows for DNA 
replication to start re-synthesising, hence restarting the replication fork (Lydeard, 
Jain et al. 2007, Hashimoto, Puddu et al. 2012, Costantino, Sotiriou et al. 2014). 
There are two models that have been described to how DNA synthesis is continued: 





2010, Donnianni and Symington 2013). The end result of BIR is complete DNA 
replication of the dsDNA.  
Stalled forks do not necessarily require the formation of DSBs to allow fork restart 
via HR. Recent studies have indicated a role for replication restart requiring HR 
without the formation of a DSB (Lambert, Mizuno et al. 2010, Petermann, Orta et al. 
2010). This suggests a novel role of RAD51 in restarting forks in a DSB 
independent manner, differing from its role in BIR mediated restart. This model 
required RAD51 to bind to ssDNA and lead to formation of a HJ (Petermann, Orta et 
al. 2010). The exact mechanism will be described in more detail below. 
Recently a study showed that replication fork reversal happened in response to a 
variety of different genotoxic sources causing replication stress. Replication stress 
lead to the persistence of ssDNA accumulation which acted as a precursor for fork 
reversal upon different types of genotoxic stress (Zellweger, Dalcher et al. 2015). 
This study identified HR factor RAD51 as a cellular factor helping cells deal with 
replication stress by inducing the replication fork reversal process. This study also 
showed an important role of RAD51 in slowing down forks in response to genotoxic 










1.5.8: Replication fork reversal 
 
As previously mentioned, fork reversal can occur in order to help prevent formation 
of DSBs and restart replication forks after they have encountered replication stress 
(Ciccia and Elledge 2010). 
Replication fork reversal describes the process of the conversion of a normal 
replication fork (three-way junction) into a four-way junction (chicken foot structure). 
This can occur via the annealing of the newly synthesised strands with the re-
annealing of the parental strands (Neelsen and Lopes 2015). Reversed forks were 







   
 
Figure 1.22: Model of fork reversal, regression and protection.  
 
By allowing replication fork reversal, cells prevent increased genomic instability as 
these structures are stable thereby allowing more time for the block to be removed 
or DNA to be repaired (Branzei and Foiani 2010). Fork reversal keeps these DNA 
replication forks not only stable but also in a paused structure which helps to 
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to be formed. This helps the cell to either repair or bypass the lesion without having 
to deal with more complex and toxic lesions such as DSBs (Neelsen and Lopes 
2015). 
The frequency of reversed forks can be dependent on cell type, for instance in 
embryonic stem (ES) cells the frequency of fork reversal is 30% compared to 8% 
seen in somatic cells (Ray Chaudhuri, Ahuja et al. 2015). These higher reversal 
rates seen in ES cells may be due to the cells having increased amounts of ssDNA 
gaps as well as increased expression levels of two key proteins involved in fork 
reversal RAD51 and RPA (Ray Chaudhuri, Ahuja et al. 2015). 
Recent research has identified a number of different proteins that are involved in the 
fork reversal process. One such protein mentioned before is the HR factor 
recombinase RAD51. RAD51 has been elucidated to be able to convert uncoupled 
forks (with extended ssDNA stretches) to reversed forks after treatment with a 
variety of different genotoxic sources causing various DNA damage as mentioned 
earlier (Zellweger, Dalcher et al. 2015). How RAD51 promotes reversed forks is still 
being further investigated, but it may act in combination with other enzymatic 
activities. Reports have stated that potentially RAD51 and RAD54 may work in 
combination to promote fork regression (Bugreev, Rossi et al. 2011). F-box DNA 
helicase 1 (FBH1 helicase), Poly-ADP ribose-polymerase 1 (PARP1), SMARCAL1 
and ZRNAB3 are other proteins that have been identified to play a role in replication 
fork reversal (Berti, Ray Chaudhuri et al. 2013, Couch, Bansbach et al. 2013, 
Fugger, Chu et al. 2013). Studies have shown that FBH1 promotes fork reversal in 
a helicase dependent manner (Masuda-Ozawa, Hoang et al. 2013, Fugger, Mistrik 





dependent DNA helicase Q1 (RECQ1) helicase which functions to resolve reversed 
fork structures as will be discussed later on as well as by promoting branch 
migration which describes a process where homologous strands successively 
exchange their base pairs at a HJ (Berti, Ray Chaudhuri et al. 2013). SMARCAL1 
can bind to both three-way and four-way junctions and reverse forks by fork 
regression and branch migration (Betous, Mason et al. 2012). Studies have shown 
that also zinc finger RNA-binding domain containing 3 (ZRANB3) is involved in 
promoting reversed forks (Couch, Bansbach et al. 2013). ZRANB3 can recognize 
forks encountering replication stress by interacting with polyubiquitinated PCNA and 
remodel forks by its DNA translocase activity (Vujanovic, Krietsch et al. 2017). 
Although fork reversal can act as a protective process to prevent more toxic lesions, 
they can also be vulnerable to hyper-resection by a number of nucleases which can 
lead to increased genomic instability (Schlacher, Christ et al. 2011, Schlacher, Wu 
et al. 2012). When reversed forks are formed, the nascent DNA has to be protected 
from unregulated degradation by nucleases to allow for DNA repair and fork restart. 
BRCA2 is a protein whose involvement is critical in helping stabilize the nascent 
DNA and prevent hyper resection at persistently stalled forks (Schlacher, Christ et 
al. 2011). Research showed that cells deficient in BRACA2, were subject to 
MRE11-dependent hyper-resection leading to nascent DNA degradation and 
increased genomic instability (Schlacher, Christ et al. 2011).  
A plethora of studies have highlighted the importance of RAD51 in protecting stalled 
replication forks from hyper-resection. Firstly, RAD51 was shown to protect nascent 





Chaudhuri et al. 2010). A study conducted with mammalian cells deficient of RAD51 
paralog RAD51C were again subject to increased hyper-resection (Somyajit, 
Subramanya et al. 2012). Further studies again showed the importance of RAD51 
as well as identifying additional HR factors such as FANCD2 and BRCA1 in 
protecting newly synthesised DNA from hyper-resection (Schlacher, Wu et al. 
2012). If cells were deficient in any of the three proteins it lead to increased 
degradation of newly synthesised DNA via hyper resection (Schlacher, Wu et al. 
2012). 
More factors recently have been identified involved in protecting stalled forks and 
preventing genomic instability. These include BOD1L which functions to stabilise 
RAD51 binding at the reversed fork as well as preventing DNA2 hyper-resection. 
Cells lacking BOD1L have increased degradation of nascent DNA and increased 
genomic instability (Higgs, Reynolds et al. 2015). Another factor is WRNIP which 
protects nascent DNA by again stabilizing RAD51 binding as well as being involved 
in allowing replication fork restart of stalled forks (Leuzzi, Marabitti et al. 2016).  
Interestingly, PARP1 also has a role in stabilising stalled replication forks (Ding, Ray 
Chaudhuri et al. 2016). PARP1 inhibition or depletion reduced MRE11 hyper-
resection in cells without BRCA2, and hence rescued cell viability (Ding, Ray 
Chaudhuri et al. 2016). Overall the research shows the importance of factors 
BRCA1, BRCA2, RAD51, SMARCAL1, ZRANB3 and PARP1 in replication fork 








1.5.9: Fork restart 
 
Once a fork is reversed it needs to be able to restart which requires the four-way 
junction to revert back to the three-way junction. As previously mentioned, RECQ1, 
an ATP-dependent DNA helicase, is the main factor involved in restoring reversed 
forks. Research showed that RECQ1 restarted reversed forks after Top 1 inhibition 
either by its ATPase dependent mechanism or by promoting branch migration 
(Berti, Ray Chaudhuri et al. 2013).  
PARP1 can suppress fork restart as PARP1 can inhibit RECQ1 (Berti, Ray 
Chaudhuri et al. 2013). Further research identified additional factors DNA2 nuclease 
and Werner syndrome ATP-dependent helicase (WRN) which can help promote 
fork restart after genotoxic prolonged stalling (Thangavel, Berti et al. 2015). Both of 
these factors help restart stalled replication forks via their regulated ATPase 
mediation degradation of the regressed arm (Thangavel, Berti et al. 2015).  
After reversed forks have been resected and processed, RAD51 and XRCC3 can 
be recruited and fork restart can occur where the replication fork is returned back to 
a three-way junction (Petermann, Orta et al. 2010, Carr and Lambert 2013). The 
mechanism of how regressed forks are formed, controlled and reversed requires 







Previous work from the lab had shown a potential role for BET proteins in DNA 
replication. Treatment with BET inhibitor JQ1 in Nalm6 cells led to replication fork 
slowing, indicating replication stress. Understanding of the roles of BET proteins in 
processes such as DNA replication and DNA damage is vital for clinical 
applications. As such, the aims of this study were as follows: 
 
 To investigate whether BET inhibitors slow replication fork speeds across a 
number of cell lines. 
 To investigate the mechanism by which loss of BET activity causes 
replication fork slowing. 
  To investigate which specific BET protein is required to maintain replication 
fork speeds. 
 To investigate the DNA damage response to BET inhibitor-induced 





2  Materials and methods 
 
  2.1: Buffers and chemicals 
 
2.1.1: General buffers 
 
PBS 1X: 
1 Phosphate buffered saline (PBS) tablet (Sigma) in 200ml H2O 
 
LB broth: 
10 g Luria Bertani (LB) Broth powder (Thermo Fisher) in 400 ml H2O 
 
LB agar: 
400 g LB agar powder (Thermo Fisher) in 400 ml H2O 
 





JQ1 1 µM BET inhibitor Tocris 
IBET-151 1 µM BET inhibitor Tocris 
DRB 100 µM RNA Pol 2 inhibitor, 
weak RNA Pol 1 
inhibitor 
Sigma 
α-amanitin 10 µg/ml Strong RNA Pol 2 
inhibitor, weak RNA 
Pol 3 inhibitor 
Sigma 
Triptolide 1 µM RNA Pol 2 and RNA 






Roscovotine 25 μM Cdc2, CDK2 and 
CDK5 inhibitor 
Sigma 
RO-3006 10 μM CDK 1 inhibitor Sigma 
PHA-767491 10 μM Cdc7/CDK9 inhibitor Tocris 
HYDROXYUREA 
(HU) 
2 mM Ribonucleotide 
reductase 
Sigma 
Camptothecin 1 µM Topoisomerase I 
inhibitor 
Sigma 
Etoposide 25µM Topoisomerase II 
inhibitor 
Sigma 
HMBA 5-10 mM HEXIM1 inducer Sigma 
CldU 25 µM Thymidine analogue Sigma 
IdU 250 µM Thymidine analogue Sigma 
Olaparib 5 µM PARP inhibitor Selleckchem 
CX-5461 100 µM RNA Pol 1 inhibitor Medchem 
Express 
ML-60218 100 µM/ 25 µM RNA Pol 3 inhibitor Cayman Chemical 
AZ20 2.4 µM ATR inhibitor Tocris 
ML216 1.4 µM BLM inhibitor Sigma 
PD-407824 300nM CHK1 inhibitor Tocris 
 








2.2: Bacterial work 
 
2.2.1: Bacterial transformation 
 
100 ng of the required plasmid was transferred to thawed One Shot TOP10 
chemically competent E. coli High copy Plasmid (Fisher) of around 25 µl and 
incubated on ice for around 20 mins. Bacteria were than heat shocked for exactly 
30 seconds at 42°C before being transferred back onto ice for another 2 mins. This 
was followed by addition of 250 µl of pre-warmed S.O.C media (Fisher) to the 
bacterial cells before being placed in a 37°C shaker for around 1 hour of recovery. 
LB agar plates either containing ampicillin (Sigma, 50 µg/ml) or kanamycin (Alfa 
Aesar, 50 µg/ml) depending on which antibiotic resistance the transformed plasmin 
contained were pre-made up-to a month before. Cells were then spread on these 
plates and incubated overnight at 37°C incubator.  
 
2.2.2: Maxi-prep plasmid preparation 
 
Bacterial colonies were selected from the plates and were grown in 200-400 ml of 
Luria Bertani (LB) media overnight at 37°C and shaking at 200 rotations per minute 
(rpm). Once the bacterial cultures were grown, they were spun down for 10 mins at 
4000 rpm to form a bacterial pellet. The supernatant was removed and extracting 
the DNA was carried out using the PureLink HiPure Plasmid Filter Maxi-prep kit 






2.2.3: DNA quantification 
 
Following DNA purification, the DNA was quantified using a Labtech 
Spectrophotometer with ND-1000 software. Blank measurements were taken using 
1 μl of TE buffer 1x which the plasmids were re-suspended in. 1 μl of the DNA 
sample was used to measure the concentration.  
 
2.3: Cell culture methods 
 
2.3.1: Cell culture 
 
MEC1 and C2 suspension cell lines were grown in Roswell Park Memorial institute 
(RPMI) 1640 medium (Life Technologies) supplemented with 10% Fetal Bovine 
Serum (FBS, Sigma), 1% Penicillin streptomycin (Sigma). Cells were grown in a 
humidified atmosphere at 37°C containing 5% CO2. Cells were cultured in T-75 
flasks and passaged twice a week to prevent cells growing too confluent. Passaging 
involved discarding some cells in media from the flask before adding more fresh 
media to rest of cells left in the flask. Cells were passaged once every three to five 
days depending on confluency. 
Adherent U2OS and human BJ-hTERT (ATCC) cell lines were grown in Dulbecco’s 
Modified Eagle Medium (DMEM, Sigma) with 10% FBS supplemented with 1% l-
glutamine (Sigma) and 1% Penicillin streptomycin. Cells were grown at 37°C in a 
humidified atmosphere containing 5% CO2. Cells were cultured in T-75 flasks and 





cells with 1x PBS before trypsinizing the cells by adding 1x Trypsin before 
incubating at 37°C until all cells have fully detached. Cells were passaged once 
every two to three days depending on confluency. 
  
2.3.2: siRNA transfection 
 
Small interfering RNA (SiRNA) targeting BRD4, BRD3, BRD2, HEXIM1, RAD51, 
SMARCAL1 and ZranB3 and control siRNA was used in this project.  
 
Table 2.2: siRNA sequence or catalogue number. 
 
U2OS cells were transfected using Dharmafect 1 reagent (Dharmacon). Cells were 
plated in a 6 well plate a day before. 6 µl of 20 µM siRNA was added to 282 µl of 
OptiMEM (Gibco by Life Technologies) and Dharmafect 1 was incubated with 
OptiMEM for 5 mins at room temperature. 288 µl of the Dharmafect 1 and OptiMEM 
reagent incubated previously was added to siRNA mixture and mixed well before 
SiRNA 5’-3’ sequence or Cat. No. 
siControl (Ntsi) Qiagen Allstars Negative control siRNA SI03650318 
BRD2 Dharmacon ON-TARGETplus SMARTpool L-004935-00 
BRD3 Dharmacon ON-TARGETplus SMARTpool L-004936-00 
BRD4 Dharmacon ON-TARGETplus SMARTpool L-004937-00 
Hexim1 Dharmacon ON-TARGETplus SMARTpool L-012225-01 
RAD51 GAGCUUGACAAACUACUUC 
Smarcal1 Dharmacon ON-TARGETplus SMARTpool L-013058-00 





being incubated for 20 mins. 480 µl of mixture was added to the 1.5 ml of DMEM 
media on the cells before being grown for 48 hours. After 24 hours media on cells 
was disposed and fresh DMEM media was added to the cells. After 48 hours cells 
were detached by trypsin and either harvested for Western blotting, fibre labelling, 
immunofluorescence (IF) or EU (Ethynyl Uridine) assay.   
 
2.3.3: Plasmid transfection 
 
U2OS cells were transfected using Transit-2020 transfection reagent (Mirius bio). 
Cells were plated in a 6 well plate a day beforehand. 250 µl of pre-warmed 
OptiMEM was added with 2.5 µg of the required plasmid. The OptiMEM and 
plasmid were mixed thoroughly before 7.5 µl of Transit-2020 was added. The 
solution was mixed thoroughly again before incubated at room temperature for 20 
mins. The solution is then added dropwise around the well of 2.5 ml fresh media 
before being grown for 24-48 hours. 
 
2.3.4: Simultaneous plasmid and siRNA transfection 
 
U2OS cells were transfected using the TransIT-X2 transfection reagent (Mirius bio). 
U2OS cells were seeded into a 6 well plate and grown overnight.  250 µl of pre-
warmed OptiMEM was added to 2.5 µg of plasmid and mixed thoroughly. This was 
followed by adding 3.4 µl of 20 µM siRNA stock and mixed thoroughly. 7.5 µl of 
TransIT-X2 was added to the solution and mixed thoroughly before incubated at 
room temperature for 20 mins. The solution is then added dropwise around the well 








Recombinant DNA Source 
pcDNA6.2/N-EmGFP-BRD4(long)-
DEST 
Philpott et al., 2014 
Kind gift from Dr Catherine Rogers 
pCDNA5-3HA-BRD4(short)-DEST Kind gift from Prof Panagis 
Fillipakopoulos 




Table 2.3: Plasmids. 
 
2.4: DNA replication and repair assays 
 
2.4.1: Flow cytometry 
 
Cells were seeded into a 10 cm dish and left to grow overnight. After cells were 
treated, they were harvested and spun down for 5 mins at 3000 rpm. Cells were 
then re-suspended in ice cold PBS before being spun down once again. This was 
repeated once more, and cells were re-suspended in 3 ml of ice-cold PBS. To fix 
these cells, ice cold 100% ethanol was added slowly to the cells while being 
vortexed to try and avoid cell clumping. Samples could be stored overnight in the 
fridge.  
Samples were spun at 2000 rpm for 4 mins. The supernatant was removed and 10 
ml of PBS was added again to sample and was spun again. This procedure was 





solution ((2 µl of 2 mg/ml propidium iodide (Fisher Scientific) in 500 µl of PBS)) and 
0.3 µl of RNaseA (Sigma, 50 mg/ml). Cells could be stored in the fridge up to a 
week before analysing data.  
Cell cycle profiles were than gathered from the samples using the BD LSR Fortessa 
X20 and analysed using the BD FacsDiva software.  
 
2.4.2: Labelling of adherent cells for DNA fibres 
 
Cells are plated into a 6 well plate and grown overnight. The cells were than pulse-
labelled with 25 µM thymidine analogue 5-chloro-2’-deoxuridine (CldU) for 20 mins 
at 37°C. This is followed by pulse-labelling with 250 µM thymidine analogue 5-Iodo-
2’-deoxyuridine (IdU) for 20 mins at 37°C. Labelled cells were than harvested in 
cold PBS and spun down. Cells were re-suspended to a concentration of 2x105 
cells/ml. Each sample were used to spread 5 microscope slides. 2 µl of a sample 
was placed on top of a microscope slide. The drop was dried for up to 5 mins until it 
was sticky. This was followed by addition of 7 µl of spreading buffer (200 mM Tris 
pH7.4, 50 mM EDTA, 0.5% SDS) which was gently stirred with cell suspension with 
a pipette tip. This was to help lyse the cells to ensure spread of DNA. The mixture 
was incubated for a further 2 mins before the microscope slide was tilted until the 
drop at the top of the slide has spread down the entire length of the slide leaving 
spread DNA on the slide. The slides were than air-dried at room temperature before 
being fixed in 3:1 mixture of methanol and acetic acid for 10 mins. Slides were than 







2.4.3: DNA fibre labelling in suspension cells 
 
Cells are plated in 6 well plates with 1 ml of cells added to 1 ml of fresh RPMI media 
and can be left upwards of an hour to settle. As described above the cells are than 
provided with two pulses of 20 mins of thymidine analogues CldU and IdU. After 
cells have been labelled the cells are treated with 1 mM thymidine (Fisher Scientific) 
for 5 mins at 37°C to stop further incorporation of the analogues. Cells were then 
spun down at 1000 rotations per minute (rpm) for 5 mins. Cells were re-suspended 
in ice cold PBS 1x and then spun down again. This was repeated once more before 
cells were re-suspended in 1 ml of ice-cold PBS. Cells were re-suspended to a 
concentration of 7.5*105 cells/ml. Further fibre spreading using these cells followed 
the previous protocol described for adherent cells above.  
 
2.4.4: Staining fibres 
   
Slides were washed twice for 5 mins with distilled H2O. Slides were then rinsed with 
2.5 M HCl before being incubated with 2.5 M Hydrochloric acid (HCl) for 75-80 
mins. Slides were than washed with PBS twice before being washed twice with 
blocking solution (PBS, 1% BSA, 0.1% Tween20) for 10 minutes before a longer 
incubation of 30 mins. Primary antibodies were made up in blocking solution with 
Rat anti-BrdU (see Table 2.5) diluted at 1:1000 for the CldU and mouse anti-BrdU 
(see Table 2.5) diluted at 1:500 recognising the IdU. After blocking is finished 115 µl 
of antibody solution was added to the slide and then covered with a glass coverslip 





slides were washed three times with PBS and then slides were fixed with 1 ml of 4% 
paraformaldehyde (PFA). Slides were subsequently washed three times with PBS 
and then washed with blocking solution three times. After being washed with 
blocking solution the slides were incubated with secondary antibody. The secondary 
antibody is diluted in blocking solution with α-mouse Alexa Fluor 488 (see Table 
2.6) diluted at 1:500 and α-rat Alexa Flour 555 (see Table 2.6) diluted at 1:500. 
115µl of antibody solution was added to the slide and covered with glass coverslip 
and was incubated for 90 mins at room temperature. Slides were then washed twice 
with PBS and washed three times with blocking solution. Slides subsequently 
washed twice more with PBS. Slides were then mounted with a glass coverslip with 
flouroshield mounting medium (Sigma). Slides were than stored at -20°C.  
DNA fibres were visualised on a Nikon E600 microscope using a Nikon Plan Apo x 
60 oil lens. Images were taken from two slides per sample and imaged acquired 
using a Hamamatsu digital camera and Velocity acquisition software. Images were 
analysed using the Image J software (http://rsbweb.nih.gov/ij/). Each experimented 
was repeated at least three times with at least 100 DNA fibres measured for 




Immunofluorescence was used to identify and observe formation of 53BP1, γH2AX, 
RPA and RAD51 foci. Cells were grown in 24 well plates with a coverslip. Cells 
were than treated before being fixed in 4% PFA (Thermo Fisher) for 10 mins at 





permeabilised with 0.25% Triton X-100 (Thermo Fisher) solution for 5 minutes at 
room temperature. Cells were washed twice with PBS and were blocked with 4% 
FBS for one hour. Cells were then treated with a specific primary antibody (see 
Table 2.5) in 4% FBS and incubated at 4°C overnight. Cells were than rinsed twice 
with PBS and washed three times with blocking solution for 5 mins. Cells were 
incubated with specific secondary antibody raised against species of primary 
antibody (see Table 2.6) in 4% FBS and incubated at room temperature protected 
from light for 2 hours. Cells were then washed twice with PBS before being washed 
three times with blocking solution. The coverslips were transferred from the 24 well 
plate and placed on the microscope slides cells facing downwards into flouroshield 
mounting media containing DAPI (Sigma). Immunofluorescence microscopy was 
done using the Nikon E600 microscope. Cells were identified using DAPI and cells 
with more than a certain pre-determined threshold were deemed positive cells. This 
was >5 foci for RAD51, >8 for γH2AX and >8 for 53BP1 foci. Images were taken 




Cells were seeded into a 24 well plate with a coverslip and grown overnight. Cells 
were treated with 2 µg/ml of cytochalasin-B (Sigma) and incubated for 24 hours at 
37°C with or without JQ1 treatment. After 24 hours cells were treated with ice cold 
methanol for fixation for 20 mins before being permeabilised with 0.5% Triton X-100 
for 10 mins. Cells were blocked for 20 mins. The coverslips were transferred from 





flouroshield mounting media containing DAPI. Microscopy was done using the 
Nikon E600 microscope. Images were taken using Velocity software and images 
were adjusted in ImageJ.  
 




Urea Tris Buffer (UTB): 




Running buffer 10x: 
30.3g Tris Base 
187.7g Glycine 
10g Sodium Dodecyl Sulphate (SDS) 
1l of H2O 
 
Transfer buffer 1x: 
10% Methanol  
10% Towbin 10x 
80% H2O 
 
Loading buffer 5x: 
5ml 1M Tris pH 6.7 
2g SDS 










12.1g Tris Base 
81.8g NaCl 
pH to 7.9 with HCl 
In 1l of H2O 
 
TOWBIN 10x: 
24g Tris Base 
112.6g Glycine 
In 1 L of H2O 
 
TBST (TBS-Tween): 
10% TBS 10x 
0.05% Tween 20 
 
1.5 M Tris pH 8.8: 
18.15g Tris Base 
80ml H2O 
Adjust pH to 8.8 with either concentrated NaOH or HCl – top up to 100ml once at 
desired pH 
 
1M Tris pH 6.7: 
6.06g Tris Base 
80ml H2O 







2.5.2: Western blotting 
 
Cells were grown and treated in 6 cm dishes before harvesting. Cells were 
typsinised and re suspended in 1 ml of cold PBS. Cells were counted using a 
haemocytometer and cells were spun down at 7500 rpm for 2 mins. PBS was 
removed, and pellets were re-suspended in UTB buffer to a concentration of 2x106 
cells/ml.  
Samples were then put on ice and sonicated for 10 seconds before being cooled for 
20 seconds before being sonicated again at between 4-5 input powers. Once 
sonicated samples were put on ice and spun down at full speed at 4 for 10 mins. 
Supernatant was transferred to new tubes and 5x loading buffer was added at a 
ratio 1:4. Samples were mixed by pipetting before being spun and boiled at 80°C for 
five mins. Samples were either run afterwards or stored at -20°C. SDS PAGE was 
carried out using a Bio-Rad Mini-PROTEAN 3 cell apparatus. Gel were cast at 









Table 2.4: SDS polyacrylamide gel solutions. 
 
The resolving gel was coated with isopropanol to remove bubbles. Upon 
polymerisation, the isopropanol was washed off and the stacking gel was poured on 
top with a comb. Once set the comb was removed. Samples were run next to a 
protein ladder (Himark, Thermo Fisher, or Blue Prestained Protein Standard, Broad 
Range, New England Biolabs). 20 µl of protein sample was loaded onto the gel and 
run in running buffer 1x diluted from 10x stock running buffer. After separation, the 
gel was transferred onto a nitrocellulose membrane (Fisher Scientific). Transfer 
sponges, blotting paper and membrane was pre-soaked in transfer buffer 
beforehand. The gel was placed in cassette in the following order: Clear side, 
sponge, blotting paper, membrane, gel, blotting paper, sponge, black side. Place 
 Resolving (ml) Stacking(ml) 
 12% 9% 6% 5% 
H20 6.6 8.8 10.3 6 
30% 
acrylamide 
8 6 4 1.34 
1.5 M Tris 
pH8.8 
5 5 5 - 
1 M Tris pH 
6.7 
- - - 2.5 
10% SDS 0.2 0.2 0.16 0.1 
10% APS  0.2 0.2 0.16 0.1 





the cassette in a cassette holder and top tank with transfer buffer with an ice block. 
Transfer at 100 V for 100 mins. The membrane was placed in Ponceau S solution 
(Sigma) for 1 min to stain proteins and subsequently washed. If needed the 
membrane was cut into strips with relevant size bands. The membrane was placed 
in 5% milk and blocked on the rocker for 1 hour. The membranes were then 
incubated in primary antibodies (see Table 2.5) in 5% milk overnight at 4°C on a 
rotator.    
After primary antibody incubation the membranes were washed three times with 
TBST on the rocker. The membrane was then incubated with secondary antibodies 
(see Table 2.6) in 5% milk at room temperature on a rotator for 90 mins. The 
membranes were then washed another three times with TBST on the rocker. 
Excess TBST was washed off the membrane with distilled H20 before addition of 
Pierce ECL Plus Western blotting substrate (Fisher) made with equal parts of 
Substrate A and B. ECL was incubated for 1 min before being placed in film 
cassette and developed with X-ray film (SLS) in a dark room. Membranes were 
exposed for different exposures depending on signal strength. 
 
2.5.3: Quantification of Western blot 
 
Western blots were scanned and opened with ImageJ. The file is converted into 8-
bit. A rectangle is drawn around the first lane of interest. After the rectangle is 
drawn, the analyse tab is selected on ImageJ, followed by gels and select first lane. 
The 2nd lane is selected by copying the first rectangle and dragging it over the 2nd 





Repeat this until all the lanes have been selected. Once all the lanes are selected, 
plot lanes are selected in the gels tab. Once the peak for the lane appears, a line 
can be drawn to close off the peak for accurate measurements and to get rid of any 
background. The area for this peak is calculated by clicking the wand tool on the 
peak. To accurately compare the quantified area against other lanes, the loading 
control must be analysed as well. To quantify the relative density of each lane the 












2.5.4: Primary antibodies 
 
 
Table 2.5: Antibodies including species raised in, dilution, conditions and protocols. 
 
 
Antigen Dilution Supplier Species Method 
RAD51 1:1000 Abcam Rabbit WB/IF 
BRD4 1:1000 Abcam Rabbit WB 
BRD2 1:1000 Abcam Rabbit WB 
BRD3 1:500 Abcam Rabbit WB 
Hexim1 1:50000 Abcam Rabbit WB 
ZranB3 1:500 Proteintech Rabbit WB 
Smarcal1 1:150000 Santa Cruz Mouse WB 
BrdU  1:1000 Abcam Rat Fibres 
BrdU 1:500 Becton 
Dickinson 
Mouse Fibres 
Actin 1:5000 Cell Signalling Rabbit WB 
Tubulin 1:10000 Sigma Mouse WB 
p-
Chk1(S317) 
1:1000 Cell Signalling Rabbit WB 
p-RPA(S4/8) 1:1000 Bethyl Rabbit WB 
RNAPOL2S2 1:500 Abcam Rabbit WB/IF 
RNAPOL2S5 1:5000  Mouse WB 
YH2AX 1:1000 Millipore Mouse IF 
53BP1 1:300 Bethyl Rabbit IF 





2.5.5: Secondary antibodies 
 
 
Table 2.6: Antibodies including species raised in, dilution, conditions and protocols. 
 
2.6: RNA methods 
 
2.6.1: EU assay 
 
EU incorporation was performed using the Click-It RNA Alexa Flour 594 Imaging kit 
(Thermo Scientific). Cells were seeded in a 24 well plate with a coverslip inside. 
Cells were treated before being incubated with 1 mM EU for 1 hour. Cells were fixed 
at room temperature using 4% PFA for 10 mins at room temperature. Cells were 
washed three times with PBS before being permeabilised for 15 mins with 0.5% 
Triton X-100. Cells are then treated with 100 µl of Click-It reaction cocktail (see 
Table 2.7) protected from light at room temperature for 30 mins. Before the cocktail 
is made, the reaction buffer additive is diluted ten times. After incubation the 
reaction cocktail is removed, and cells are washed with Click-IT reaction wash 
buffer for 5 mins before being washed with PBS. The coverslips are removed from 
Antigen Dilution Supplier Species Method 
Goat anti-
mouse HRP 
1:500 Dako Mouse WB 
Goat anti-rabbit 
HRP 
1:500 Dako Rabbit WB 
Anti-rat 
AlexaFluor 555 

















the 24 well plate and placed on the microscope slides cells facing downwards into 
Flouroshield mounting media containing DAPI. The slides are then stored at 4°C 
and can be analysed within 24 hours. EU microscopy was performed on the Nikon 
e600 microscope using Velocity software. Images of DAPI staining for nuclei and 
Alexa Fluor 594 intensity were taken. Images were analysed on Image J where 
DAPI was used to generate a nuclear mask and mean Alexa Fluor 594 intensity per 
pixel was quantified for every nucleus.  
 
2.6.2: EU assay in suspension cells  
 
Cells were seeded in a 24 well plate with 1 ml of cells and 1 ml of fresh RPMI media 
with a circular poly-l-lysine coated glass 12 mm coverslips (Becton-Dickinson 
Biosciences) for 1 hour to allow cells to attach properly. The rest of the EU assay 












Table 2.7: Components and amounts to make reaction cocktail. 
 
2.6.3: RNA purification 
 
Cells were seeded into a T75 flask and grown overnight. Cells were washed twice 
with PBS before being typsinised. Cells were re-suspended in 10 ml of media. 10 µl 
of cells was mixed with trypan blue stain before being counted using a Countess II 
cell counter (Thermo Fisher). Cells were then spun down and re-suspended to 
achieve a concentration of 3x106 cells/ml. Cells were than pelleted and the 
supernatant was removed. The rest of the RNA purification was carried out 










1 coverslip(100 ml) 5 coverslips(500 ml) 
Click-iT RNA 
Reaction buffer 
85.6 µl 428 µl 
CuSO4 4 µl 20 µl 
Alexa-Fluor 594 
azide 









2.6.4: RNA quantification 
 
Following RNA purification, the RNA was quantified using a Labtech 
Spectrophotometer using ND-1000 software. Blank measurements were taken 
using 1 µl of RNase free water which the purified RNA was eluted in 1 µl of the RNA 














BET proteins have been at the cutting edge of new targets for cancer treatment, 
with multiple BET inhibitors now undergoing clinical trials. However, a more detailed 
understanding of BET proteins and how they function is necessary for development 
of possible future therapeutic applications.  
Previously the lab showed that BET proteins may play a role in maintenance of 
DNA replication, using BET protein inhibitor JQ1 (Da Costa, Agathanggelou et al. 
2013). These data showed that JQ1 treatment can cause replication fork slowing in 
NALM-6 leukaemia cells. As previously detailed, replication stress can have severe 
effects on the cells, leading to promotion of DNA damage such as DSBs. Many 
cancer therapies use the induction of replication stress to lead to the formation 
DSBs (Kotsantis, Jones et al. 2015). These results may indicate a new role of BET 
proteins in the maintenance of DNA replication. To understand how BET inhibition 
leads to replication stress is therefore crucial for potential basis of future clinical 
applications. 
As mentioned previously, there are numerous sources which can cause replication 
stress in cells (Zeman and Cimprich 2014). The main aim in this chapter is to 





As cells normally undergo replication stress response which can either lead to cell 
survival, cell death or increased genomic instability, another major aim is to test the 
effect BET inhibitors have on the cell, downstream of fork slowing.  
Hence by understanding this, we will have a much better understanding of BET 
proteins and their role in replication, which will be important for any new potential 
therapies using BET inhibitors down the line. 
 
3.2: BET inhibitors induce replication stress 
 
As mentioned earlier, previous data showed JQ1 leads to the onset of replication 
stress in NALM-6 cells. Replication stress is often characterised by replication fork 
slowing (Ciccia and Elledge 2010). We wanted to confirm the effects JQ1 has on 
replication fork progression in U2OS cells. U2OS cells were used as the effects of 
replication stress and DNA damage have been well studied and documented in this 
cell line (Bryant and Helleday 2006, Oplustilova, Lukas et al. 2009, Giunta, 
Belotserkovskaya et al. 2010, Jones, Mortusewicz et al. 2013). To analyse the 
progression of fork speeds we used the DNA fibre technique. This produces long 
unbroken fibres of labelled DNA, which allows us to measure fork speeds or origin 
firing. 1 µM JQ1 was added for 1 hour, and then cells were labelled for 20 mins 
each with thymidine analogues CldU and then IdU, before fibres are spread and 
stained (Figure 3.1 A-B). We decieded to treat cells using a JQ1 concentration of 
1 µM, as previous preliminary data had shown that 1 µM JQ1 induces replication 





to what had been shown earlier we saw that 1 µM JQ1 led to a significant decrease 
in fork progression speeds (Figure 3.1 D-E). To compare replication fork speeds 
between the treatments we calculated the average median fork speeds. In each 
repeat the median of the distribution of every fibre analysed was calculated and 
averaged over the number of repeats carried out. Control treated cells had an 
average median fork speed of 1 kilobase (kb)/min, while JQ1 treated cells showed 
an average median fork speed of 0.6 kb/min (Figure 3.1 D). These results indicate 












Figure 3.1: JQ1 leads to increased replication stress.     
A) DNA fibre labelling performed in U2OS cells after 1 µM JQ1 treatment for 1 hour. 
B) Diagram illustrating the DNA fibre protocol from labelling the DNA to visualising 
the DNA under the microscope. C) Representative images of DNA fibres after 1 µM 
JQ1 addition for 1 hour. D) The average median speed was calculated from all 
ongoing replication forks measured after 1 µM JQ1 treatment for 1 hour. E) 
Distribution of replication fork speeds in cells treated with 1 µM JQ1 for 1 hour or 
control treated cells. (N=3, error bars: Standard error of the mean (S.E.M), 





The previous figure showed that JQ1 induced replication fork slowing after JQ1 
treatment. The concentration used for this was 1 µM. A variety of previous studies 
and research using JQ1 as a cancer therapy drug had used lower concentrations of 
JQ1 to look into the effects it has on cells (Herrmann, Blatt et al. 2012, Kumar, Raza 





were a result of JQ1 effects on replication and not due to an artefact of using high 
concentrations of JQ1 we decided to repeat the experiments using a range of lower 
concentrations of JQ1. Previous research had shown JQ1 to be effective in 
inhibiting growth of cancer cells from concetrations of 250 nM, so I decided to test 
concentrations of 250 nM upwards to 750 nM of JQ1 (Filippakopoulos, Qi et al. 
2010, Herrmann, Blatt et al. 2012, Kumar, Raza et al. 2015). I treated cells with the 
desired JQ1 concentrations before using the same protocol for DNA fibres as before 
(Figure 3.2 A). Cells treated with lower concentrations of JQ1 showed the same 
effects as 1 µM treatment, with all showing significantly reduced average median 
fork speeds compared to control treated samples (Figure 3.2 B-C). Even the lowest 
concentration of 250 nM JQ1 showed a significant drop in average median 
replication fork speed from 1 kb/min to around 0.77 kb/min (Figure 3.2 B). The data 
show that replication fork speeds are reduced over a range of JQ1 concentrations 
and the most prenounced fork slowing of the concentrations analysed was seen 
with 1 µM JQ1. As 1 µM JQ1 seemed to have the most pronounced effect on 
replication speeds (Figure 3.2 C), we decided to carry on using this concentration of 








Figure 3.2:  A titration of lower JQ1 concentrations also show induced 
replication stress.                         
                
 A) DNA fibre labelling performed in U2OS cells with either 1 µM, 500 nM or 250 nM 
JQ1 treatment for 1 hour. B) Average median replication fork speeds for cells 
treated with 1 µM or 500 nM or 250 nM JQ1 for 1 hour. C) Distribution of replication 
fork speeds in cells treated 1 µM or 500 nM or 250 nM JQ1 for 1 hour. (N=3, error 












The previous results showed the impact of JQ1 on replication fork speeds after 1 
hour of treatment. To understand the long-term effects of JQ1 on replication fork 
speeds, we looked at a range of different time points after JQ1 addition. To test this 
we used the DNA fibre technique as stated previously, with labelling after the stated 
1 µM JQ1 treatment time (Figure 3.3 A).   
Fork speeds between 1 and 8 hours after continuous JQ1 addition were significantly 
slowed down, compared to control treated cells. The average median fork speeds 
for these times were all around 0.6 kb/min compared to 0.9 kb/min in control treated 
samples. After 24 hours, fork speeds were rescued to control treated levels (Figure 
3.3 B). To test if this was due to JQ1 being degraded and loss of JQ1 activity, we 
added fresh JQ1 to cells after 23 hour treatment for further 1 hour before fibre 
labelling. Fork speeds were unaffected by the addidtion of fresh JQ1 after 23 hours, 
indicating JQ1 activity was not lost (Figure 3.3 B). Anlaysis of fork progression was 
also conducted for further timepoints after 48 and 72 hours of JQ1. Fork speeds 
remained unperturbed for these timepoints, with fork speeds mirroring those seen in 
control-treated samples (Figure 3.3 C). These results indicate that JQ1 leads to 
replication fork slowing after 1-8 hours but the replication forks are able to overcome 








Figure 3.3: Time course of fork speeds after JQ1 treatment.   
A) DNA fibre labelling performed in U2OS cells for 24, 8, 4, 1 and 23+1 hour 1 µM 
JQ1 treatments. B) Average median replication fork speeds in cells treated for 24, 8, 
4, 1 and 23+1 hour 1 µM JQ1 treatments. C) Average median replication fork 
speeds in cells treated for 48 and 72 hour 1 µM JQ1 treatments. (N=5, error bars: 












Proliferating cells undergo cell cycle which has four main parts, G1, S, M, G2. Each 
phase is controlled by checkpoints. Replication occurs during S phase. During 
replication stress an S phase checkpoint is activated to stop replication progression 
until the blockage causing replication stalling or slowing is removed (Heffernan, 
Unsal-Kacmaz et al. 2007). Cell cycle effects leading to pertubed S phase or 
dergulate S phase entry, can lead to replication problems such as replication stress 
(Petermann and Caldecott 2006, Petermann, Maya-Mendoza et al. 2006). To test 
this was not causing BET inhibitor induced fork slowing we checked cell cycle 
profiles of JQ1 treated cells.  
To analyse the cell cycle profiles of cells treated with JQ1 between 1 and 24 hours 
we used flow cytometry. After treatment of the cells they were fixed and stained with 
PI before being analysed to measure the percentage of cells in each stage of the 
cell cycle (Figure 3.4 A). JQ1 treatment between 1 and 8 hours showed no changes 
in cell cycle profile compared to control cells, with S phase percentages being 
almost identical (Figure 3.4 B). Only after 24 hours, JQ1 lead to accumulation of 
cells in G1 with the percentage going up form 54% to 78%, indicating a G1 arrest 
(Figure 3.4 B). This data suggests that fork stalling is due to a direct effect of JQ1 










Figure 3.4: JQ1 treatment shows no change in cell cycle profile up to 8 hours 
before cells undergo G1 arrest. 
A) Cells were harvested, fixed and stained for cell cycle analysis after 1 µM JQ1 
treatment for 24, 8, 4 and 1 hour. B) Cell cycle distribution measured by flow 
cytometry of U2OS cells treated with 1 μM JQ1 for 24, 8, 4- and 1-hour time points. 
(N=3, error bars: S.E.M.) 
 
 
3.3: BET inhibitors induce increase in RNA synthesis 
 
As previously stated, there are a myriad of different obstacles for replication that 
can result in the induction of replication stress. Transcription has been shown 
recently to be a problem for replication and interference between the two 
machineries can lead to replication stress (French 1992, Poveda, Le Clech et al. 
2010, García-Muse and Aguilera 2016). The lab had previously reported 
transcription as a mechanism of replication stress in both Cyclin E and H-RASV12 





2016). We decided to look into BET inhibitors effect on RNA synthesis. To analyse 
nascent RNA synthesis we used an assay that measures incorporation of the RNA-
specific modified nucleoside 5-ethynyluridine (EU). 1 μM JQ1 was added to U2OS 
cells for 1, 4, 8 and 24 hours, matching the time points we used in the DNA fibre 
assay. EU was added for the last hour before cells were fixed, stained and 
quantified (Figure 3.5 A). As shown by Figure 3.5 B, staining cells for EU gives a 
red signal under the microscope, the brightness of which can be quantified to give a 
read-out of total nascent RNA synthesis in the cells. EU incorperation after JQ1 
went up around 35% after just 1 hour after addition (Figure 3.5 C). This level of EU 
incorperation remained upwards after 24 hours with an increase of around 25% 
(Figure 3.5 C). To look at long term effects of JQ1 and transcription, we looked at 
longer time points of 48 and 72 hours. EU incorporation remained steadily 
increased for these timepoints, with a 50% increase after 48 hours and 60% after 72 
hours (Figure 3.5 D). To confirm these results an alternative method was used, 
isolating total RNA from cells followed by RNA quantification and normalising RNA 
yields to cell numbers to accuratley compare (Figure 3.5 E) (Lin, Loven et al. 2012, 
Nie, Hu et al. 2012). After 8 hours of JQ1 treatment there was an increase of total 






Figure 3.5: JQ1 treatment leads to prolonged increase in total RNA synthesis.  
A) U2OS cells were treated with JQ1 for 1, 4, 8 and 24 hours and nascent RNA 
synthesis was quantified by incorporation of a nucleoside analogue of uridine, 5-
Ethynyl Uridine (EU) into the cells. B) Representative images of click-stained with 
Alexa-Flour 594 EU cells and DAPI +/- 8 hours 1 µM JQ1 treatment. Scale bar 10 
µm. C) Nuclear EU intensities after 24, 8, 4 and 1 hour 1 µM JQ1 treatment. (n=4). 
D) Nuclear EU intensities after 72 and 48 hour 1 µM JQ1 treatment. (n=3). E) Total 
RNA was extracted after 8 hours 1 µM JQ1 treatment. F) Fold change in total RNA 
expression between DMSO and 1 µM JQ1 after treatment for 8 hours. (n=6). (Error 








In further experiments carried out by Dr. Marco Saparano analysing a published 
dataset using BRD4 degradation (Muhar, Ebert et al. 2018), we showed that 1 hour 
after BRD4 degradation, genome-wide net occupancy of RNA Pol II increased by 
53.8% (Bowry, Piberger et al. 2018) (Figure 8.1/Appendix A2). This increase was 
shown to be particularly high for transcribed genes that produce non-polyadenylated 
RNAs such as histone and non-coding RNA genes. qRT-PCR was undertacken  to 
see whether this increased RNA Pol II occupancy was also increasing gene 
expression. Expression of candidate genes we selected were also up-regulated by 
JQ1 in U2OS cells after 1 and 8 hour treatments (Bowry, Piberger et al. 2018) 
(Figure 8.2/Appendix A2). Taken together this data shows that JQ1 treatment leads 
to an observed increase in total RNA synthesis as short as 1 hour after treatment.  
 
3.4: JQ1 phenotypes are mirrored in different cell lines, and by 
different BET inhibitors 
 
The previous experiments were all undertaken in U2OS cells. We wanted to test 
whether the same phenotypes could be shown in other cell lines. Previously, fork 
slowing had been shown in (ALL) cell line Nalm6 (Da Costa, Agathanggelou et al. 
2013). We then tested three other cell lines: fibroblasts BJ-hTert, Chronic 
lymphocytic leukemia (CLL) cell lines Mec1 and C2. Firstly, JQ1 was added for 1 
hour before fibre labelling and staining in these cells (Figure 3.6 A). JQ1 had no 





fork slowing in MEC1 (1.2 kb/min in control to 0.65 kb/min) and BJ-hTert (1.03 
kb/min to 0.73 kb/min) cell lines (Figure 3.6C-D).  
 
Figure 3.6: BJ-h-Tert, and MEC1 cells show JQ1 induced replication stress, C2 
cells show no visible change in fork speeds.  
A) DNA fibre labelling performed in C2, MEC1 and BJ-hTert cells with 1 µm JQ1 
treatment for 1 hour. B) Average median replication fork speeds in C2 cells after 1 
hour 1 µM JQ1 treatment. C) Average median replication fork speeds in MEC1 cells 
after 1 hour 1 µM JQ1 treatment. D) Average median replication fork speeds in BJ-
hTert cell lines after 1 hour 1 µM JQ1 treatment. (N=3, error bars: S.E.M, Statistical 







The EU assay was performed the same way as stated previously in these cells to 
see the effect on total RNA synthesis (Figure 3.7 A). Preliminary data done 
previously by the lab showed JQ1 treatment after 1 hour in Nalm6 cells lead to 
increased EU incorperation. JQ1 had no effect on EU incorperation in C2 cells 
(Figure 3.7 B). However, JQ1 induced significant increases in EU incorperation in 
MEC1 (18%) and BJ-hTert (21%) cell lines (Figure 3.7C-D). These results show that 
three cell lines tested, Nalm6, BJ-hTert, MEC1, all showed the exact same 
phenotype as observed in U2OS cell lines, however one cell line C2 had no 









Figure 3.7: BJ-h-Tert, and MEC1 cells show JQ1 induced increase in total RNA 
synthesis, C2 cells show no visible change in total RNA synthesis.  
A) MEC1, C2 and BJ-hTert cells were treated with JQ1 for 1, 4, 8 and 24 hours and 
transcription elongation were quantified by incorporation of EU into the cells. B) 
Nuclear EU intensities after 1-hour JQ1 treatment in C2 cells. C) Nuclear EU 
intensities after 1-hour JQ1 treatment in MEC1 cells. D) Nuclear EU intensities after 
1-hour JQ1 treatment in BJ-h-Tert cells. (N=3, error bars: S.E.M, Statistical analysis: 









The experiments so far involve the use of one BET inhibitor JQ1. To confirm that 
the previous shown effects caused by JQ1 treatment were due to BET inhibition in 
general and not due to some specific effect of JQ1, we tested another BET protein 
inhibitor, I-BET151. I-BET151 works similarly to JQ1 by preventing binding of 
acetylated histones by BET proteins (Dawson, Prinjha et al. 2011, Dawson, 
Kouzarides et al. 2012, Hewings, Fedorov et al. 2013). I-BET151 was added for 1 
hour before cells were labelled and stained (Figure 3.8 A). A range of 
concentrations of 500 nM, 750 nM and 1 µM were used. I-BET151 led to 
significantly decreased fork speeds even at the lowest concentration of 500 nM 
(Figure 3.8 B-C). An EU assay was then performed using 1 µM I-BET151. I-BET151 
caused an increase in EU incorporation (Figure 3.8 D). These results mirror what 
was previously seen with JQ1. This suggests that the effects seen in replication 

















Figure 3.8: I-BET151 mirrors the phenotypes in fork slowing and RNA 
synthesis change as observed with JQ1 treatment.  
A) DNA fibre labelling and quantification of incorporation of EU were performed in 
U2OS cells after 1-hour treatment with 1 µM I-BET151. B) Average median 
replication fork speeds treated with 1 µM, 750 nM, and 500 nM I-BET151 for 1 hour. 
C) Distribution of replication fork speeds in cells treated, 1 µM, 750 nM, and 50 0nM 
I-BET151 for 1 hour. D) Nuclear EU intensities after 1 hour I-BET151 treatment in 
U2OS cells. (N=4, error bars: S.E.M, Statistical analysis: Student’s t-test. * P value 









3.5: BET inhibitor-induced replication stress depends on 
transcription-replication conflicts 
 
Replication-transcription conflicts as mentioned earlier are a major cause of 
replication fork slowing in cells (French 1992, Poveda, Le Clech et al. 2010, García-
Muse and Aguilera 2016). JQ1 had shown increases in RNA synthesis as well as 
causing forks to be slowed down, therefore transcription-replication conflicts 
seemed to be a likely candidate for causing JQ1-induced fork slowing. To test this 
hypothesis we used three different transcription inhibitors, DRB, α-amanitin and 
triptolide to inhibit transcription and see if this rescued the replication fork slowing 
induced by JQ1 treatment. DRB is known to prevent activating phosphorylation of 
the RNA Pol II C-terminal domain, α-amanitin which is a potent inhibitor of RNA Pol 
II, and triptolide which inhibits transcription initiation by inhibiting XPB/TFIIH 
(Bensaude 2011, Wang, Johnson et al. 2014, Chen, Gao et al. 2015). Firstly EU 
assays were performed with transcription inhibitors DRB, triptolide, and α-amanitin 
to check they work in presence of JQ1. α- amanitin was added 3 hours before JQ1 
was added for 1 hour, as α-amanitin takes approximatley 4 hours to suppress 
transcription (Bensaude 2011, Kotsantis, Silva et al. 2016). DRB and triptolide were 
added at the same time as JQ1 for 1 hour (Figure 3.9 A). All three transcription 
inhibitors inhibited EU incorperation into the cells in the presence of JQ1 treatment 
(Figure 3.9 B). Using the fibre technique where α-amanitin was added 3 hours 
before JQ1 was added, while DRB and triptolide were added at same time as JQ1, 
before labelling and staining the fibres (Figure 3.9 A). The fork speeds where 





towards control levels (Figure 3.9 C-D). JQ1 caused an average median fork speed 
of around 0.52 kb/min compared to 1 kb/min in control treated samples, while 
treatment with transcription inihbitors caused fork speeds to increase to between 
0.76-0.83 kb/min (Figure 3.9 C). Transcription inhibitor treatment without the 
treatment of JQ1 had no effect on fork speeds compared to control, showing 
transcription inhibitors have no effect on replication by themselves (Figure 3.9 C). 
We observed a similar effect in BJ-hTert cells, observing a partial rescue of fork 
speeds in cells treated with both JQ1 and transcriptional inhibitor DRB towards 
control levels (Figure 3.9 E). All together, these results indicate that by inhibiting 
transcription we can rescue JQ1-induced fork slowing in cells, indicating 












Figure 3.9: Transcriptional inhibitors rescue BET inhibitor induced fork 
slowing.  
A) DNA fibre labelling and quantification of incorporation of EU were performed in 
U2OS cells with transcriptional inhibitors α-amanitin (AM, 10 µg/ml) for 3 hours or 
DRB (100 µM) or Triptolide (TRIP, 1 µM) for 1 hour, +/- 1 µM JQ1 treatment for 1 
hour B) Nuclear EU intensities in cells treated with transcription inhibitors α-
amanitin/DRB/Triptolide with 1 µM JQ1 treatment for 1 hour. C) Average median of 
replication fork speeds treated with transcriptional inhibitors α-
amanitin/DRB/Triptolide +/- 1 µM JQ1 treatment for 1 hour. D) Distribution of 
replication fork speeds in cells treated transcriptional inhibitors α-amanitin or DRB or 
Triptolide +/- 1 µM JQ1 treatment for 1 hour. E) Average median of replication fork 
speeds in BJ-hTert cells treated with transcriptional inhibitors DRB +/- 1 µM JQ1 
treatment for 1 hour. (N=3, error bars: S.E.M, Statistical analysis: Student’s t-test. * 
P value <0.05, ** P value < 0.01.) 
 
Approximately 80% of total RNA synthesis in cells is performed by RNA Pol I and III 
(Paule and White 2000). This large amount of total RNA synthesis could also 





and Pol III has a contributing role in BET inhibtion-induced replication slowing we 
used the DNA fibre technique with 100 µM RNA Pol I inhibitor (CX-5461) and 25 µM 
or 100 µM of RNA Pol III inhibitor (ML-60218). Cells were treated with these 
inhbitors in combination with JQ1 for 1 hour before cells were labelled, fibres spread 
and stained (Figure 3.10 A). RNA Pol I and Pol III inhibitors in combination with JQ1 
led to a rescue in fork speeds. In particular RNA Pol I inhibitor showed a complete 
resuce of JQ1-induced fork slowing (Figure 3.10 B). The RNA Pol I inhbitor 
treatment showed a small increase in replication fork speeds (0.92 kb/min in control 
compared to 1 kb/min with RNA Pol I inhibitor treatment), indicating that it has no 
large effect on replication by itself (Figure 3.10 B). RNA Pol III inhibitor caused slight 
slowing of replication fork speeds (Figure 3.10 B), but this effect should have no 
bearing on our conclusion that these inhibitors rescue JQ1-induced fork slowing. 
An EU assay was also conducted using these RNA polymerase inhibitors. 
Interestingly, we see no effect of RNA Pol I or Pol III inhibitor alone on EU 
incorporation, but see a decrease when combined with JQ1 treatment compared to 
JQ1 treatment alone (Figure 3.10 C). DRB, a potent transcription inhibitor was used 
as a positive control, caused EU intensity decrease as expected. RNA Pol I and Pol 
III inhibitors have been shown to be potent inhibitors of these RNA polymerases 
(Wu, Pan et al. 2003, Drygin, Lin et al. 2011). We conclude from this that RNA 
synthesis is decreased when these inhibitors are combined with JQ1, and hence the 
effects we see in the fibre assay could be due to the suppression of RNA synthesis. 
These results show that RNA Pol I and Pol III may have a role in BET inhibitor 








Figure 3.10: Inhibiting RNA polymerase 1 or 3 rescues BET inhibitor induced 
fork slowing.  
A) DNA fibre labelling and quantification of incorporation of EU were performed in 
U2OS cells with RNA polymerase l (RNA POL 1) inhibitor CX-5461(250 nM) and 
RNA polymerase 3 (RNA POL 3) inhibitor ML-60218 (100 µM or 25 µM) for 1 hour 
+/-1 µM JQ1 treatment for 1 hour.  B) Average median fork speeds in cells treated 
with RNA POL 1 inhibitor, 25 µM RNA POL 3 inhibitor and 100 µM RNA POL 3 
inhibitor +/- JQ1 treatment for 1 hour. C) Nuclear EU intensities in cells treated with 
RNA POL 1 inhibitor and RNA POL 3 inhibitors for 1 hour +/- 1 µM JQ1 treatment 
for 1 hour (n=2). (N=3, error bars: S.E.M, Statistical analysis: Student’s t-test. * P 









3.6: BET inhibition leads to increased origin firing 
  
Replication stress can be caused by a myriad of different sources on the DNA 
causing replication fork blocks leading to fork slowing and replication stress (Zeman 
and Cimprich 2014). As shown previously, BET inhibition leads to the quick slowing 
of fork speeds which indicates an important role for BET proteins in the 
maintenance of fork progression. Understanding how this occurs is important for a 
more detailed understanding of how these proteins work and how BET inhibition 
can be used as a therapeutic. Previously, our work showed transcription-replication 
interference as a major source of BET inhibition induced fork slowing. It has been 
shown before, using Cyclin E overexpressing cells, that replication stress can be 
caused by increased transcription as well as increased number of replication origins 
being fired (Jones, Mortusewicz et al. 2013).  
Eukaryotic cells have a multitude of licenced replication origins in the genome which 
can be fired to allow establishment of bi-directional replication forks. Licencing and 
firing of replication origins is tightly regulated. If the tight regulation of the number of 
active origins is lost this can lead to aberrant fork progression and can cause later 
DNA damage and genomic instability. Tight control of origin firing is crucial for 
allowing normal fork progression (Woodward, Gohler et al. 2006, Masai, Matsumoto 





We then decided to test whether BET inhibition has any effects on the numbers of 
new origins that are fired and whether any changes observed in replication origin 
firing may be causing replication fork progression to be slowed down.  
To test whether BET inhibition may increase origin firing, we used the DNA fibre 
technique. 1 µM of JQ1 was added 1 hour before cells were labelled and stained in 
exactly the same way as mentioned previously. Instead of measuring fork speeds 
we quantified replication fork structures. As seen in Figure 3.11 A, we quantified five 
different fibre structures, of which green only labelled (IdU) and green labels on 
either side of a red label (CldU) show origins that have been newly fired. Green only 
labelled are 2nd labelled origins and green labels on either side of a red label are 1st 
labelled origins. By counting the number of first and second labelled origins in each 
treatment as a proportion of all labelled fibre structures, we found that BET inhibition 
led to increased origin firing (Figure 3.11 B). For first label origins we observed 
almost four times as many origins being fired (4-15%) and also observed a 
significant increase in second label origins (15-25%) after BET inhibition (Figure 
3.11 B). This result shows that 1 hour of BET inhibition leads to increased new 








Figure 3.11: JQ1 leads to increased origin firing. 
A) Diagram showing the replication structures formed during the fibre assay. B) % 
of 1ST label and 2nd label new origin firing in U2OS cells after treatment with 1 μM 








3.7: Inhibition of CDKs rescues BET inhibitor-induced fork slowing 
 
We wanted to elucidate whether this increase in origin firing was a causative source 
of replication stress or just a downstream effect to compensate for replication fork 
slowing seen with BET inhibitor treatment. To do this the DNA fibre technique was 
used again by using three CDK inhibitors RO3306, PHA-767491 and Roscovotine 
to inhibit origin firing. RO3306 is a specific Cyclin dependent Kinase 1 (CDK1) 
inhibitor (Vassilev 2006). PHA-767491 is a potent dual Cdc7/CDK9 inhibitor 
(Montagnoli, Valsasina et al. 2008). Roscovotine inhibits cell division cycle 2(Cdc2), 
Cyclin dependent kinase 2 (CDK2) and Cyclin dependent kinase 5 (CDK5) (Meijer, 
Borgne et al. 1997). RO3306 and PHA-767491 were used for 1-hour treatment and 
Roscovotine for 30 minutes before fibre labelling in combination with JQ1 treatment 
(Figure 3.12 A). Firstly, we quantified the amount of 1st and 2nd labelled origins in 
the same method as before to check that these inhibitors did cause suppression of 
origin firing in the presence of JQ1. For each CDK inhibitor tested we saw a major 
decrease in both 1st and 2nd label origin firing in response to JQ1 treatment (Figure 
3.12 B). The levels of 1st and 2nd label origins also decreased below control levels, 
indicating that these inhibitors where acting to suppress origin firing in cells. Thus, 
we quantified fork speeds in the same samples and observed a full rescue of fork 
speeds to that of control cells with combination treatment of JQ1 and the CDK 
inhibitors (average median fork speed around 1.3 kb/min) (Figure 3.12 C-D). There 
were slight decreases in average fork speeds of fibres treated with only CDK 





the conclusion that the CDK inhibitors are rescuing BET inhibitor induced fork 
slowing.  
These results taken together strongly indicate that BET inhibition increases origin 
firing which may be a mechanism by which BET inhibition can causes fork speeds 
to slow down.  
 
 
Figure 3.12: CDK inhibitors rescue BET inhibitor-induced fork slowing. 
A) DNA fibre labelling in U2OS cells treated with JQ1 and either PHA (10 µM) or 
RO3306 (10 µM) for 1 hour or roscovitine (25 µM) for 30 mins. B) % of 1ST label and 
2nd label new origin firing in cells treated with JQ1, JQ1+roscovitine, JQ1+ RO3306 
and JQ1+PHA shown as percentages of labelled tracks. Statistics for P-values 
correspond to values compared to JQ1 only. JQ1 only is compared to DMSO. C) 
Average median replication fork speed in cells treated with CDK inhibitors RO3306 
or roscovitine or PHA +/- 1 µM JQ1 treatment for 1 hour. D) Distribution of 
replication forks in cells treated with CDK inhibitors PHA, RO3306 and Roscovitine 
and 1µM JQ1 treatment for 1 hour. (N=3 error bars: S.E.M, Statistical analysis: 






3.8: The interplay between origin firing and transcription-
replication interference during BET inhibition  
 
Our experiments now indicated that there were two potential mechanisms, 
increased transcription-replication interference and increased firing of origins that 
may act to cause BET inhibition induced fork slowing. Whether these two 
mechanisms may act separately or together to cause this fork slowing is undefined. 
To better gain an insight into how these two potential mechanisms may work 
together we undertook a further experiment. Global RNA synthesis is measured 
after adding CDK inhibitors to control and JQ1 treated cells (Figure 3.13 A). We 
observed quite prominent decreases in EU intensity after treatment with CDK 
inhibitors in both combination with JQ1 or by themselves (Figure 3.13 B). This 
indicated that CDK inhibitors were suppressing total RNA synthesis in cells, the 
mechanism of which is still unclear. This means that we cannot distinguish whether 
CDK inhibitors rescue JQ1-induced fork slowing by inhibiting origin firing or by 












Figure 3.13: CDK inhibitors suppress nascent RNA synthesis. 
A) U2OS cells were treated with CDK inhibitors RO-3306 (10 µM) and PHA (10 µM) 
for 1 hour and 1 µM JQ1 for 1 hour and transcription elongation was quantified by 
incorporation of EU into the cells. B) Nuclear EU intensities in cells treated with 
CDKi and 1 µM JQ1 for 1 hour. (N=3 error bars: S.E.M, Statistical analysis: 








3.9: BET inhibition does not activate a replication stress response 
 
Replication fork slowing is often a hallmark of replication stress. Persistent 
replication stress in cells leads to activation of a replication stress reponse pathway 
involving ATR kinase (Ciccia and Elledge 2010). The ATR response firstly results in 
the accumulation of RPA followed by increased levels of γH2AX at the site of stress 
(Flynn and Zou 2011). Persistent replication stress can lead to fork collapse into 
DSBs and recruitment of 53BP1 into nuclear foci (Zeman and Cimprich 2014). As 
BET inhibtion has been shown to slow down fork progression, it was important to 
test whether this leads to acitvation of the replication stress repsonse. To do this we 
used immunofluorescence to look at damage foci. Staining for γH2AX and RPA was 
used as replication stress markers and 53BP1 was used to visualise formation of 
DSBs after JQ1 treatment for 1, 4 and 8 hours. Interestingly, we saw no increases 
in either γH2AX, 53BP1 or RPA foci at these time points compared to control 
treatment (Figure 3.14 A-B). 8 hour treatment with 2 mM HU acted as a positive 
control. HU depletes the cells of dNTPs, which initially results in stalled replication 
forks that, after prolonged treatment, collapse into DSB’s (Koç, Wheeler et al. 
2004). HU treatement induced significant increases in all three DNA damage 
response foci (Figure 3.14 A-B). This suggests JQ1-induced fork slowing does not 






Figure 3.14: JQ1 treatment does not activate a replication stress response.  
A) Nuclear foci of 53BP1, γH2AX, RPA in U2OS cells treated with DMSO, HU (2 
mM), and JQ1 treatment for 1, 4 and 8 hours. Scale bar 10 µm. B) Quantification of 
% foci positive cells (more than 8 foci). Statistics for P-values correspond to values 
compared to respective control. (N=3, error bars: S.E.M, Statistical analysis: 
Student’s t-test. * P value <0.05, *** P value < 0.001.) 
 
 
There are two possible explanations for the observation seen with BET inhibition and 
DNA damage response markers: either JQ1-induced fork slowing does not result in 
DNA damage, or JQ1 inhibits the ATM- and ATR-dependent DNA damage signalling 
pathways that recruit 53BP1 and promote phosphorylation of H2AX and other targets. 
To investigate whether BET inhibition may lead to suppression of DNA damage 
signalling, further DNA damaging agents were used: HU, etoposide and 
Camptothecin (CPT). CPT inhibits the nuclear enzyme DNA topoisomerase I, causing 
SSBs and DSBs when replication encounters the initial SSBs (Liu, Desai et al. 2000). 





topoisomerase II (Hande 1998). We tested whether JQ1 suppressed the response to 
DNA damaging agents HU, CPT and etoposide, using phosphorylation of CHK1 
(serine 317) as readout for ATR activity and RPA32 (serine 4/8) as readout for ATR, 
ATM and DNA-PK activity (Ciccia and Elledge 2010, Liaw, Lee et al. 2011). JQ1 
treatment alone did not seem to lead to an observed increase in either CHK1 or 
RPA32 phosphorylation either by itself or when combined with HU or CPT treatment 
(Figure 3.15 A). γH2AX levels were also looked at in response to these damage-
inducing drugs. JQ1 treatment leads to a decrease in γH2AX levels compared to 
control, when HU and CPT were added together with JQ1, similar effects were seen 
with γH2AX levels decreasing compared to control treated samples (Figure 3.15 B-
C). However, with etoposide the opposite effect on γH2AX and RPA32 
phosphorylation was observed (Figure 3.15 A-B). In agreement with a previous report 
showing that JQ1 amplifies the ATM-mediated response to directly induced DSBs, 
combination of JQ1 and etoposide led to increased RPA phosphorylation compared 














Figure 3.15: JQ1 may lead to a suppression in the replication response 
pathway. 
A) Protein levels of phospho-S4/8 RPA32, phospho-S317 CHK1 and Actin after 
treatment with HU (2mM 8hrs), Camptothecin (CPT, 1 µM 1 hour) and Etoposide 
(Eto, 25 µM 2 hours) +/- JQ1 treatment for 8 hours (N=1). B) Protein levels of 
γH2AX and actin (loading control) after treatment with JQ1, HU, CPT and Etoposide 
(N=1). C) Quantification of cells containing 8 or more γH2AX or 53BP1 foci after 










Secondly, we looked into whether inhibition of the replication stress response 
proteins ATR, CHK1 or BLM lead to an increase in DNA damage signalling in JQ1-
treated cells, because these proteins can protect stressed replication forks by 
binding to them and help to stabilise stalled forks and prevent the formation of DNA 
damage or fork collapse via various cellular processes as discussed in more detail 
in Chapter 1 (Cortez, Guntuku et al. 2001, Ammazzalorso, Pirzio et al. 2010, Ciccia 
and Elledge 2010, Zeman and Cimprich 2014). BLM inhibitor (ML216) and JQ1 lead 
to no increase in DNA damage foci (Figure 3.16 A). In response to ATR inhibitor 
(AZ20) and CHK1 inhibitor (PD-407824) (1-hour treatment) combination with JQ1, 
an increase in γH2AX positive cells was seen indicating more DNA damage 
signalling (Figure 3.16 B-C). These data suggest that some DNA lesions are formed 
at JQ1-slowed replication forks, and that the functions of replication stress response 
pathways ATR and CHK1 may stabilise these stalled forks and help prevent them 
from being converted into downstream DNA damage/DSB’s that would activate the 
replication response signal more strongly.    
This data firstly suggests a potential mechanism where JQ1 could prevent the 
formation of DNA damage, as shown when there were reduced signal of DNA 
damage markers with DNA damage inducing agents when treated in combination 
with JQ1. There is also a suggestion that replication stress factors such as ATR and 
CHK1 which are involved in the replication stress response pathway could help 
prevent DNA damage as inhibition of both factors led to increased signalling of DNA 
damage markers. The precise mechanism of how JQ1 could prevent DNA damage 







Figure 3.16: CHKi and ATRi co-treatment with JQ1 gives rise to a replication 
stress response.  
A) Percentages of cells containing more than 8 γH2AX foci after treatment with 
ML216 (1.4 µM) with and without 1 µM JQ1 8-hour treatment. B) Percentages of 
cells containing more than 8 γH2AX foci after treatment with AZ20 (2.4 µM) +/- 1 µM 
JQ1 8-hour treatment. C) Percentages of cells containing more than 8 γH2AX foci 
after treatment with PD-407824 (300nM) +/- 1 µM JQ1 8-hour treatment. (N=3, error 








Preliminary data from the lab suggested a role for BET proteins in the maintenance 
of replication progression. JQ1, a BET inhibitor, had been previously shown to slow 
down replication fork speeds. Work presented in this chapter firstly shows that JQ1 
can cause replication progression impedement as quickly as 1 hour of treatment 
(Figure 3.1 C-D). This occurred over a range of different cell lines including U2OS, 
NALM6, BJ-hTert and MEC1 cell lines (Figure 3.6 C-D). This observation shows 
that the effect of BET inhibtion is not limited to just cancer cell lines, but may also 
have similar effects on non cancer cell lines as well. The effect was not seen in C2 
CLL cells which appeared resistance to JQ1 treatments (Figure 3.6 B). The reason 
for the apparent resistant is unknown and requires further investigation. JQ1 
induced significant fork slowing over numerous concentrations starting from 250 nM 
to 1 µM. This finding was important as a lot of research currently published on JQ1 
as a potential therapeutic drug has been done at these concentrations. As all 
concentrations showed the same effect, 1 µM JQ1 was further used in the rest of 
the experiments as it provided the most robust and striking phenotypic change. JQ1 
is a synthesised chemical with a specific chemical structure used to inhibit BET 
proteins, but is one of a number of of different BET inhibitors. Our works suggest 
that it is not only JQ1 that provides this phenotypic effect. I-BET151 is another BET 
inhibitor and works to inhibit BET proteins as well. By mirroring the effect shown by 
JQ1 it provides evidence that inhibiting BET proteins is the mechanism of action 
rather than some other effect of JQ1. This is important as we can assume that 





BET proteins do have a functional role in assisting normal replication fork 
progression.  
Work in this chapter showed that BET inhibitor treatment increases total RNA 
synthesis (Figure 3.5 C-F). This is rather a surprising result as the prevailing view is 
that BET proteins act as transcription factors and BET inhibitors therefore would act 
as transcription inhibitors. Our results however report that treatment with BET 
inhibitors actually has the reverse effect leading to increased RNA synthesis, 
especially at highly transcribed histone and other non poly-adenylated non-coding 
RNA genes.  
A major question that needed to be adressed in this work was what were the 
causes for this replication fork slowing. There are a many of different obstacles on 
DNA that have potential to cause replication fork slowing (Zeman and Cimprich 
2014). One particular obstacle is transcription-replication interference that has been 
shown to cause replication stress in cells (French 1992, Poveda, Le Clech et al. 
2010, García-Muse and Aguilera 2016).  
After observing fork slowing and RNA synthesis increase after BET inhibitor 
treatment, we hypothesised that transcription-replication interference may be a 
major source of BET inhibitor induced replication stress. Our work with three 
different transcription inhibitors showed that by inhibiting transcription, replication 
progression is rescued in BET inhibitor treated cells (Figure 3.9 B-C). Each inhibitor 
works differrently as explained previously, and may have some other cellular side 
effects. By using three different inhibitors, especially α-amanitin which is a known 





due to transcription inhibition. RNA Pol I and Pol III inhibitors were also tested in 
coordination with JQ1 and showed similar results (Figure 3.10 B-C). Although the 
EU assay proved unable to show that these inhibitors worked effectively, they have 
been widely studied and shown to be potent inhibitors (Wu, Pan et al. 2003, Drygin, 
Lin et al. 2011). There could be many reasons for this such as RNA Pol I and III 
transcribe in small regions of the genome, for example RNA Pol I only transcribes 
ribosomal RNA which is concentrated in the nucleoli and therefore less likely to 
affect the mean EU intensity across the nucleus (White 2005). Another method such 
as qRT-PCR could be used in further assays to ensure that the inhibitors are 
effectively working. We decided not to persue this further as we concluded that 
these inhibitors were effectively working, as we saw a change in phenotype in 
replication and could visualise reductions in EU intensity around the nuclei coupled 
with the literature of them being potent inhibitors and previous data in our lab 
showing that these inhibitors worked in BJ-hTert cells. However, our results so far 
are in agreement with the idea that BET inhibition may lead to increased 
transcription of highly transcribed non-coding RNA genes. These results provide a 
clear mechanism, in which BET inhbitors lead to increase in RNA synthesis which 
causes increased transcription-replication interference that leads to replication fork 
slowing. How BET inhibition can lead to this increase in RNA synthesis is unclear 
and required further work which will be discussed later. 
Timecourse analyses showed that RNA synthesis was increased for up to 72 hours 
after JQ1 addition, while replication fork slowing was slowed down from 1 to 8 
hours, before being rescued back to normal fork speeds by 24 hours after JQ1 





synthesis coincides with fork slowing. It is however unclear how replication fork 
speeds can be recovered later on, whilst RNA synthesis is still increased. This will 
be futhur investigated in chapters 5 and 6.   
Previous work in the lab had shown that replication fork slowing could occur via two 
different mechanisms. The first of which, transcription-replication interference, had 
been demonstrated to be a major cause for HRASV12 overexpression induced fork 
slowing (Kotsantis, Silva et al. 2016). The second was that of increases in newly 
firing replication origins, which has been shown in the overexpression of oncogenes 
such as C-MYC or Cyclin E which then induces replication fork slowing (Jones, 
Mortusewicz et al. 2013, Srinivasan, Dominguez-Sola et al. 2013).  
Another aim of this chapter was to see whether this could be seen with BET 
inhibitor induced fork slowing too. Firstly, BET inhibitor JQ1 treated cells have a 
dramatic increase in origin firing compared to that of control cells, suggesting that 
an increase in origin firing may be a cause of fork slowing (Figure 3.11 B). However, 
an increase in origin firing could also be due to BET inhibitors inducing replication 
fork slowing and hence more origins are fired to rescue fork speeds. To further 
investigate whether increased origin firing caused fork slowing three different CDK 
inhibitors were used. The CDK inhibitors, which reduce origin firing below control 
levels shown in (Figure 3.12 B), rescued BET inhibitor-induced fork slowing back to 
control levels when co-treated with BET inhibitor JQ1 (Figure 3.12 C). This 
potentially suggests a mechanism in which increase origin firing in JQ1 treated cells 
can cause the fork slowing associated with JQ1. There are various ways increased 
origins can cause replicative stress such as depletion of nucleotides or other 





suggested another potential mechanism of BET inhibitor induced fork slowing, but 
more research was needed to fully characterise this as a potential mechanism for 
JQ1-induced replication stress in cancer cells.  
As there were now two potential mechanism for fork slowing to occur, we decided to 
investigate whether they acted separately to cause fork slowing, or together where 
increased origin firing leads to more transcription replication interference. Before we 
could address this question, we first wanted to test if CDK inhibitors had any effect 
on total RNA synthesis. CDK inhibitors decreased total RNA synthesis compared to 
JQ1 and control (Figure 3.13 B). This meant that CDK inhibitors also acted as 
transcriptional inhibitors as they inhibited RNA synthesis below the control level just 
as the transcriptional inhibitors did in figure 3.6. This meant that it was very hard for 
us to interpret whether CDK inhibitors were rescuing fork speeds due to the fact that 
they can decrease origin firing or because these inhibitors are able to reduce 
transcription levels in the cell. It may well be that increased origins are having a role 
in causing BET inhibitor induced fork slowing or that they are a by-product of the 
cell already being stressed due to slow forks.  
At this point it is hard to resolve this issue, as it quite hard for us to try and further 
investigate origin firing as a mechanism of BET inhibitor induced fork slowing. Our 
data doesn’t allow us to dissect and distinguish these as two separate mechanisms 
and it is unclear whether increased firing of origins play any role in causing BET 
inhibitor induced fork slowing. As our data provided clear evidence of transcription-
replication interference causing BET inhibitor induced fork slowing, we decided to 
concentrate on understanding the mechanism of transcription-replication 





Work from this chapter has reported that inhibition of BET proteins in U2OS cells 
caused no increases in nuclear foci of γH2AX, 53BP1 and RPA (Figure 3.14 A-B). 
H2AX is normally phosphorylated by activated ATR in a response to replication fork 
stalling. RPA foci are normally seen in response to excessive amounts of ssDNA 
which it can bind to before recruiting ATR-ATRIP (Flynn and Zou 2011).This would 
suggest that JQ1 induces fork slowing but does not cause excessive ssDNA. Also 
despite persistent fork slowing there does not seem to be formation of DSBs. These 
methods are measuring DNA damage signalling in response to BET inhibitor 
induced fork slowing, but may not prove that there is no damage in cells. The 
signalling pathway may have been surppressed and research has shown that both 
HR factors and ATR factors such as TOBP1 and WEE1 are downregulated in 
response to BET inhibitor treatment (Karakashev, Zhu et al. 2017, Sun, Yin et al. 
2018). When JQ1 was combined with DNA damaging agents, γH2AX, p-CHK1 and 
p–RPA32 induction was lower in cells treated with JQ1 compared to the control 
(Figure 3.15 A-C). This indicates some suppression of the DNA damage response 
pathways when BET proteins are inhibited. With DNA damaging agents HU and 
CPT, JQ1 caused a decrease in γH2AX, p-CHK1 and p–RPA32. However, when 
etoposide was added the opposite effect was seen. Etoposide is known to directly 
induce DSBs in DNA, while HU and CPT interfere with replication to cause DNA 
damage and DSBs. Previous research showed increased γH2AX in BRD4-depleted 
cells after ionising irradiation, which induces DSBs directly similar to etoposide. This 
was due to enhanced signalling from DSBs in BRD4 depleted cells, rather than 
increased amount of damage. It was suggested that BRD4-depleted cells have 





2013). Our results so far would indicate that there is reduced ATR activation in BET 
inhibited cells which is also supported by recent publications (Pawar, Gollavilli et al. 
2018, Sun, Yin et al. 2018, Zhang, Dulak et al. 2018). There is also evidence 
supporting that BET inhibition may be prevented from causing DNA damage by 
replication stress response factors such as ATR or CHK1, which are known to help 
stabilise the replication fork and prevent DNA damage (Figure 3.16 A-B).  
To summarise this chapter, BET inhibitors cause replication fork slowing by 
increasing transcription leading to transcription-replication interference. This does 
not activate the normal replication stress response pathways, and the replication 
stress response could even be supressed.  
The main questions that arise from the work in this chapter are firstly how RNA 
synthesis is increased after BET inhibitor treatment, and secondly, what happens 
downstream of the replication fork slowing. There may be damage occuring in the 
cells which is not inducing a signal or there may be another mechanism which 
happens after fork slowing which may cause no DNA damage signalling to occur. 















As mentioned previously, BET proteins consist of four different BET family members 
BRD2, BRD3, BRD4 and BRDT. All members act as transcription factors and 
epigenetic regulators (Zeng and Zhou 2002). Each BET protein family member has 
a conserved architecture consisting of two N-terminal tandem bromodomains and 
an ET domain (Filippakopoulos, Qi et al. 2010). BET proteins have important 
functions in transcription and are recruited to chromatin by acetylated histones on 
lysine tails, before recruiting various transcription factors to chromatin (Sanchez and 
Zhou 2009).  
All the BET proteins have been implicated in cancer and so are important proteins 
to study. Each BET protein has specific functions in regulating transcription as well 
as possessing specific diverse cellular roles. BET inhibitors work by binding to the 
acetylated lysine binding pockets of BET proteins and therefore stopping their 
recruitment to chromatin. BET inhibitors equally affect each BET protein, stopping 
all BET protein functions in the cell (Filippakopoulos, Qi et al. 2010).  
To further understand the role of BET inhibitors in DNA replication, it is important to 
know which BET protein is crucial for this function. To do this we would want to 





treating with BET inhibitors. Thus, the specific aim of this chapter is to elucidate the 
BET protein involved in DNA replication function. By understanding which BET 
protein is required for normal fork progression, we will have new insights into 
biological functions of BET proteins which may be important in developing better 
therapeutics.  
 
4.2: Loss of BRD4 leads to replication stress 
 
To begin to investigate which BET proteins are the targets responsible for BET 
inhibitors induced fork slowing, we used siRNA depletion to test which BET protein 
prevents replication stress following the Dharmafect protocol. First, we depleted 
BRD4 as it was the protein that is known to interact with P-TEFB as well as 
replication factor proteins such as Replication factor C (RFC), TICRR and CDC6 
(Maruyama, Farina et al. 2002, Quaresma, Bugai et al. 2016, Sansam, Pietrzak et 
al. 2018, Zhang, Dulak et al. 2018). Firstly, we treated cells with siRNA specifically 
for BRD4 for 48 hours (Figure 4.1 A). By Western blot we showed that BRD4 
protein levels are reduced indicating that the BRD4 siRNA works (Figure 4.1 B). 48 
hours after treatment with the siRNA, DNA fibre labelling was undertaken. BRD4 
depleted cells showed replication fork speeds decreased significantly compared to 
cells treated with control siRNA, mirroring the effects of treatment with JQ1 (Figure 
4.1 C-D). No additional fork slowing was seen when JQ1 was added to BRD4 









Figure 4.1: BRD4 depletion induces fork slowing. 
A) U2OS cells were transfected with BRD4 siRNA or control siRNA (nonTsi). Cells 
were processed for DNA fibre analysis 48 hours later. B) Protein levels of BRD4 
and Actin after siRNA transfection. C) Average median replication fork speeds of 
cells treated with NonTsi or BRD4 siRNA +/- 1 µM JQ1 treatment for 1 hour. D) 
Distribution of replication forks in cells treated with NonTsi or BRD4 siRNA +/- 1 µM 
JQ1 treatment for 1 hour. (N=3, error bars: S.E.M, Statistical analysis: Student’s t-
test. * P value <0.05, ** P value < 0.01.) 
 
Rescue experiments were also performed to test whether the BRD4 siRNA-induced 
replication fork slowing can be rescued when re-expressing wild type BRD4. To do 
this we combined siRNA and plasmid transfections for 48 hours using the Transit-





siRNA with either empty vector or BRD4 long isoform-expressing plasmid (Figure 
4.2 A). To show that the plasmid transfections had worked, we first tried a Western 
blot. However, due to technical difficulties in trying to visualise the antibody against 
the long isoform plasmid we decided to use an alternate method. We showed that 
the plasmid transfections worked by observing emGFP-BRD4 expression in cells. 
Cells that were treated with the BRD4 plasmid showed Green fluorescent protein 
(GFP) expression indicating successful transfections (Figure 4.2 B). DNA fibres 
were performed after these transfections. We observed that expressing BRD4 long 
isoform in cells treated with BRD4 siRNA restored fork speeds towards control fork 
speeds (Figure 4.2 C-D). When BRD4 plasmid transfection was combined with 
control siRNA, this had a slight effect on fork speeds, causing mild replication fork 
slowing (Figure 4.2 C-D). This data together shows fork speeds in BRD4-depleted 
cells can be rescued by re-expression of BRD4. This indicated that the BRD4 
siRNA specifically knocked down BRD4 in U20S cells including BRD4 long isoform. 
This also indicates that the loss of BRD4 alone impacts on normal ongoing 
replication in the cell.     
Thus, all this data taken together supports that BRD4 plays an important role in 








Figure 4.2: BRD4 long isoform-expressing plasmid rescues BRD4 depleted 
fork slowing. 
A) DNA fibre labelling after cells treated with either pcDNA or BRD4 long isoform 
expression for 48 hours with either nonTsi or BRD4 siRNA treatment. B) 
Representative pictures of EmGFP-BRD4 expression in U2OS cells after plasmid 
transfection with and without BRD4 siRNA treatment. C) Average median replication 
fork speeds with cells treated pcDNA or BRD4 long isoform expression plasmids +/- 
BRD4 siRNA treatment. D) Distribution of replication forks with cells treated pcDNA 
or BRD4 long isoform expression plasmids +/- BRD4 siRNA treatment. (N=3, error 










4.3: BRD4 depletion leads to increased RNA synthesis 
 
BRD4 depletion led to fork slowing, similar to that seen with BET inhibitor treatment. 
This then led to the idea that BRD4 depletion may also promote increased RNA 
synthesis mirroring BET inhibitor treatment. An EU assay was performed after both 
24 and 48 hours BRD4 siRNA treatment (Figure 4.3 A). We observed that as early 
as 24 hours of BRD4 depletion, there is an increase in total RNA synthesis (30% 
increase) which is similarly maintained in cells after 48 hours of BRD4 depletion 
(Figure 4.3 B-C). This is similar to what is observed with BET inhibitor treatment. 
This data shows that BRD4 depletion leads to increased RNA synthesis again 








Figure 4.3: BRD4 depletion causes increase in total RNA synthesis. 
A) U2OS cells were treated with nonTsi or BRD4 siRNA treatments and 
transcription elongation was quantified by incorporation of EU into the cells after 24- 
or 48-hours siRNA treatment. B) Representative images of click-stained EU cells 
with either nonTsi or BRD4 siRNA treatments for 48 hours. Scale bar 10 µm C) 
Nuclear EU intensities after BRD4 siRNA treatment after 24 and 48 hours. (N=5, 











4.4: BRD4 loss-induced replication fork slowing depends on 
transcription-replication conflicts 
 
As the phenotypes of increasing RNA synthesis and replication fork slowing were 
seen in cells depleted of BRD4 protein, we wanted to investigate whether 
transcription-replication interference was a major cause of this fork slowing. To do 
this we used a similar DNA fibre protocol as previously with JQ1 (Figure 3.9 A). 
Three transcriptional inhibitors DRB (100 µM for 1 hour), triptolide (1 µM for 1 hour) 
and α-amanitin (10 µg/µl for 4 hours) were added after BRD4 siRNA treatment for 
48 hours followed by DNA fibre labelling (Figure 4.4 A). The same effect was seen 
as was observed earlier with JQ1 treatment, wherein all three transcriptional 
inhibitors lead to a rescue of BRD4 depletion-induced fork slowing towards the 
control levels (0.66 kb/min in BRD4 siRNA treated cells to 0.84-1.03 kb/min in 
BRD4 siRNA treated cells combined with transcription inhibitors (Figure 4.4 B-C). 
The transcriptional inhibitors had slight effects of fork slowing when combined with 
control siRNA (Figure 4.4B). However, the levels of fork slowing observed where 
quite minimal, with forks still progressing at least 0.83 kb/min. This also does not 
impact the conclusion of this experiment that by inhibiting transcription in BRD4 










Figure 4.4: Transcriptional inhibitors rescue BRD4 depletion induced fork 
slowing. 
A) DNA fibre labelling in U2OS cells with transcriptional inhibitors α-amanitin (AM,10 
µg/ml) for 3 hours or DRB (100 µM) or Triptolide (TRIP,1 µM) for 1 hour with BRD4 
siRNA or nonTsi treatment for 48 hours. B) Average median of replication fork 
speeds treated with transcriptional inhibitors α-amanitin, DRB or Triptolide with 
BRD4siRNA or nonTsi treatment for 48 hours. C) Distribution of replication fork 
speeds in cells treated transcriptional inhibitors α-amanitin, DRB or Triptolide with 
BRD4siRNA or NonTsi treatment for 48 hours. (N=3, error bars: S.E.M, Statistical 









4.5: BRD2 and BRD3 loss has no major effect on replication and 
RNA synthesis 
 
In the previous experiments we had observed that BRD4 depletion had mirrored the 
phenotype of BET inhibitor treatment, hence indicating it as a target of BET inhibitor 
induced fork slowing. However, BRD2 and BRD3 had not been tested to see if they 
may also have the same effect. BRDT was excluded from this as it is only 
expressed in testes so would not be expressed in U2OS cells (Pivot-Pajot, Caron et 
al. 2003) (Appendix A1).  
Firstly, we investigated the effects of BRD2 depletion. We treated the cells with 
BRD2 siRNA for 48 hours (Figure 4.5 A). Using Western blot, we observed that 
BRD2 siRNA treatment for 48 hours led to the depletion of BRD2 protein in the cell 
(Figure 4.5 B). To test whether the same phenotypic effects observed with BET 
inhibitor treatment were seen in BRD2 depleted cells we used the DNA fibre assay 
and EU assay. Using the same approach detailed previously for BRD4, we 
observed that BRD2 depletion caused no major changes in fork speed (0.91 kb/min 
– 0.84 kb/min) (Figure 4.5 C). JQ1 treatment still caused fork slowing in combination 
with BRD2 depletion (Figure 4.5 C). BRD2 depletion also caused a slight decrease 
in EU intensity (by 0.18%) indicating a slight decrease of total RNA synthesis in 
BRD2 depleted cells (Figure 4.5 C). These results show that BRD2 depleted cells 







Figure 4.5: BRD2 depletion shows no significant changes in fork slowing or 
total RNA synthesis. 
A) DNA fibre labelling in U2OS cells with BRD2 siRNA or NonTsi treatment for 48 
hours. B) Protein levels of BRD2 after siRNA depletion. C) Nuclear EU intensities 
after BRD2 siRNA treatment after 48 hours. D) Average median replication fork 
speeds of cells treated with NonTsi or BRD2 siRNA +/- 1 µM JQ1 treatment for 1 
hour. (N=3, error bars: S.E.M, Statistical analysis: Student’s t-test. ** P value <0.01, 










Lastly, we looked into the effects of BRD3 depletion. We treated the cells with 
BRD3 siRNA for 48 hours (Figure 4.6 A). Using Western blot, we observed that this 
led to the depletion of BRD3 protein in the cell (Figure 4.6 B). To test whether the 
same phenotypic effects caused by BET inhibitor treatment were seen in BRD3 
depleted cells we used the DNA fibre assay and EU assay. Using the same 
approach detailed previously for BRD4, we observed that BRD3 depletion caused 
no major changes in fork speed (1.10 kb/min – 0.95 kb/min) (Figure 4.6 D). JQ1 
treatment induced fork slowing in combination with BRD3 depletion. BRD3 depletion 
also caused no change in EU intensity indicating there are no changes of total RNA 
synthesis in BRD3 depleted cells (Figure 4.6 D). These results show that BRD3 
depleted cells do not mirror the phenotypes induced by BET inhibitors or BRD4 
depletion. 
As this excluded roles for BRD2 and BRD3 in replication-transcription conflicts 
induced by BET inhibitor treatment, we decided not to pursue any additional 











Figure 4.6: BRD3 depletion shows no significant changes in fork slowing or 
total RNA synthesis. 
A) DNA fibre labelling in U2OS cells with BRD3 siRNA or nonTsi treatment for 48 
hours. B) Protein levels of BRD3 after siRNA depletion. C) Nuclear EU intensities 
after BRD3 siRNA treatment after 48 hours. D) Average median replication fork 
speeds of cells treated with NonTsi or BRD3 siRNA +/- 1 µM JQ1 treatment for 1 










4.6: BRD4 knockdown does not activate a replication stress 
response 
 
As previously shown in Chapter 3, JQ1 does not induce a DNA damage response 
despite replication fork slowing. BRD4 depleted cells had shown a similar 
phenotype to JQ1 with induced fork slowing and increased RNA synthesis. We now 
wanted to test whether BRD4 depletion could activate a DNA damage response. To 
look at this we used the same method as before with JQ1, performing 
immunofluorescence to analyse γH2AX and 53BP1 foci in presence of BRD4 
depletion. 
Like JQ1 treatment, BRD4 depletion caused no increase in the amount of foci 
compared to control (Figure 4.7). This data indicates that when cells are BRD4 
depleted an ATR response is not activated and there is no DNA damage response 















Figure 4.7: BRD4 depletion does not activate the replication stress response 
pathway. 
A) Percentages of cells containing more than 8 γH2AX after BRD4 depletion. B) 
Percentages of cells containing more than 8 53BP1 after BRD4 depletion. (N=3, 














The main aim for this chapter was to establish which BET protein was a specific 
target for BET inhibitors in inducing transcription-replication interference. There are 
four members of BET proteins of which three were thought to be a possible target 
for BET inhibitor-induced transcription-replication interference in U2OS cells.  
This chapter first investigated the effects of loss of BRD4 activity. BRD4 is the most 
studied member of the BET proteins. BRD4 is a transcriptional and epigenetic 
regulator but also has a number of different functions ranging from regulating 
development to regulating cell cycle progression (Yang, He et al. 2008, Di Micco, 
Fontanals-Cirera et al. 2014). When cells were depleted of BRD4, the effects 
mirrored those seen when cells were treated with BET inhibitors JQ1 or IBET151. 
Forks were slowed down, and total RNA synthesis had increased too (Figures 4.1 
and 4.3). By inhibiting RNA synthesis in the same way as done with JQ1 this fork 
slowing could be rescued (Figure 4.4). This indicated to us that BRD4 was 
important in preventing transcription-replication interference and was crucial in 
maintaining normal fork speeds in the cell. We can also conclude that BET inhibitors 
work by inhibiting BRD4 and hence we see a similar phenotype. This can be shown 
when JQ1 addition to BRD4 depleted cells caused no additional fork slowing (Figure 
4.1). It is important to note that fork speeds were rescued after 24 hours with JQ1 
but not after BRD4 depletion. The exact reason for this is still unclear but may be 
due to cells being able to adapt to drug treatment, but unable to adapt when BRD4 






While this was a positive result, there were still BRD2 and BRD3 which had not 
been tested before. Both BRD2 and BRD3 are involved in transcriptional regulation 
as well. We depleted both BRD2 and BRD3 in cells and observed that depletion of 
either protein caused no fork slowing or significant changes in RNA synthesis. This 
indicated that neither BRD2 nor BRD3 were involved in maintaining replication fork 
progression (Figures 4.5 and 4.6). As neither BRD2 nor BRD3 mirrored what was 
seen during BET inhibitor JQ1 treatment we concluded that they must not be the 
target of BET inhibitor induced replication-transcription interference. From these 
results we can be pretty certain that BRD4 is the most important BET protein target 
in replication fork progression that prevents fork slowing via transcription-replication 
interference. By establishing BRD4 as the only BET protein family member to 
phenotypically mirror BET inhibitors in our system, we have established a potential 
new role of BRD4 in fork maintenance. This could be important in a better 
understanding of BRD4 role in the cell as well as potential importance in future 
therapeutics. Recently studies have used a specific molecule (dBET6) to degrade 
BRD4 (Winter, Mayer et al. 2017). As BET inhibitors are non-specifically targeting 
all BET proteins this new molecule could provide useful in future therapeutics, 
especially since only BRD4 is implicated in maintaining normal replication fork 
progression.   
BRD4 depletion led to replication fork slowing which normally leads to the activation 
of replication stress response pathway driven by ATR. Previously, we observed that 
there was no activation of this response with JQ1 (Figure 3.14). We also observed 





increase in γH2AX or 53BP1 foci. This again mirrors what is seen with BET 
inhibition. This showed that the lack of replication stress response activation in BET 
inhibitor treated cells is not due to a side effect of JQ1 treatment on the cell, but 
potentially a mechanism that involves BRD4 being inhibited in cells.   
Now we know that BRD4 is the target of BET inhibition and it leads to increased 
transcription-replication interference, the main issues arising from this chapter are 
firstly what happens after BRD4 depletion induced fork slowing. Is there some 
mechanism preventing damage in these cells? Secondly, what causes this increase 







5.  BET inhibitor-induced replication-transcription 





Our previous results showed that BET inhibition, and BRD4 depletion, led to an 
increased amount of total RNA synthesis. Increased RNA synthesis led to more 
transcription-replication interference causing a slowing of replication forks. Thus far 
the mechanism of how RNA synthesis increases after BET inhibition was unknown 
and required further investigation.  
As mentioned previously, BET proteins are recruited to acetylated lysine residues 
on histone tails which then act to further recruit transcription factors to chromatin. 
One such transcription factor is P-TEFb which is required for RNA Pol II to undergo 
productive elongation. P-TEFb is a heterodimeric complex consisting of the catalytic 
CDK9 kinase and a regulatory CycT1 subunit (Price 2000, Zhou, Li et al. 2012). P-
TEFb can form active complexes with either BRD4 or the Super Elongation complex 
(SEC) and once activated can lead to the phosphorylation of CTD on RNA Pol II 
activating transcription initiation and elongation. The understanding of P-TEFb 
function was obtained using transcriptional inhibitor DRB which inhibits the CDK9 
kinase activity, hence stops CTD phosphorylation and inhibits transcription 
elongation (Marshall, Peng et al. 1996). P-TEFb can also be held in an inactive 





Recent studies have shown a mechanism in which loss of P-TEFb activation by 
BRD4, induced by BET inhibitors JQ1 or I BET-151, leads to compensatory 
disruption of the 7SK-P-TEFb complex leading to increased free (active) P-TEFb in 
the cells (Bartholomeeusen, Xiang et al. 2012, Chaidos, Caputo et al. 2014). 
Interestingly JQ1 treatment has been shown to increase HEXIM1 levels across cell 
lines (Bartholomeeusen, Xiang et al. 2012, Devaraj, Fiskus et al. 2016, Huang, 
Garcia et al. 2016, Zhu, Enomoto et al. 2017). 
The main aim of this chapter is to try and elucidate how this increase in RNA 
synthesis occurs after BET inhibition or BRD4 loss. Secondly, we will try and 
investigate the role of HEXIM1 and 7SK- P-TEFb in this process and test whether 
they could be involved in a potential mechanism of increased total RNA synthesis. 
 
5.2: BET inhibition leads to RNA Pol II phosphorylation 
 
Firstly, we wanted to investigate the potential evidence for BET inhibition leading to 
the disruption of the 7SK complex. As shown in figure 5.1 A, P-TEFb can be 
sequestered by HEXIM1 of the 7SK complex. JQ1 can lead to the disruption of this 
complex, which leads to more free P-TEFb which can then be recruited to the RNA 
Pol II either via BRD4 or the SEC. This can lead to increased phosphorylation of 
serines on the CTD on RNA Pol II by P-TEFb. These phosphorylation events lead to 
RNA Pol II being able to escape from a paused state to be able to perform 
productive elongation. This leads to increased RNA synthesis. A feedback loop 





the 7SK complex. This allows 7SK complex to form more complexes with P-TEFb 
again, hence leading to re-inhibition of P-TEFb as observed by Western blot probing 
for free P-TEFb (Bartholomeeusen, Xiang et al. 2012). 
To look at whether this mechanism could be why we see increased RNA synthesis, 
we first looked at whether we observed an increase in serine phosphorylation of 
RNA Pol II. To investigate this we looked at CTD serine 2 and serine 5 
phosphorylation. Both of these residues are on the CTD and involved in helping 
RNA Pol II produce stable elongation (Buratowski 2009, Zaborowska, Egloff et al. 
2016). We first tried to use Western blots to look at serine 2 phosphorylation, 
however we had some technical problems with this approach. We then used 
immunofluorescence after BET inhibitor treatment and quantified serine 2 
phosphorylation intensity. We observed an increase in this phosphorylation after 
BET inhibition treatment for 1 to 8 hours which returns to normal levels after 24 
hours (Figure 5.1 B-C). We looked at the effects on serine 5 phosphorylation as well 
and observed an increase in phosphoylation after 1 hour using Western blots 
(Figure 5.1 D-E). However, the results for later timepoints were not as reproducible 
and gave rise to inconsistent results (Figure 5.1 E). Potentially, this could be due to 
technical issues with the Western blot and using another technique may have 
helped to produce more re-producible results. 
Taken together these results indicate that BET inhibitor treatment in the first few 










Figure 5.1: JQ1 leads to increases in RNA polymerase II S2 phosphorylation. 
A) Current model of the role of HEXIM1 in JQ1-induced transcription increase. B) 
Representative images of nuclear foci for phospho-S2 RNA polymerase II and DAPI 
+/- JQ1 1 µM JQ1 treatment. Scale bar 10 µm C) Nuclear phospho-S2 RNA 
polymerase II intensity after 1µM treatment for 1, 4, 8- and 24-hour treatments or 10 
µM DRB. D) Representative protein levels of phospho-S5 RNA polymerase II after 1 
µM JQ1 treatment for 1, 4, 8 and 24 hours. E) Quantification of protein levels after 1 
µM JQ1 treatment for 1, 4, 8 and 24 hours (N=4, error bars: S.E.M, Statistical 






5.3: HEXIM1-7SK disruption leads to same phenotype as BET 
inhibition 
 
The previous result supported the hypothesis shown in Figure 5.1 A. We further 
wanted to confirm that disrupting the complex between 7SK-HEXIM1 and P-TEFb 
can lead to the same phenotypes observed with BET inhibitor treatment. This would 
provide further evidence that the disruption if the 7SK-HEXIM1 complex is the 
underlying cause of BET inhibitor-induced fork slowing.  
To test this, we needed a drug that is known to disrupt the 7SK-HEXIM1 complex 
from P-TEFb. HMBA is a drug known to be able to dissociate 7SK-snRP from P-
TEFb. HMBA is a hybrid bipolar compound which can induce cell differentiation in 
transformed cells. HMBA leads to the activation of the  PI3K/Akt signalling pathway, 
which in turn leads to HEXIM1 being phosphorylated which disrupts the 7SK-
HEXIM1 complex leading to increasd free P-TEFb (Contreras, Barboric et al. 2007, 
Fujinaga, Luo et al. 2015).  
To test whether HMBA mirrors the phenotype of BET inhibitor treatment we first 
looked at fibre experiments to see the effect on fork speeds. HMBA has no known 
effect on replication so any effects seen would be due to the 7SK complex 
disruption. We used two concentrations, 5 mM and 10 mM, as these concentrations 
had been effective in previous literature (Napolitano, Varrone et al. 2007, 
Bartholomeeusen, Xiang et al. 2012). We tested the effect of HMBA on RNA 
synthesis using the EU assay. We observed that the nuclear EU intensity increased 
with HMBA treatment with 5 mM (+21%) and 10 mM (+14%) indicating an increased 





where HMBA was added to the cells 1 hour before cells were labelled, spread and 
stained (Figure 6.2 A). HMBA treatment led to signinifcant fork slowing compared to 
control with either 5 mM (1.05 kb/min in control treated samples to 0.66 kb/min) or 
10 mM concentrations (1.05 kb/min in control treated samples to 0.65 kb/min) 
(Figure 5.2 C-D). There was no additional fork slowing with JQ1 co-treatment with 
HMBA, indicating that JQ1 had an identical method of fork slowing (Figure 5.2 C-D).  
These results taken togther show HMBA mirrors the phenotype seen with BET 
inhibitors, indicating that BET inhibitor-induced fork slowing is due to the 7SK 
complex being disrupted. A study has suggested that HMBA can function as a BET 
inhibitor and disrupts BET proteins from chromatin (Nilsson, Green et al. 2016). As 
we know that HMBA disupts the 7SK complex, this would again support that BET 















Figure 5.2: HMBA treatment leads increased RNA synthesis and increased 
fork slowing. 
A) DNA fibre labelling and quantification of incorporation of EU were performed in 
U2OS cells after treatment with HMBA (10 or 5 mM) for 1 hour. B) Average median 
replication fork speeds with cells treated with HMBA 5 mM +/- 1 µM JQ1 treatment 
for 1 hour. C) Average median replication fork speeds with cells treated with HMBA 
10 mM +/- 1 µM JQ1 treatment for 1 hour. D) Nuclear EU intensities after treatment 
with HMBA 5 mM or 10 mM for 1-hour treatment. (N=3, error bars: S.E.M, Statistical 









 5.4: BRD4 requires interaction with P-TEFb to maintain normal 
fork progression 
 
As we hypothesised that BET inhibitor induced fork slowing was caused by the 
disruption of the inhibitory complex of P-TEFb, we wanted to invesitgate if loss of 
the BRD4-P-TEFb interaction is involved in fork slowing when BRD4 is depleted 
from cells. 
BRD4 has three different isoforms, isoform A, isoform B and isoform C. Isoform A, 
which is commonly referred to as the long isoform, includes a CTD which can 
interact with P-TEFb. Isoform B lacks the CTD but has a unique 75 amino acid 
extension instead. Isoform C, commonly referred to as the short isoform, lacks this 
CTD and therfore cannot interact with P-TEFb (Figure 5.3 A) (Sakamaki, Wilkinson 
et al. 2017). BRD4 siRNA had been shown to knock down both the long and short 
isoforms (Figure 4.1 B). We had also shown that we could rescue the BRD4 
depletion-induced fork slowing by re-expressing BRD4 long isoform plasmid (Figure 
4.2 D). We wanted to see what the effect would be when re-transfecting BRD4 
depleted cells with the short isoform which cannot interact with P-TEFb but still 
interacts with replication proteins RFC,TICRR and CDC6 (Schroder, Cho et al. 
2012, Sakamaki, Wilkinson et al. 2017).  
To do this we used combined siRNA and plasmid transfections for 48 hours using 





with either pEGFP-C2 control plasmid or the BRD4 short form isoform-expressing 
plasmid (Figure 5.3 B). We first used Western blots to confirm that we can re-
express the BRD4 short isoform even in combination with BRD4 siRNA treatment 
(Figure 5.3 C). We next performed DNA fibre assays after these transfections 
(Figure 5.3 B). We observed that when combined with BRD4 depletion, short 
isoform re-expression does not rescue the fork speeds, which are still slowed to the 
same level as after BRD4 depletion alone (from 1.01 kb/min to 0.63 kb/min) (Figure 
5.3 D). 
These results showed that, unlike the long isoform of BRD4, the short isoform of 
BRD4 cannot rescue the BRD4 loss-induced fork slowing. This indicates a role for 
the interaction of BRD4 with P-TEFb, but not the known interactions with replication 



















Figure 5.3: BRD4 short isoform expression does not rescue fork slowing after 
BRD4 depletion. 
A) Schematic of BRD4 long and short isoforms. B) DNA fibre labelling after cells 
treated with either GFP or BRD4 short isoform expression for 48 hours with either 
nonTsi or BRD4 siRNA treatment. C) Protein levels of BRD4 short isoform +/- BRD4 
siRNA treatment and +/- BRD4 short isoform plasmid transfection. D)  Average 
median of replication fork speeds with cells treated GFP or BRD4 short isoform 
expression plasmids +/- BRD4 siRNA treatment. (N=3, error bars: S.E.M, Statistical 








5.5: Replication-transcription conflicts induced by BET inhibition 
require HEXIM1 
 
We had shown that P-TEFb had a role in BET inhibitor induced fork slowing and 
increased total RNA synthesis. Our hypothesis stated that after P-TEFb was 
realeased from its 7SK-HEXIM1 inhibitory complex, it led to more RNA Pol II 
phosphorylation, which would lead to an increase in HEXIM1 levels leading back to 
P-TEFb being inhibited by the 7SK complex again. We therefore decided it was 
important to further investigate the role that HEXIM1 played in BET inhibitor induced 
fork slowing.  
Firstly, we wanted to test what happened to the levels of HEXIM1 after 1 to 72 
hours of BET inhbitor treatment (Figure 5.4 A). To do this we performed a Western 
blot with cells treated with either control or HEXIM1 siRNA for 48 hours before being 
JQ1 treated for another 1 to 24 hours. We firstly observed that the HEXIM1 levels 
were depleted after treatment with HEXIM1 siRNA for all timepoints with JQ1 
treatment. We also observed no significant change in HEXIM1 levels across these 
treatment times (Figure 5.4 B). To investigate this further we looked at HEXIM1 
levels for 48-72 hours after JQ1 treatment and observed a slight increase in 
HEXIM1 levels compared to control levels (Figure 5.4 C).  
These results indicate that we see an increase in HEXIM1 levels after BET inhibitor 
treatment supporting the model outlined in Figure 5.1 A, however this increase is 






We also tested the HEXIM1 baseline protein expression among all cell lines we had 
previously tested (Figures 1.6 and 1.7), to try and elucidate whether the baseline 
HEXIM1 levels correlates with BET inhibitor-induced replication stress.  
We tested HEXIM1 protein levels in these cell lines and found that the cell lines in 
our panel displayed comparable HEXIM1 protein levels (Figure 5.4 D). The non-
cancer BJ cells had lower HEXIM1 levels than the cancer lines, the reason for this 
is unknown. This suggests that JQ1 should be able to induce RNA synthesis and 
replication stress in all cell lines tested. The reason for the lack of replication stress 
in C2 cells is still unknown and will require further investigation.  
This cell line panel currently does not allow us to draw conclusions about the 
correlation between HEXIM1 levels and JQ1-induced replication stress, and this 













Figure 5.4: HEXIM1 levels after HEXIM1 siRNA depletion with JQ1 treatment. 
A) Cells were treated with HEXIM1 siRNA for 48 hours before JQ1 treatment for 
indicated times before cells were harvested. B) Protein levels of HEXIM1 after 48 
hours siRNA transfection followed by 1 µM JQ1 treatment for 1, 4, 8 and 24 hours 
(n=3). C) Protein levels of HEXIM1 after 1 µM JQ1 treatment for 48 and 72 hours 
(n=3). D)  Protein levels of HEXIM1 with and without 1 µM JQ1 treatment for 1 hour 











We decided to further study the role HEXIM1 plays in BET inhibitor induced fork 
slowing and increased RNA synthesis. To do this we used both the DNA fibre and 
EU assays. After HEXIM1 siRNA transfection for 48 hours followed by JQ1 treatment 
for different times, fibres were labelled and spread, or EU was added for 1 hour 
(Figure 5.5 A). HEXIM1 depletion seemed to delay the BET inhibitor-induced increase 
in EU intensity (Figure 5.5 B). After 1 hour of BET inhibitor treatment, HEXIM1 
depletion actually led to a decrease in EU intensity. The increase in RNA synthesis 
was comparable to values in NonTsi treated cells after 24 hours after BET inhibitor 
treatment, where we saw the same levels of EU intensity as seen with JQ1 treatment 
alone (Figure 5.5 B). We also observed this delayed effect when HEXIM1 is depleted 
in the DNA fibre assay (Figure 5.5 C). Here when cells are depleted of HEXIM1, cells 
show no visible fork slowing after BET inhibitor treatment from 1-8 hours. However, 
cells depleted of HEXIM1 showed fork slowing when combined with JQ1 treatment 
for 24 hours (Figure 5.5 C).   
Together, this data shows that HEXIM1 depletion delays the BET inhibitor induced 
increase in RNA synthesis as well as delaying fork slowing until after 24 hours of BET 
inhibitor treatment. This data suggests that HEXIM1 is required for the rapid induction 












Figure 5.5: HEXIM1 depletion reverses effect on fork speeds and RNA 
synthesis of JQ1.  
A) DNA fibre labelling in U2OS cells were treated with HEXIM1 siRNA for 48 hours 
before 1 µM JQ1 treatment for indicated times. B) Nuclear EU intensities with 
HEXIM1 siRNA or NonTsi siRNA treatment with +/- 1 µM JQ1 treatment for 1 and 
24 hours. C) Average median replication fork speeds after HEXIM1/ nonTsi siRNA 
and +/- 1 µM JQ1 treatment for 1, 4, 8 and 24 hours. (N=3, error bars: S.E.M, 
Statistical analysis: Student’s t-test. * P value <0.05, ** P value <0.01, *** P value 









5.6: HEXIM1 depletion leads to increased DNA damage during BET 
inhibition 
 
We had previously observed that JQ1 treatment or BRD4 loss slowed fork speeds 
but showed no induction of a downstream replication stress response (Figure 3.14, 
Figure 4.7). We decided to investigate the relationship between BET inhibition, 
HEXIM1 and DNA damage. HEXIM1 depletion causes replication forks to slow later 
during JQ1 treatment, when gene expression changes might make them more 
vulnerable to damage. 
To test this, we used the same methods as before, using immunofluorescence to 
look at γH2AX and 53BP1 foci after HEXIM1 depletion coupled with JQ1 treatment 
(Figure 5.6 A). HEXIM1-depleted cells showed more active DNA damage signalling 
after 24 h JQ1, in contrast to control cells as there were increases in percentage of 
53BP1 foci positive cells (from 9% to 15%) (Figure 5.6 B-C) and γH2AX positive 
cells (from 2% to 5%). Unexpectedly, HEXIM1-depleted cells also accumulated 
DNA damage early during JQ1 treatment (Figure 5.6 B-C). This suggests that 
HEXIM1 prevents JQ1-induced DNA damage. DNA damage can contribute to cell 
death, so Dr Eva Petermann performed colony assays to see how sensitive cells 
depleted of HEXIM1 were to JQ1. HEXIM1-depleted cells were more sensitive to 
24-hour JQ1 treatment than control-depleted cells (Figure 5.6 D). We also 
compared the effect of HEXIM1 depletion to the effect of ATR inhibition, a treatment 





depletion alone and ATR inhibitor alone lead to similar sensitivity and observed that 
ATR inhibition in combination with HEXIM1 depletion leads to increased sensitivity 
of cells to JQ1. Cells depleted of HEXIM1 were just as sensitive as cells treated with 
ATR inhibitor which correlated with the damage seen in cells where HEXIM1 is 
depleted at this time point.  
These results taken together suggest that HEXIM1 is important in helping prevent 
DNA damage in response to JQ1 treatment and also contributes to helping cells 














Figure 5.6: HEXIM1 depletion activates a BET inhibitor replication stress 
response. 
A) Cells were treated with HEXIM1 siRNA for 48 hours before 1 µM JQ1 treatment 
for 1- or 24-hours treatment before cells were fixed and stained. B) Percentages of 
cells containing more than 8 53BP1 after HEXIM1 depletion +/- 1 µM JQ1 for 1- and 
24-hour treatments. C) Percentages of cells containing more than 8 γH2AXafter 
HEXIM1 depletion +/- 1 µM JQ1 for 1- and 24-hour treatments. D) Colony survival of 
U2OS cells treated with indicated concentrations of JQ1 for 24 hours, +/- HEXIM1 
siRNA and 2.4 µM ATRi AZ20 for 24 hours. The statistical test used was 2-way 
ANOVA with Tukey’s, **** = p<0.0001. (N=3, error bars: S.E.M, Statistical analysis: 










5.7: BET inhibition leads to increased genomic instability 
 
Persistent replication stress can lead to genomic instability in cells (Carr and 
Lambert 2013, Zeman and Cimprich 2014, Gaillard, Garcia-Muse et al. 2015). 
Genomic instability is a major hallmark of tumorigenesis in cells (Hanahan and 
Weinberg 2000). Understanding what can drive genomic instability is crucial, 
especially in the case of therapeutics or drugs where genomic instability could 
promote secondary cancers. BET inhibitors had not shown to induce DNA damage 
signalling, however they induced transcription-replication conflicts, RAD51 
recruitment and potentially still induce DNA damage. It therefore was important to 
check if BET inhibitors may potentially promote genomic instability.  
To investigate this further we looked to see if JQ1 treatment could increase 
micronuclei formation. Micronuclei are biomarkers of genomic instability (Fujisawa, 
Nakajima et al. 2015, Higgs, Reynolds et al. 2015, Reynolds, Bicknell et al. 2017). 
They are extra-nuclear bodies that contain displaced or damaged chromosomes 
that are not incorporated into the daughter nucleus during mitosis (Luzhna, Kathiria 
et al. 2013, Gekara 2017). They can be visualised around the cells under the 
microscope with DAPI stained cells (Figure 5.7 A). We measured micronuclei in 
both control treated cells and JQ1 treated cells and calculated the percentage of 
cells with micronuclei over number of cells counted. We observed that JQ1 
treatment after 24 hours leads to increased amount of micronuclei (Figure 5.7 B). 
To see if this effect would be amplified after depletion of proteins that prevent DNA 
damage signalling, we measured micronuclei after HEXIM1 depletion with JQ1 co-





micronuclei, this increase was similar with and without JQ1 treatment (Figure 5.7 
C). 
Overall this data suggests that BET inhibitors and HEXIM1 depletion lead to 
increased genomic instability in the cell, possibly in an independent manner. 
 
 
Figure 5.7: BET inhibitor treatment increases genomic instability. 
A) Representative images showing micronuclei formation of DAPI stained cells after 
1 µM JQ1 treatment for 24 hours. Scale bar 10 µm B) Percentage of total cells 
containing micronuclei after 24 hours JQ1 treatment. C) Percentage of total cells 
containing micronuclei after HEXIM1 siRNA treatment +/- 1 µM JQ1 treatment for 
24 hours. (N=3, error bars: S.E.M, Statistical analysis: Student’s t-test. * P value 







The main aim of the chapter was to try and elucidate the mechanism of increased 
RNA synthesis. HEXIM1 is the only gene whose expression is regularly up-
regulated after JQ1 treatment across cell lines (Bartholomeeusen, Xiang et al. 2012, 
Devaraj, Fiskus et al. 2016, Huang, Garcia et al. 2016, Zhu, Enomoto et al. 2017). 
Previous literature indicated a role for JQ1 to disrupt the 7SK-HEXIM1 inhibitory 
complex of P-TEFb (Bartholomeeusen, Xiang et al. 2012, Chaidos, Caputo et al. 
2014). Hence, we hypothesised that BET inhibitors increase RNA synthesis by 
disruption of the P–TEFb and 7SK-HEXIM1 inhibitory complex. 
Our data suggests a mechanism of how BET inhibitors can lead to increased RNA 
synthesis. Increased CTD phosphorylation after JQ1 treatment (Figure 5.1 B-E) 
agrees with increased activity of P-TEFb, which phosphorylates and activates RNA 
Pol II. We showed that by using a drug HMBA that can disrupt the inhibitory 
complex of P-TEFb and 7SK-HEXIM1 but doesn’t impair any factors involved in 
allowing faithful DNA replication, we can induce fork slowing (Figure 5.2). This 
agrees with the model that disrupting the P-TEFb-7SK-HEXIM1 complex can lead to 
fork slowing. This fork slowing was not exacerbated by JQ1 addition, which may 
suggest that the disruption of the 7SK complex may act as a primary cause of fork 
slowing. Hence, from our data we suggest a potential mechanism where BET 
inhibitors can disrupt the 7SK-HEXIM1 complex which may liberate P-TEFb from its 
inhbitory complex, which can cause more RNA Pol II phosphorylation which 
suggests more RNA synthesis which would lead to increased transcription-






We showed that BRD4 regulates DNA replication via its P-TEFb interaction domain 
(Figure 6.3). The sites for the interactions with replication proteins TICRR and RFC 
are contained in the BRD4 short isoform but the CDC6 interaction has not been 
mapped as of yet (Maruyama, Farina et al. 2002, Sansam, Pietrzak et al. 2018, 
Zhang, Dulak et al. 2018). We showed that re-expressing the BRD4 short isoform, 
containing the interaction domains for TICRR and RFC  but not P-TEFb, was unable 
to rescue replication fork slowing, while the long isoform with a P-TEFb interaction 
domain could rescue fork speeds (Figure 3.2 and 5.3). Hence, our data suggest that 
TICRR and RFC replication proteins are not involved in the phenotypes seen with 
BRD4 loss. Instead, our data supports a novel mechanism of how BRD4 regulates 
DNA replication progression via its P-TEFb interactions. There is a caveat in that 
BRD4 long isoform has recently been shown to interact with NELF, which is also an 
important factor in transcription elongation (Lambert, Picaud et al. 2019). Further 
work is required to see if the interaction between NELF and BRD4 is playing a role 
in the regulation of replication fork speeds. 
As HEXIM1 protein is consistently up-regulated by JQ1 treatment, we decided to 
investigate if HEXIM1 displayed the same behaviour in the U2OS cell line being 
tested (Bartholomeeusen, Xiang et al. 2012, Devaraj, Fiskus et al. 2016, Huang, 
Garcia et al. 2016, Zhu, Enomoto et al. 2017). HEXIM1 protein levels slowly 
increased during 48–72 hr JQ1 treatment (Figure 5.4 C), although this was a very 
slow induction of HEXIM1 levels compared to what had been shown in other studies 
(Bartholomeeusen, Xiang et al. 2012, Devaraj, Fiskus et al. 2016, Huang, Garcia et 





correlated with no decrease in nascent RNA synthesis at these time points (Figure 
5.4 D). These results suggest that the hypothesised mechanism of a feedback loop 
highlighted in Figure 5.1 A is not occurring with the U2OS cells. This suggests that 
the process of replication adaptation after 24 hours of JQ1 (Figure 3.2 B-C) is more 
complex than the hypothesised HEXIM1-mediated feedback loop suppressing 
transcription. How cells adapt to BET inhibitor treatment to rescue fork speeds 
requires further investigation.  
In cells depleted of HEXIM1, JQ1 treatment caused delayed replication fork slowing 
and delayed increases in RNA synthesis (Figure 5.5). Our findings suggest that 
HEXIM1 is required for BET inhibitor-induced replication fork slowing, which is 
delayed by at least 8 hours in the absence of HEXIM1. This data suggests that both 
these processes are altered when HEXIM1 is depleted, but we have no model for 
how this works yet. The most likely explanation would be that in absence of 
HEXIM1, the initial disrupting of the P-TEFb-7SK-HEXIM1 complex does not occur, 
but cells eventually adapt to this as well. There could be numerous explanations 
such as JQ1 inducing gene expression changes after 24 hours (Delmore, Issa et al. 
2011, Muralidharan, Bhadury et al. 2016). Another explanation may be 
compensation by HEXIM2, which can bind to P-TEFb when HEXIM1 is depleted 
compensating for HEXIM1 loss. Studies have shown that these two proteins are 
regulated differently in response to external stimuli so may act differenty to BET 
inhibitor treatment (Byers, Price et al. 2005). However, this again requires further 
investigation.  
Interestingly, the lack of replication fork slowing in HEXIM-depleted cells is 





HEXIM1 depletion leads to JQ1 sensitivity in response to short treatments of 1 hour 
(Figure 5.6 D). Research had shown that HEXIM1 depletion could lead to long-term 
BET inhibitor resitance, which did not conflict with our findings as it was only seen 
with over 24 hours treatment. The authors proposed that loss of HEXIM1 decreases 
overall JQ1 effectiveness by allowing higher P-TEFb activity (Devaraj, Fiskus et al. 
2016). In addition to modulating transcription-dependent fork slowing, HEXIM1 
might have more undiscovered roles in controlling the replication stress response 
pathway and DNA damage signalling.   
We also observed an increase in micronuclei, a genomic instability marker in cells 
after BET inhibitor treatment (Figure 5.7). Genomic instability is crucial in driving 
tumorigenesis and could be an important side-effect if BET inhibitor drugs are used 
as cancer therapeutics (Hanahan and Weinberg 2000, Gaillard, Garcia-Muse et al. 
2015).  
How BET inhibitor-treated cells acquire more micronuclei is unclear. It may be due 
to reversed forks collapsing before they can be restarted or being subjected to 
nucleophilic attack. This can lead to cells with under-replicated DNA after S-phase, 
which when undergoing mitosis can generate ultra-fine anaphase bridges and 
ultimately lead to micronuclei or chromosome breakage (Naim and Rosselli 2009). 
However, it must be noted that micronuclei generation is not solely caused by 
replication stress. There is potential that BET inhibitors could be interfering with the 
mitotic machinery which could give rise to mis-segregation of chromosomes and 
form micronuclei. Another mechanism could be BET inhibitor causing increased 





may help determine if there is more total DNA damage in the cell after BET inhibitor 
treatment.  
So far, we have provided data supporting that disruption of the 7SK-HEXIM1 
inhibitory complex with P-TEFb leads to increased RNA synthesis after BET 
inhibitor treatment, hence leading to replication fork slowing. BRD4 regulates 
replication fork speeds via its interaction with P-TEFb, and loss of this interaction 
causes replication fork slowing. We have also shown that HEXIM1, which is 
upstream of transcription-replication conflicts, is required for BET inhibitor-induced 
fork slowing and increased RNA synthesis.  
Our data also suggests that HEXIM1 prevents DNA damage signalling after BET 












Despite replication fork slowing in response to either BET inhibition or BRD4 loss, 
there was no activation of the replication stress response or any DNA damage 
signalling. Fork speeds were also rescued after 24 hours of BET inhibition, 
suggesting that there is some adaptation mechanism in response to BET inhibition.  
RAD51 is a homologous recombination protein involved in helping cells deal with 
DSB’s (West 2003, Ciccia and Elledge 2010, Bhat and Cortez 2018). RAD51 also 
has a role in fork re-modelling and reversal in a DSB independent manner (Hanada, 
Budzowska et al. 2007, Petermann, Orta et al. 2010, Carr and Lambert 2013, 
Zellweger, Dalcher et al. 2015, Bhat and Cortez 2018). RAD51 has been proposed 
to help replication restart after replication forks slow or stall (Petermann, Orta et al. 
2010, Zellweger, Dalcher et al. 2015, Bhat and Cortez 2018). This is thought to 
involve the formation of a reversed fork which can help stabilise and promote fork 
restart. Fork reversal is a tightly regulated process whereby the replication fork 
regresses into a Holliday junction (chicken foot structure) (Neelsen, Chaudhuri et al. 
2014, Zellweger, Dalcher et al. 2015).  
Recent studies show that HR and RAD51 are able to play roles at replication fork 
processes such as replication stress. Studies have indicated that RAD51 can be 
recruited to stalled forks after treatment with stress inducing compounds such as 





replication fork collapse and potentially lead to fork restart as well (Arnaudeau, 
Lundin et al. 2001, Lundin, Schultz et al. 2003, Carr and Lambert 2013, Willis, 
Chandramouly et al. 2014). Further research has indicated a role for fork reversal 
by RAD51 has been shown to be able to modulate fork progression in response to 
genotoxic stress (Zellweger, Dalcher et al. 2015). RAD51 loss led to the rescue of 
stressed replication fork speeds indicating a role of RAD51 slowing forks down in 
response to replication stress. They also observed no ATR activation upon 
treatment with several genotoxic compounds such as Etoposide, Mitomycin C, 
Aphidicolin, Doxorubicin and Cisplatin all of which caused fork slowing under the 
same conditions. These results have similarity to our data with BET inhibitors 
(Zellweger, Dalcher et al. 2015). RAD51 levels have also been shown to be 
gradually depleted after JQ1 treatment across a variety of cell lines (Yang, Zhang et 
al. 2017, Pawar, Gollavilli et al. 2018). These observations led us to hypothesise a 
potential role for RAD51 in modulating fork progression and reversing and 
stabilising stressed replication forks after BET inhibitor treatment.  
In this chapter we aim to investigate the cell’s response to BET inhibitor-induced 
replication stress. In particular we want to investigate if there is a potential role 
RAD51 plays at BET inhibitor-induced slowed replication forks in either modulating 
fork progression or stabilising these replication forks after replication stress has 
occurred. We also try to elucidate whether RAD51 levels are important in rescuing 






6.2: BET inhibition increases RAD51 foci formation 
  
To firstly test whether RAD51 is recruited to chromatin during BET inhibitor induced 
fork slowing, we used immunofluorescence. Cells were treated with 1 µM JQ1 for 8 
hours, with or without the presence of ATR inhibitor and then stained with RAD51 
antibody. We observed an increase in positive RAD51 foci cells with JQ1 treatment 
from 7.4% to 14%. This increase in RAD51 foci was lost when JQ1 was co-treated 
with 2.4 µM ATRi (Figure 6.1 A-B). This suggested that RAD51 recruitment after 
JQ1 treatment requires a basal level of ATR activation in response to BET inhibitor 
treatment. In addition, a time-course of JQ1 treatment from 1 to 24 hours was 
performed by Dr Ann Liza Piberger in our laboratory. Dr Piberger observed a 
significant increase in RAD51 foci after 4 hours of treatment (16%-26%), while after 
24 hours RAD51 foci were reduced back to control levels (Figure 6.1 C). As this 
was observed with BET inhibitor treatment, we next tested whether RAD51 foci 
formation could also be seen after BRD4 depletion. After treating cells with control 
siRNA or BRD4 siRNA, we again observed similar results where BRD4 depleted 
cells showed increased percentages of RAD51 foci positive cells, from 11% to 18% 















Figure 6.1: JQ1 and BRD4 depletion leads to increased RAD51 foci. 
A) Percentages of cells containing more than 5 RAD51 foci after 1 hour 1 µM JQ1 
treatment +/- ATR inhibitor 2.4 µM AZ20. B) Representative images of RAD51 foci 
after 8 hour 1 µM JQ1 treatment. Scale bar 10 µm. C) Percentage of cells 
containing more than 5 RAD51 after 1 µM JQ1 treatment for 1, 4, 8- and 24-hour 
treatment. D) Percentages of cells containing more than 5 RAD51 foci after BRD4 
depletion for 48 hours. (N=3, error bars: S.E.M, Statistical analysis: Student’s t-test. 










RAD51 foci were induced after JQ1 treatment, suggesting that RAD51 is recruited 
to sites of transcription-replication conflicts. To see if RAD51 foci formation was 
dependent on ongoing transcription, we looked at RAD51 foci formation with or 
without treatment with potent transcriptional inhibitor α-amanitin as used previously 
in chapter 3. This experiment was carried out by Dr.Piberger. Cells were co-treated 
with JQ1 and α-amanitin for 4 hours. Again we observed an increase in the 
percentage of RAD51 foci positive cells after JQ1 treatment, which after co-
treatment with α-amanitin was reduced from 26% to 19% (Figure 6.4 A). α-amanitin 
by itself had no effect on the recruitment of RAD51 foci compared to control. This 
suggests that RAD51 is recruited in response to the transcription-replication 
conflicts, as transcription inhibition prevents the increase in RAD51 foci. 
Overall these results indicate that BET inhibitor treatment and BRD4 loss lead to the 
induction of RAD51 foci formation in correspondence with transcription-associated 
replication fork slowing, dependent on a basal level of ATR activity.  
 
6.3: RAD51 promotes BET inhibitor-induced fork slowing 
 
A previous report had showed a role for RAD51 in slowing down fork progression in 
response to genotoxic stress (Zellweger, Dalcher et al. 2015). As we observed an 
acummlation of RAD51 foci after BET inhibitor treatment, we decided to investigate 
if RAD51 could potentially be playing a similar role in fork slowing in response to 





with either control or RAD51 siRNA for 48 hours before JQ1 treatment for 1 or 24 
hours, followed by harvesting the cells (Figure 6.2 A). We used Western blots to 
confirm the effect of siRNA treatment on RAD51 protein levels. RAD51 siRNA 
treatment depleted RAD51 protein levels in presence or absence of JQ1 (Figure 6.2 
B). We also observed that the levels of RAD51 were slowly decreasing after JQ1 
treatment in control siRNA treated cells (Figure 6.2 B). This mirrored what had 
previously be seen in the other reports (Yang, Zhang et al. 2017, Pawar, Gollavilli et 
al. 2018).  
To test the effects of RAD51 on BET inhibitor fork progression we used DNA fibre 
assays, using the same method as above but labelling and spreading fibres after 
the JQ1 treatment (Figure 6.2 A). We observed that RAD51 depletion rescued the 
fork slowing induced by 1 hour BET inhibitor treatment (Figure 6.2 C). There was no 
change in fork speeds after 24 hours with or wihout RAD51 depletion, as fork 
speeds were not slowed in either case. RAD51 siRNA by itself had no effect on fork 
speeds compared to control indicating RAD51 was having no effects on replication 
progression in the absence of BET inhibitor treatment. This would indicate that 
RAD51 has an important role in controlling fork speeds in response to BET 
inhibitors, similar to what was observed in response to genotoxic stress.  
We observed that in response to JQ1 treatment, RAD51 levels were slowly being 
decreased (Figure 6.2 B). This effect was most prominently seen after 24 hours 
where a major reduction in RAD51 levels was occuring. This lead us to hypothesise 








Figure 6.2: RAD51 depletion rescues BET inhibitor induced fork slowing. 
A) DNA fibre labelling in U2OS cells treated with RAD51 siRNA for 48 hours 1 µM 
JQ1 treatment for 24 or 1 hour. B) Protein levels of RAD51 and actin after nonTsi or 
RAD51 siRNA treatment +/- 1 µM JQ1 treatment for 1 or 24 hours. C) DNA fibre 
labelling in U2OS cells were treated with RAD51 siRNA for 48 hours before 1 µM 
JQ1 treatment for 1 or 24 hours. (N=3, error bars: S.E.M, Statistical analysis: 











To investigate this further, we transfected cells with a RAD51 expression plasmid 
using to overexpress RAD51 in cells. We performed DNA fibre assays, after cells 
were treated with either control or RAD51 plasmid for 24 hours, followed by 
treatment with or without JQ1 for 24 hours (Figure 6.3 A). We first tested that the 
transient plasmid transfection worked using a Western blot. Here we observed that 
RAD51 plasmid transient overexpression with or without JQ1 increased levels of 
RAD51 compared to control (Figure 6.3 B). This indicated that the plasmid transient 
transfection was working. 
We observed that RAD51 transient overexpression after 24 hour JQ1 treatment led 
to fork speeds being reduced compared to the control as usually obserevd after 1 
hour BET inhibitor treatment (Figure 6.3 C). RAD51 overexpression in control 
treated cells had no effect on fork speeds, indicating that RAD51 overexpression 
has no adverse effects on fork speeds by itself. Overall this data provides another 
indicator that RAD51 is slowing forks on response to BET inhibition. This data also 
provide a potential mechanism of how fork speeds are rescued after 24 hours of 














Figure 6.3: RAD51 overexpression stops BET inhibitor adaptation to replication 
stress after 24 hours. 
A) DNA fibre labelling after cells treated with either GFP or RAD51 expression 
plasmid for 48 hours with or without 1 µM JQ1 treatment for 1 or 24 hours. B) 
Protein levels of RAD51 +/- RAD51 plasmid transfection and +/- 1 µM JQ1 
treatment. C) Average median of replication fork speeds after transient 
overexpression of RAD51 or eGFP (control) +/- 1 µM JQ1 treatment for 24 hours. 
(N=3, error bars: S.E.M, Statistical analysis: Student’s t-test. * P value <0.05, NS= 








We wanted to see whether this rescue in fork speeds after RAD51 depletion was 
due to reduced RNA synthesis as we observed with HEXIM1 depletion (Figure 5.5). 
To do this we used the EU assay, depleting RAD51 for 48 hours before adding EU 
for an additional hour (Figure 6.4B). RAD51 knockdown cells showed high levels of 
RNA synthesis and produced variable results with or without JQ1 treatment (Figure 
6.4 C). This makes interpreting the data difficult, but it can be concluded that there 
is no decrease in total RNA synthesis after RAD51 depletion.  
Overall this data would indicate that RAD51-induced fork slowing is in response to 
transcription-replication conflicts, and that the rescue seen when RAD51 is depleted 












Figure 6.4: RAD51 foci formation after BET inhibitor treatment depends on 
RNA synthesis. 
A) Percentages of cells with 8 or more RAD51 foci after 4-hour treatment of 1 µM 
JQ1 and transcription inhibitor α-amanitin (AM, 10µg/ml) for 4 hours. B) 
Quantification of incorporation of EU performed in U2OS cells after 48 hours RAD51 
siRNA or NonTsi treatment followed by +/- 1 µM JQ1 treatment for 1 hour. C) 
Nuclear EU intensity after RAD51 siRNA treatment and +/- 1 µM JQ1 treatment for 
either 1 or 24 hours (N=3, error bars: S.E.M, Statistical analysis: Student’s t-test. ** 








6.4: Fork reversal may play a role in response to BET inhibition 
 
RAD51 had previously been shown to slow forks down in response to genotoxic 
compounds. The authors had suggested that RAD51 slows forks by mediating fork 
reversal (Zellweger, Dalcher et al. 2015). Fork reversal helps stabilise the 
replication fork until the lesions or other sources of replication slowing have been 
removed (Branzei and Foiani 2010, Neelsen and Lopes 2015). This suggested a 
role for fork reversal in response to BET inhibition as a means to stabilise and slow 
down fork speeds in response to transcription-replication conflicts.  
To test this hypothesis, we used DNA fibre assays, firstly using 5 µm PARP inhibitor 
Olaparib (PARPi) for 2 hours before labelling the cells (Figure 6.5 A). PARP1 is a 
crucial mediator of fork reversal and is needed for fork stabilisation (Ding, Ray 
Chaudhuri et al. 2016). PARP1 acts to inhibit RECQ1, a helicase that counteracts 
fork reversal (Berti, Ray Chaudhuri et al. 2013). Hence using PARPi can prevent the 
accumulation and stabilisation of reversed forks. We observed that when PARPi 
was combined with JQ1 this helped rescue fork speeds towards the control levels. 
PARPi alone had no effects on fork speeds, indicating the effect was specific to the 











Figure 6.5: PARP inhibition rescued fork slowing induced by BET inhibition. 
A) DNA fibre labelling performed in U2OS cells treated with PARP-I olaparib for 2 
hours followed by JQ1 for 1 hour. B) Average median replication fork speeds after 
treatment +/- PARP-I olaparib (5 µM) followed by +/- 1 µM JQ1 treatment. C) 
Distribution of replication fork speeds in cells treated with +/- PARPi olaparib 
followed by +/- 1 µM JQ1 treatment. (N=3, error bars: S.E.M, Statistical analysis: 










We also looked at other fork reversal factors to test if the same effect was seen. We 
used siRNA to deplete DNA translocases SMARCAL1 and ZRANB3. Both of these 
proteins have been shown to use their translocase activity to reverse replication 
forks, and inhibiting or depleting these proteins would block fork reversal (Betous, 
Mason et al. 2012, Couch, Bansbach et al. 2013, Vujanovic, Krietsch et al. 2017).  
To investigate the effects that these proteins have on BET inhibitor induced fork 
speeds, DNA fibre assays were performed. Either protein was depleted with specific 
siRNA targeted against each protein for 48 hours before DNA fibre labelling. To 
check that both proteins were depleted we used Western blots. We observed that 
SMARCAL1 protein and ZRANB3 protein levels were strongly reduced after siRNA 
treatments, indicating that both proteins were being successfully knocked down 
(Figure 6.6 A, C).  
We observed that when either protein was depleted, fork speeds were significantly 
increased towards the control levels (0.93 kb/min for SMARCAL1 depletion in 
presence of JQ1 and 0.90 kb/min for ZRANB3 depletion in presence of JQ1 from 
0.65 kb/min after JQ1 treatment alone) in the presence of JQ1 (Figure 6.6 B, D). 
Depletion of both proteins in absence of JQ1 treatment showed no impact on 
replication fork speeds, again indicating the effect was specific to JQ1 treatment. 
Overall, these results suggest that fork reversal proteins PARP1, ZRNAB3 and 
SMARCAL1 are crucial for forks to be slowed down in response to BET inhbitor 
treatment. This suggests a role for forks being reversed to help fork slowing during 






Figure 6.6: SMARCAL1 and ZRANB3 depletion both rescue BET inhibitor 
induced fork slowing. 
A) Protein levels of SMARCAL1 after 48 hours treatment with NonTsi or 
SMARCAL1 siRNA transfection. B) Average median replication fork speeds with 
cells treated with NonTsi or SMARCAL1 siRNA +/- 1 µM JQ1 treatment for 4 hours. 
C) Protein levels of ZRANB3 after 48-hour treatment with nonTsi or ZRANB3 siRNA 
transfection. D) Average median replication fork speeds with cells treated with 
nonTsi or ZRANB3 siRNA +/- 1 µM JQ1 treatment for 4 hours. (N=3, error bars: 











6.5: RAD51 depletion leads to increased DNA damage during BET 
inhibition 
 
RAD51 slows fork speeds down in response to BET inhibitor treatment, suggesting 
that it acts downstream of the transcription-replication conflicts that occur. 
Previously, we had yet to detect any DNA damage signalling in response to BET 
inhibitor treatment, but saw increased DNA damage signalling after depletion of 
HEXIM1 which acted upstream of these collisions. We hypothesised that RAD51 
depletion may also serve to proctect cells from DNA damage by slowing and 
stabilising replication forks.  
We used immunofluorescence microscopy of γH2AX and 53BP1 foci after RAD51 
depletion. Cells were treated with RAD51 siRNA for 48 hours followed by control or 
JQ1 treatment for 8 hours before fixing and staining. We observed that RAD51 
depletion in presence of JQ1 led to the increase in both γH2AX and 53BP1 foci 
formation compared to control (6% in control to 15% in presence of JQ1 for Yh2ax 
and 14% in control to 21% in presence of JQ1 for 53BP1) (Figure 6.7 A-C). RAD51 
depletion in the absence of JQ1 showed only a small increase in DNA damage foci, 
indicating that the effect was specific to JQ1.  
These results indicate that RAD51 is involved in preventing DNA damage after BET 
inhibitor treatment, and depletion of RAD51 serves to promote BET inhibitor-







Figure 6.7: RAD51 depletion activates a BET inhibitor replication stress 
response. 
A) Representative images of γH2AX and 53BP1 foci after 1 µM JQ1 treatment with 
RAD51 or NonTsi siRNA transfection. Scale bar 10 µM. B) Percentages of cells with 
8 or more γH2AX foci after 1 µM JQ1 treatment for 8 hours with either RAD51 or 
NonTsi siRNA transfection. C) Percentages of cells with 8 or more 53BP1 foci after 
1 µM JQ1 treatment for 8 hours with either RAD51 or NonTsi siRNA transfection. 
N=3, error bars: S.E.M, Statistical analysis: Student’s t-test. * P value <0.05, ** P 











The main aim of this chapter was to try and further characterise the downstream 
DNA damage response to BET inhibitor-induced fork slowing. We had previously 
shown no activation of DNA damage signalling after fork slowing. In this chapter we 
showed that BET inhibitor treatment or BRD4 depletion activate RAD51 (Figure 
6.1), a homologous recombination factor which has been shown to play a crucial 
role during replication stress in cells (Petermann, Orta et al. 2010, Zellweger, 
Dalcher et al. 2015, Bhat and Cortez 2018). The RAD51 response is transient 
occurring at the same time as fork slowing, but this may also be due to RAD51 
protein levels being reduced after 24 hours as well (Figure 6.2 B) or due to cell 
cycle arrest. This illustrates a picture where RAD51 is activated but there is not a 
full damage response to BET inhibitor treatment.  
Previous literature indicated a role for RAD51 in directly slowing replication fork 
speeds in response to specific types of DNA damage (Zellweger, Dalcher et al. 
2015). We observed that RAD51 also plays a role in slowing fork speeds during 
transcription-replication conflicts (Figure 6.4). Depletion of RAD51 lead to fork 
speeds being rescued towards control speeds during BET inhibitor treatment 
(Figure 6.2). RAD51-mediated fork slowing might involve fork reversal. Inhibition of 
PARP1, and depletion of ZRNAB3 and SMCARCAL1, all of which are crucial for 
formation and stabilisation of reversed forks, also showed fork speeds being 
returned to control levels (Figure 6.5-6.6). This potentially suggests a mechanism 





which leads to fork stabilization and prevents further DNA damage signalling. We 
are yet to determine whether fork reversal happens directly at sites of these 
conflicts or is due to indirect effects of transcription-replication conflicts.  
One potential way to answer this question is to see if the transcription machinery is 
in close proximity to proteins that are involved in fork reversal such as SMARCAL1. 
This may suggest that fork reversal is happening at sites of transcription-replication 
conflicts. One way to try and address this question would be to carry out a proximity 
ligation assay. This technique would allow us to see whether fork reversal proteins 
are in close proximity to either transcription factors or RNA Pol 2, which has been 
phosphorylated at either serine 2 or serine 5. We could also look to see whether 
fork reversal proteins or RAD51 co-localize with RNA Pol 2 or other transcription 
proteins after JQ1 treatment. This may help address the question as to whether fork 
reversal happens at sites of transcription-replication conflicts.  
RAD51 protein levels are significantly reduced after 24 hours of BET inhibitor 
treatment (Figure 6.2 B). This provides a potential mechanism where RAD51 loss 
allows fork speeds to be rescued after 24-hour BET inhibitor treatment. We 
observed that by over-expressing RAD51, we can promote BET inhibitor-induced 
fork slowing even after 24 hours JQ1 (Figure 3.2). This again shows RAD51 playing 
a role in fork progression and a potential mechanism of how BET inhibitor treated 
cells rescue fork speeds after this time point. Whether this is the main mechanism 
of rescue requires more investigation. Fork reversal can lead to forks being 





RAD51 not only controlled fork speeds in response to BET inhibitor treatment, but 
also prevented DNA damage signalling (Figure 6.7). Here when RAD51 is depleted, 
there are increases in DNA damage foci formation. RAD51 might prevent BET 
inhibitor-induced DNA damage signalling by helping to slow down and stabilise 
replication forks hence preventing accumulation of ssDNA for an ATR response, or 
by preventing forks from collapsing into DNA breaks after persistent replication 
stress.  
In this chapter, I have described a new downstream DNA damage response 
mechanism that occurs during BET inhibitor induced transcription-replication 
conflicts. RAD51 is activated in response to transcription-replication conflicts and 
helps slow down fork speeds and prevents DNA damage signalling. Furthermore, 
decreased levels of RAD51 after 24 hours of BET inhibitor treatment may explain 
the rescue of fork speeds at this time point. BET inhibitor treatment also leads to 
signs of increased genomic instability after 24 hours. RAD51 could play a crucial 






7.  Discussion 
 
BET bromodomain proteins are epigenetic transcriptional regulators that bind to 
acetylated lysine’s in proteins, including histone tails on the chromatin. They have 
been shown to promote oncogenic functions such as MYC-dependent transcription 
driving cancer formation (Delmore, Issa et al. 2011). BET proteins have established 
roles in transcription functions. Research over the past few years has also led to the 
discovery of BET protein involvement in a number of different cancer types 
(Dawson, Prinjha et al. 2011, Delmore, Issa et al. 2011, Cheng, Gong et al. 2013, 
Da Costa, Agathanggelou et al. 2013). Interestingly BET proteins have recognition 
sites that allow for the development of specific inhibitors, which can target the 
function of BET proteins (Filippakopoulos, Qi et al. 2010, Dawson, Prinjha et al. 
2011). These inhibitors have emerged as a new approach for targeted cancer 
therapy.  
The lab had previously shown that treatment with BET inhibitor JQ1 had slowed 
replication fork progression in Nalm 6 cells (Da Costa, Agathanggelou et al. 2013). 
Slowed replication fork progression, if persistent, can lead to promotion of DNA 
damage and genomic instability in the cell (Zeman and Cimprich 2014, Kotsantis, 
Jones et al. 2015, Kotsantis, Silva et al. 2016). Research performed in this thesis 
aimed to uncover the causes of BET inhibitor-induced fork slowing and the effect 
that this would have on the cell. A more detailed understanding of the impact of BET 
proteins on processes such as DNA replication is necessary for development of 







7.1: BET inhibition causes P-TEFb induced replication-
transcription conflicts 
 
In this thesis, we first sought out how BET inhibitors were causing replication stress. 
Here we identified that BET inhibition leads to an increase in total nascent RNA 
synthesis as measured by EU assay and total RNA quantification. In contrast to our 
findings, recent papers had shown that BET inhibitor treatment led to suppression of 
nascent transcription of protein encoding genes such as MYC (Winter, Mayer et al. 
2017, Muhar, Ebert et al. 2018). By re-analysing the RNA Pol II ChIP-seq data-sets 
published in Muhar et al, we showed that following BRD4 depletion after 1 hour led 
to an increase in genome-wide occupancy of RNA Pol II (Bowry, Piberger et al. 
2018) (Figure 7.2). This was seen especially over transcription of non-poly-
adenylated histone and non-coding RNA genes. More analysis using qRT-PCR 
showed increased gene expression of candidate genes and also corresponded with 
previous reports where we observed decreases in MYC transcript levels (Bowry, 
Piberger et al. 2018) (Figure 7.1). These experiments were carried out by the 
Saporano group. This suggested that BET inhibition leads to increased transcription 
of non-poly-adenylated histone and non-coding RNA genes suggesting that this was 










Figure 7.1: Fold change in the normalized expression levels of indicated transcripts 
± JQ1 as indicated (n = 4). Retrieved from (Bowry, Piberger et al. 2018) 
 
 
Figure 7.2: BRD4 degradation increases RNA Pol II occupancy in histone and non-
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Increased transcription has recently been shown to cause replication fork slowing in 
cells (Kotsantis, Silva et al. 2016, Stork, Bocek et al. 2016, Gorthi, Romero et al. 
2018, Lavado, Park et al. 2018, Nojima, Tellier et al. 2018). We identified that this 
increase in transcription indeed was the cause of fork slowing after BET inhibitor 
treatment by using transcriptional inhibitors.  
The mechanism of how BET inhibitors cause this increase in RNA synthesis was 
next investigated. Research had suggested that BET inhibitors could lead to 
disruption of a 7SK inhibitory complex of P-TEFb (Bartholomeeusen, Xiang et al. 
2012). This would lead to increase in free and active P-TEFb in the cell. P-TEFb is 
crucial in allowing productive elongation of RNA Pol II via CTD phosphorylation 
(Peterlin and Price 2006, Jonkers, Kwak et al. 2014, Jonkers and Lis 2015). We 
showed that BET inhibitor treatment lead to increased RNA Pol II CTD 
phosphorylation indicating that BET inhibitor treatment lead to more free P-TEFb. 
To confirm that disruption of the 7SK complex can lead to increased replication-
transcription interference we used a chemical called HMBA. HMBA is known to 
disrupt 7SK inhibitory complex, but has no known effects on DNA replication 
(Contreras, Barboric et al. 2007, Fujinaga, Luo et al. 2015). We showed that HMBA 
treatment also caused increased transcription-replication interference via a 
mechanism that involved the disruption of the 7SK complex. A caveat is that a 
recent paper showed that HMBA may act as a BET inhibitor by disrupting BET 
proteins binding to chromatin (Nilsson, Green et al. 2016). This could mean that our 
results seen with HMBA are due to the fact that it is a BET inhibitor and that it 
functions similarly to JQ1. However, it also shows further evidence that BET 





complex. As stated HMBA is known not to have any effects on replication, so as a 
BET inhibitor it causes fork slowing via the disruption of 7SK-PTEF-b. The role of 
HMBA as a potential BET inhibitor is dose dependent. HMBA has a weaker IC50 to 
that of BET inhibitors such as JQ1 (Nilsson, Green et al. 2016). We could therefore 
potentially use concentrations of HMBA where its ability to function as a BET 
inhibitor is poor to confirm whether the fork slowing phenotype is due to non-BET-
targeted effects. 
 All together, the HMBA results provide information that disrupting the 7SK-P-TEFb 
complex provides a mechanism in which forks can be slowed down due to the 
increased transcription-replication interference that it causes. 
BET inhibition illustrates a model in how small-molecule inhibitors can also lead to 
the formation of replication stress via increased RNA synthesis after treatment. We 
hypothesise that the increase in RNA synthesis we observe after BET inhibitor 
treatment represents a global increase in transcription activity. RAS activation was 
shown to lead to a global increase in RNA synthesis (Kotsantis, Silva et al. 2016). 
We observed similar phenotypic changes in RNA synthesis after BET inhibition 
treatment that were seen in cells after RAS activation (Kotsantis, Silva et al. 2016). 
We observed that BET inhibition led to increased EU incorporation. The EU assay is 
designed to show global changes in RNA synthesis. Furthermore, the observed 
increase in RNA synthesis after BET inhibitor treatment was lost when BET inhibitor 
treated cells were also co-treated with transcriptional inhibitors known to inhibit 
global transcription (Bensaude 2011, Wang, Johnson et al. 2014, Chen, Gao et al. 
2015). This loss of RNA synthesis by transcription inhibitors also coincided with fork 





stopping BET inhibitor induced transcription-replication conflicts. To further address 
this we could perform a global RNA-seq to look at what genes are up-regulated 
after BET inhibition and allows us to look at the differences in global transcriptomes 
after BET inhibition.   
 Other cancer treatments such as HDAC inhibitors that led to the disruption of the P-
TEFb-7SK-snRNP inhibitory complex could also lead to increased transcription-
replication interference (Bartholomeeusen, Xiang et al. 2012, Bartholomeeusen, 
Fujinaga et al. 2013).  
Hence our data strongly suggests that BET inhibitor-induced fork slowing is caused 
by increased transcription-replication interference via disruption of the 7SK-snRNP 
complex. This can allow for increase in free P-TEFb leading to more CTD 
phosphorylation, signalling from RNA Pol II to escape from promotor pausing. 
7.2: BET inhibition leads to increased origin firing:  
 
We observed that BET inhibitor treatment led to an increase in origins being fired. 
Origins are known to be fired locally in response to increased fork slowing as a 
mechanism to help rescue stalled forks (Woodward, Gohler et al. 2006, Ge, 
Jackson et al. 2007, Blow, Ge et al. 2011). There is also evidence to suggest that 
the regulation of origin firing is key to maintaining normal fork speeds, and that an 
increase in the number of origins being fired can cause increased replication stress 
(Petermann and Helleday 2010, Beck, Nahse-Kumpf et al. 2012, Jones, 
Mortusewicz et al. 2013). Our data suggested that the increased amount of origins 





phenotype observed. However, the CDK inhibitors used to suppress origin firing 
also seemed to interfere with transcription making it difficult to interpret our results. 
Further work is needed to understand why we see an increase in the number of 
origins fired after BET inhibitor treatment. To investigate this further we could 
deplete cells of either CDC6 or CDC7 and observe whether this would lead to a 
rescue in replication fork speeds. This would enable us to know whether increased 
origin firing is causing slower fork speeds. Increased firing of origins may also be 
involved in transcription induced replication fork slowing by altering the spatial 
coordination of replication initiation and transcription after BET inhibitor treatment 
(Helmrich, Ballarino et al. 2011, Jones, Mortusewicz et al. 2013, Sansam, 
Pietrzak et al. 2018).  
We have shown that after 24 hours of BET inhibitor treatment fork speeds are 
rescued to speeds observed in control treated samples. As mentioned earlier, an 
increase in the number of origins fired can rescue fork speeds and allow for the 
continuation of normal replication afterwards. This may indicate that the increase in 
the number of origins being fired after BET inhibitor treatment is helping rescue 
reversed forks. This would lead to replication fork speeds returning back to normal 
control speeds. This could be tested by analysing fork speeds after 24 hours of BET 
inhibitor treatment in cells depleted of either CDC6 or CDC7.  
If this increase in origin firing is lost, it could lead to increased genomic instability or 
increased damage, as JQ1 induced reversed forks are unable to be rescued. We 
could test this by looking at whether BET inhibitor treatment leads to any increases 
in DNA damage markers such as H2AX or 53BP1 in cells depleted of either CDC6 





could also lead to increased genomic instability (Shima, Alcaraz et al. 2007, 
Debatisse, Le Tallec et al. 2012). Again this could be investigated by analysing BET 
inhibitor treated cells depleted with CDC6 or CDC7 and seeing whether we observe 
increases of 53BP1 bodies or anaphase bridges.  
 
7.3: BRD4, the BET protein required for normal fork progression   
 
Our data provide insight into the roles of BRD4 in DNA replication. BRD4 depletion 
caused replication stress in cells that was not seen when BRD2 and BRD3 were 
depleted. BRDT is expressed only in the testis and is not expressed well in a whole 
range of cancer cell lines including U2OS especially compared to other BET 
proteins. This was further illustrated using the CCLE database where mRNA 
expression levels for BRDT across a range of cancer cells was miniscule (Appendix 
A1). BRD4 has been shown to have numerous roles in the cell, however our data 
suggests that it has a novel role in DNA replication. Cells depleted of BRD4 were 
unable to show normal fork speeds, suggesting that BRD4 is important in 
maintaining normal replication fork progression in the cell. Our data implied that loss 
of BRD4 led to increased RNA synthesis which caused more transcription-
replication interference hence leading to slower fork speeds. This result mirrored the 
phenotype observed with BET inhibition. However, BET inhibition caused transient 
fork slowing while BRD4 consistently slowed forks, suggesting that there is some 
mechanism of fork speed adaptation with BET inhibitor treatment not seen with 





interaction with P-TEFb and not via the interaction with the replication factors RFC 
and TICRR. This was shown via the inability of BRD4 short isoform containing RFC 
and TICRR interactions to rescue replication stress (Maruyama, Farina et al. 2002, 
Sansam, Pietrzak et al. 2018). The CDC6 interaction site in BRD4 is still unmapped, 
so we could not test it (Zhang, Dulak et al. 2018). Overall our data supports that 
BRD4 loss rapidly leads to increased P-TEFb activity.   
Together this data suggests a newly discovered role of BRD4 in the process DNA 
replication which may be potentially important in future cancer therapy applications. 
 
7.4: BET inhibitor-induced transcription-replication conflicts 
depend on HEXIM1 
 
Our results have suggested that HEXIM1 plays an important role in BET inhibitor 
induced replication fork slowing. Cells depleted of HEXIM1 do not show BET 
inhibitor-induced fork slowing for up to at least 8 hours. HEXIM1 depletion also 
leads to suppression of BET inhibitor induced RNA synthesis at early time points as 
well. The mechanism of how HEXIM1 depletion causes delay in BET inhibitor-
induced changes to fork progression and RNA synthesis is still unclear at this 
moment. What we do know is that HEXIM1 is required for the BET inhibitor induced 
fork slowing. 
After 24-hour treatment with BET inhibitor in HEXIM1 depleted cells, there is 
significant fork slowing. Why we observed this switch in phenotype around this time 





extensive gene expression changes or possibly HEXIM2 which may compensate for 
HEXIM1 loss (Byers, Price et al. 2005). HEXIM2 has been shown to compensate for 
HEXIM1 loss in cells and has been shown to be regulated differently in response to 
external stimulus. Hence, at this time point HEXIM2 could carry out the function of 
HEXIM1 and hence may explain the switch in phenotype (Byers, Price et al. 2005). 
Extensive gene changes through 24 hours of BET inhibitor treatment may also 
affect how the cell deals with HEXIM1 depletion (Delmore, Issa et al. 2011, 
Muralidharan, Bhadury et al. 2016). 
We also show that HEXIM1 loss can promote JQ1 effects, such as DNA damage. In 
addition to modulating transcription-dependent fork slowing, HEXIM1 might play 
undiscovered roles in replication stress and DNA damage response. It may be 
relevant that HEXIM1 also regulates p53 (Lew, Chia et al. 2012). HEXIM1 has been 
found to interact with p53 and enhances its stability and function. Hence by down-
regulating HEXIM1, the observed effects we see may be due to the loss of p53 
stability and loss of p53 induction. However, we have observed JQ1-induced 










7.5: The importance of RAD51 in BET inhibitor response to 
transcription-replication conflicts 
 
If the cause of replication stress is persistent, it normally results either in DNA damage 
or genomic instability (Kotsantis, Jones et al. 2015). An ATR driven response is 
normally seen in situations of prolonged fork slowing (Ciccia and Elledge 2010, 
Zeman and Cimprich 2014). In this thesis we had shown that there was little to no 
replication stress response after BET inhibitor treatment or after BRD4 depletion. We 
found that there was little activation of ATR response markers such as RPA and 
H2AX or p-CHK1 S317. This observation has also been reported in recent studies 
using CRPC cells where the authors also observed BET inhibitor-induced decreases 
in H2AX and 53BP1 foci (Pawar, Gollavilli et al. 2018). A report last year also had 
similar results shown in both U2OS and OVCAR3 cell lines where p-CHK1 S317 was 
reduced after BET inhibitor treatment. p-CHK1 activation was also reduced when BET 
inhibitor treatment was combined with HU compared to HU treatment alone (Zhang, 
Dulak et al. 2018). This confirms our results that BET inhibitor induced fork slowing 
does not activate an ATR response. This was followed up by investigating whether 
slowed replication forks may activate a different pathway in response to fork slowing 
induced by BET inhibition or BRD4 depletion. The homologous recombination factor 
RAD51 has been established to be important in binding to stalled forks and stabilizing 
forks that have encountered stress (Arnaudeau, Lundin et al. 2001, Lundin, Schultz 
et al. 2003, Petermann, Orta et al. 2010, Carr and Lambert 2013, Willis, 
Chandramouly et al. 2014, Kolinjivadi, Sannino et al. 2017). RAD51 loading onto 





(Zellweger, Dalcher et al. 2015). Our data shows that BET inhibition leads to 
increased recruitment of RAD51 shown by the increase in the percentage of RAD51 
foci positive cells. We still need to know whether this occurs transcriptionally or post-
translationally. Firstly, we could look at levels of RAD51 mRNA using qRT-PCR, and 
RAD51 protein levels by Western blot, after BET inhibitor treatment. Western blotting 
has already shown that RAD51 levels were not increased after JQ1 treatment (Figure 
6.2 B). To see whether BET inhibitor treatment is modifying RAD51 post-
translationally, we can use techniques such as tandem mass spectrometry or IP to 
look at PTMs. Tandem mass spectrometry can be used to identify and quantify PTMs 
on proteins. Here we could isolate and purify RAD51 before digesting the protein with 
trypsin, both with control and BET inhibitor treatments. This would be followed by 
peptide enrichment before analysis can take place. Shifts in mass indicate a modified 
amino acid. This technique allows for broad spectrum analysis of novel PTMs on 
proteins (Larsen, Trelle et al. 2006, Silva, Vitorino et al. 2013, Ratovitski, O'Meally et 
al. 2017). Another experiment that could be used is immunoprecipitation. Here a 
protein, both from untreated and treated samples, can be isolated and enriched 
before Western blotting using antibodies against specific PTMs. By carrying out these 
experiments we would hope to further understand how of RAD51 is regulated after 
BET inhibitor treatment and have a clearer understanding of the mechanism of 
RAD51 recruitment. Our data strongly suggests that this depends on RNA synthesis 
and that RAD51 slows down forks after BET inhibition. RAD51 has been shown to be 
able to lead to replication fork reversal to help stabilise stalled replication forks 
(Zellweger, Dalcher et al. 2015). Our data also support that fork reversal could play a 





amount of RAD51 foci indicative of a similar mechanism, however more research 
needs to be done to see if this mirrors the BET inhibitor phenotype completely. This 
data suggests that RAD51 binds to forks that have been slowed due to either direct 
or indirect effects of increased transcription-replication interference, which can lead 
to fork reversal.  
We had also shown that RAD51 helps suppress the DNA damage response in 
presence of BET inhibitors. Cells depleted of RAD51 had increased DNA damage 
signalling after BET inhibitor treatment. This would indicate that RAD51 helps not 
only to slow down fork speeds but helps prevent the formation of DNA damage. We 
also observed that BET inhibitors reduced RAD51 expression levels after treatment. 
Other research had also showed similar results, that RAD51 expression is 
downregulated in response to BET inhibition and in models of acquired BET 
inhibitor resistance (Yang, Zhang et al. 2017, Pawar, Gollavilli et al. 2018). 
Interestingly, acquired BET inhibitor resistance models also showed more DNA 
damage signalling (Pawar, Gollavilli et al. 2018). This agrees with our data that 
RAD51 downregulation increases DNA damage signalling. 
Our data also showed that JQ1 treatment could lead to genomic instability in cells. 
Genomic instability is a key hallmark for tumour progression (Hanahan and 
Weinberg 2000). Potential causes of micronuclei formation could be the inability to 
resolve replication stress intermediates so that the cell can continue normal 
replication. Here, the cell is unable to remove the replication stress source which 
results in replication fork to collapse leading to DNA breaks and potential 
micronuclei formation. This could be due to the collapse or degradation of the 





micronuclei normally occur from faulty DNA repair mechanisms which lead to mis-
repaired or unrepaired DNA breaks. Micronuclei formation may also be due to 
mitosis and cell cycle effects. This includes faulty spindle formation, de-regulation of 
cell cycle checkpoints, defects in kinetochore proteins and assembly or improper 
chromosome segregation during mitosis (Thomas, Fenech et al. 2011, Luzhna, 
Kathiria et al. 2013). Whether JQ1 causes micronuclei formation by improper 
resolution of replication stress or via another mechanism in the cell is unclear. 
However, this finding is still important as the formation of genomic instability could 
be a much unwanted side-effect of JQ1 treatment if pursued further as a cancer 
therapy treatment, as genome instability in the cell has the potential to be a major 
driving force in tumorigenesis and allow cancer cells to evolve and adapt to 
maximise cell survival.   
In this thesis we have presented novel roles of BET proteins and their inhibitors in 
the process of DNA replication. Put together we outline a model where firstly BET 
inhibitors can lead to increased RNA synthesis via disruption of 7SK-snRNP 
complex. The increase in transcription leads to increased transcription-replication 
interference causing slow fork speeds. Loss of BRD4 protein also leads to 
replication fork slowing due to increased RNA synthesis. This fork slowing 
mechanism requires the loss of BRD4 interaction with P-TEFb. HEXIM1 protein is 
involved upstream of these replication-transcription conflicts, although the 
mechanism is still unclear. These replication-transcription conflicts activate RAD51, 
which binds and slows down fork speeds. Our data also suggests that these forks 
are reversed too. Both RAD51 acting downstream of these conflicts and HEXIM1 





is outlined below (Figure 7.3). How BET inhibitor treatment leads to increased RNA 
Pol 1 and RNA Pol 3 transcription and how this contributes mechanistically to BET 
inhibitor induced fork slowing is unclear. How the observed increase in fired origins 
after BET inhibitor treatment contributes mechanistically to BET inhibitor induced 
fork slowing is also unclear at this moment. This is depicted in Figure 7.3. 
Studies have indicated that BET inhibitor resistance shows increased DNA damage 
and that cells depleted with either RAD51 or HEXIM1 showed increased BET 
inhibitor resistance. This would highlight that these factors are involved in BET 
inhibitor resistance by potentially preventing increased DNA damage in response to 
BET inhibitor treatment.   
BET inhibitors have been fast-tracked into clinical trials and it is important for cancer 
therapy that we know as much about the effects that these drugs have on different 
cellular processes. In this thesis we provide insights into the role of BET proteins, 
































7.6: Future questions and directions 
 
In this thesis we have provided a function for BET proteins in DNA replication and 
have shown a mechanism where inhibition or loss of BET proteins can cause 
impaired DNA replication fork progression and lead to downstream activation of 
homologous recombination. However, there are still some key questions to be 
resolved in the future. 
Throughout the thesis we have performed our experiments with inhibitor 
concentrations that have been used in previous literature. However, the IC50 for 
many drug inhibitors we used are much lower. For example, JQ1 has an IC50 of 77 
nM (Filippakopoulos, Qi et al. 2010). Using a higher concentration of drugs could 
increase the chances of causing off target effects. There is a potential danger that 
some of the results we have observed may be due to some off target effects 
induced by using higher drug concentrations. It is therefore crucial in future 
experiments to use drug inhibitor concentrations that are closer to their IC50s. This 
will serve to increase the confidence that my results are due to the specific inhibiting 
of the proteins or signalling pathways that we aim to target. It is also important to 
carry out experiments to observe whether there are dose dependent effects seen 
with using these drugs on our experiments. This again allows us to be more 
confident in concluding our results are due to the specificity of the drugs being able 
to inhibit our desired targets rather than some off target effects. 
Both BRD4 depletion and BET inhibition led to increased RNA synthesis and 
replication fork slowing. However, after 24 hours of BET inhibition, we see a rescue 





for this is still not clear suggesting that more research using BRD4 depletion is 
required. We see that after BET inhibitor treatment for 24 hours when RAD51 levels 
have been depleted, RAD51 overexpression leads to fork speeds being decreased. 
This suggests that when RAD51, which slows forks speeds down in response to 
transcription-replication conflicts, is downregulated due after 24 hours BET inhibitor 
treatment, this could help rescue replication fork speeds. We observed that BRD4 
depletion led to more RAD51 foci similar to BET inhibitor treatment, however we did 
not measure the protein levels of RAD51 after 48 hours of BRD4 depletion. The 
RAD51 downregulation after BET inhibitor treatment may be one explanation for 
this difference and experiments looking into levels of RAD51 protein after BRD4 
depletion will need to be done in the future. There may be other factors involved in 
this adaptation to BET inhibitor treatment, as there is potential for BET inhibitors to 
change the expression or activation of a number of target genes resulting in DNA 
replication adaptation. Again, this would require more research to look into the 
difference between the impact of BET inhibitor treatment and BRD4 depletion on 
changes in the cell.  
Due to time constraints, work on the mechanism downstream of BRD4 depletion is 
not complete. More experiments on whether RAD51 slows down replication forks in 
BRD4 depleted cells and whether BRD4 depletion can cause fork reversal and 
genomic instability needs to be looked at in the future. It would also help to see 
whether RAD51 depletion suppresses DNA damage in BRD4 depleted cells too. 
This will give insights into how BRD4 depletion and BET inhibitor treatments work 
and would identify whether their mechanisms downstream of these replication-





specific drugs that lead to BRD4 disruption and degrade BRD4 (Lu, Qian et al. 
2015, Winter, Buckley et al. 2015, Winter, Mayer et al. 2017) to counteract potential 
side-effects from using pan-BET inhibitors which inhibit numerous transcriptional 
pathways. Understanding the full roles of BRD4 loss in DNA replication and DNA 
damage may provide to be useful if these specific drugs were to be used in future 
cancer therapy. 
We showed how crucial HEXIM1 is to replication fork slowing and DNA damage in 
BET inhibitor treated cells. The full mechanism of how HEXIM1 depletion can delay 
BET inhibitor-induced fork slowing is still unclear. We speculated that perhaps there 
is a role for HEXIM2 that helps to compensate for HEXIM1 loss. Further 
experiments in depleting both HEXIM2 and HEXIM1 would likely shine more light 
onto this mechanism.  
Interestingly, reduced HEXIM1 protein levels have been observed in metastatic 
breast cancer, melanoma, acute leukaemia and colon rectal cancer (Ketchart, Smith 
et al. 2013, Huang, Garcia et al. 2016, Tan, Fogley et al. 2016). In our data reduced 
HEXIM1 levels prevent transcription-replication interference but lead to amplified 
DNA damage and genomic instability in the cells. Other research has shown that 
KRAS mutations can correlate with BET inhibitor resistance and mitogen-activated 
protein kinase (MAPK) inhibition sensitises colorectal cancer (CRC) lines to BET 
inhibition (Ma, Wang et al. 2017, Sun, Yin et al. 2018). The lab has also observed 
similar preliminary results to BET inhibitors with HRAS overexpressed cells, where 
HEXIM1 depletion causes amplified DNA damage signalling. This suggests that 





replication-transcription conflicts. As HEXIM1 loss has been reported to promote 
resistance to long-term BET inhibition, its impact on replication stress, survival and 
genomic instability in cancer require urgent investigation (Devaraj, Fiskus et al. 
2016). 
Key questions arising from this research are: What is the role of HEXIM1 in 
modulating replication-transcription conflicts? How does HEXIM1 interact with 
existing oncogene-induced replication stress? Can this be exploited as a biomarker 
and target to improve cancer therapy? Tackling these questions may help to better 
understand the function of HEXIM1 in BET inhibitor induced transcription-replication 
conflicts as well as uncover novel roles of HEXIM1 in cancer and potentially 
establish a new biomarker for future clinical work in cancer therapy research.  
To address these questions, we could firstly look to induce transcription-replication 
conflicts by treating cells with drugs, specifically BET inhibitors, to induce HEXIM1 
complex disruption. We could also use biochemistry assays to assess changes in 
the interaction between P-TEFb (consisting of CDK9 and Cyclin T1) and HEXIM1, in 
response to BET inhibition, by immunoblotting for RNA Pol II CTD phosphorylation 
for P-TEFb activity. Another experiment that could be used to assess changes in P-
TEFb and HEXIM1 interaction, is performing site directed mutagenesis targeting the 
phosphorylation sites T270 and S278 in HEXIM1. These sites are targeted by 
oncogenic signalling through PI3K-AKT and play an important role in regulating the 
dissociation of HEXIM1 and P-TEFb (Contreras, Barboric et al. 2007). We could 
also look at the effects of oncogenes on RNA synthesis after HEXIM1 depletion or 





HEXIM1 has not been detected at unperturbed or stressed replication forks, but we 
could test to see if HEXIM1 localises to replication forks or DNA damage sites under 
wither oncogene- or BET inhibitor induced replication stress using Isolation of 
Proteins on Nascent DNA (Ipond). This will help us address both the role of HEXIM 
in replication stress and its role in oncogenic stress as well. 
 To see if HEXIM1 may be a potential biomarker we can look at CRC cells or 
organoid tissues that have low levels of 7SK or HEXIM1 and investigate the 
potential effects on DNA replication and DNA damage. We can also test whether 
cells or organoids with low levels of HEXIM1 are more resistant to drugs or cancer 
treatments that either induce replication stress or induce HEXIM1 via P-TEFb 
disruption by performing cell survival assays.     
In addition to the work being done on HEXIM1 more research is needed to further 
elucidate the exact downstream effects of BET inhibitors. It is clear that RAD51 and 
HEXIM1 prevent DNA damage signalling. It is unclear still if BET inhibitor induces 
any physical DNA damage in the cell and further experiments to measure DNA 
breaks using comet assays and pulse field gel electrophoresis should allow us to 
see if DNA damage is occurring. Previous reports have only looked into the comet 
assay comparing BET inhibitor treatment in normal cells compared to BET inhibitor 
resistant cells (Pawar, Gollavilli et al. 2018). It will be more informative to compare 
total damage with BET inhibitor treatment compared to control treatment in U2OS 
cells especially at the time points where we have observed fork slowing. This would 
allow us to know whether we see suppression of DNA damage signalling pathways 
as suggested by our results and other studies or whether no damage is occurring in 





the formation of RPA foci after BET inhibitor treatment but do see RAD51 foci 
formation. Further research into how RAD51 is loaded without prior RPA loading will 
be necessary. The first step would be to see if BET inhibitor treatment leads to 
ssDNA formation, potentially using electron micrographs. This would allow us to see 
if there is either no ssDNA formed in which case maybe RAD51 is binding to other 
structures such as regressed forks. If there is ssDNA formation then maybe RPA 
binding is being suppressed, or potentially RAD51 may quickly replace RPA. 
RAD51 foci could be formed either to help reverse forks or to stabilise regressed 
forks, however this would require more research as well. It would seem that RAD51 
could bind to slowed forks helping them reverse but this is just a hypothesis and 
would require further evidence. RAD51 seems to play a role in BET inhibitor 
induced fork reversal at earlier time points after BET inhibitor addition, however we 
are unsure on what happens next. Carrying out experiments such as looking at the 
percentage of stalled forks through a JQ1 treatment time-course to see whether we 
have re-start of stalled forks after 24 hours or beyond may help us answer this 
question. This would allow us to explain the mechanism more clearly. If forks do not 
restart, then perhaps collapse of these forks later on could potentially be a cause of 
genomic instability that is observed with BET inhibitor treatment. If reversed forks 
are not being re-started it would be interesting to see whether we see more DNA 
damage signalling at later time points after BET inhibitor treatment (24 hours and 
beyond) without RAD51 depletion. This might then support reversed forks 
collapsing. It is not yet clear whether the genomic instability caused by BET inhibitor 
treatment is directly due to the effect of increased transcription-replication 





proteins are implicated in many cellular processes such as cell cycle regulation and 
regulation of many transcriptional pathways. BET inhibitors may impede the role of 
BRD4 to regulate normal mitosis in the cell which could give rise to micronuclei 
formation (Yang, He et al. 2008). Potential changes in gene expression, especially 
in the expression of DNA repair genes could also have an effect on the amount of 
micronuclei formation in the cell. More research is required to understand the exact 
mechanism of BET inhibitor-induced genomic instability. 
Further research is required to fully understand the biological functions of BET 
proteins and their role in DNA replication and DNA damage, and in understanding 
the impact of BET inhibitors on these processes too. However, our results provide 
some novel insights onto this area which will be useful in the future. It is important to 
understand the complexity and wide-ranging consequences and implications of 
using BET inhibitors as cancer therapeutics and it is vital that more research is done 














Figure A1: Data showing mRNA levels of BET proteins BRDT, BRD4, BRD3 and 
BRD2 in selected cancer cells. Arrow shows osteosarcoma cells (U2OS cells). Data 







A2: Western blot Quantification 
 
 
Quantification of protein levels for BRD4 siRNA fibre experiments, BRD2 siRNA 
fibre experiments, BRD4 short isoform overexpression experiments and HEXIM1 







Quantification of protein levels for RAD51 siRNA fibre experiments, RAD51 
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